var title_f42_48_43776="LV - aorta pullback";
var content_f42_48_43776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    LV - aorta pullback",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal LV and aortic pressures. Note pattern of LV diastolic pressure with lowest pressure earliest in diastole and gradual filling across diastole until the 'a' wave after which is the end diastolic pressure point (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Morton Kern.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43776=[""].join("\n");
var outline_f42_48_43776=null;
var title_f42_48_43777="Blistering distal dactylitis 3";
var content_f42_48_43777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Blistering distal dactylitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43777=[""].join("\n");
var outline_f42_48_43777=null;
var title_f42_48_43778="Types of parastomal hernias";
var content_f42_48_43778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Types of parastomal hernias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four types of parastomal hernias:",
"    <br>",
"     (A) Subcutaneous - bulges into the subcutaneous tissue.",
"     <br>",
"      (B) Interstitial - burrows into a muscular plane.",
"      <br>",
"       (C) Perstomal - enters the space between layers of prolapsed bowel.",
"       <br>",
"        (D) Intrastomal - enters the plane between the emerging and the everted part of the bowel forming the ostomy.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43778=[""].join("\n");
var outline_f42_48_43778=null;
var title_f42_48_43779="Madlender tubal ligation";
var content_f42_48_43779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Madlender tubal ligation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 521px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43779=[""].join("\n");
var outline_f42_48_43779=null;
var title_f42_48_43780="Pirbuterol: Patient drug information";
var content_f42_48_43780=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pirbuterol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20372?source=see_link\">",
"     see \"Pirbuterol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/1/26?source=see_link\">",
"     see \"Pirbuterol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxair&reg; Autohaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13319011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to open the airways in lung diseases where spasm may cause breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to albuterol, pirbuterol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to get the breathing attack under control.",
"       <b>",
"        Get help right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to take this drug as you have been told by your doctor. Do not use more than you were told to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Test puffer (inhaler) before use. Follow how to give puffer as you have been told.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A spacer may be used with the puffer (inhaler) for easy use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your puffer (inhaler) use checked with your doctor at each visit. Read and follow facts on how to use the puffer. Make sure you use the puffer the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using more than 1 type of puffer (inhaler), ask your doctor which puffer to use first.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breathe in a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696472",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breathe in 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is given on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away the puffer (inhaler) after the most number of sprays have been used, even if it feels like there is more drug in the can.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10979 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-221.179.173.170-A48E13D4B1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43780=[""].join("\n");
var outline_f42_48_43780=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210581\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319011\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013011\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013010\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013015\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013016\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013018\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013013\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013014\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013019\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013020\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20372?source=related_link\">",
"      Pirbuterol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/1/26?source=related_link\">",
"      Pirbuterol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_48_43781="IncobotulinumtoxinA (botulinum toxin type A, Xeomin): Drug information";
var content_f42_48_43781=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   IncobotulinumtoxinA (botulinum toxin type A, Xeomin): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/7/4213?source=see_link\">",
"    see \"IncobotulinumtoxinA (botulinum toxin type A, Xeomin): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10826166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10894929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xeomin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10826168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xeomin Cosmetic&trade;;",
"     </li>",
"     <li>",
"      Xeomin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10493109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Neuromuscular Blocker Agent, Toxin;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Toxin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10827173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Blepharospasm:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Initial: Total dose should be the same as previously administered onabotulinumtoxinA dose. If prior onabotulinumtoxinA dose is not known: 1.25-2.5 units/injection site (maximum initial dose: 35 units/eye or 70 units/both eyes). Number and location of injection sites based on disease severity and previous dose/response to onabotulinumtoxinA (in clinical trials, a mean number of 6 injections per eye were administered). Cumulative dose should not exceed 35 units/eye or 70 units/both eyes administered no more frequently than every 3 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Initial: 1.25-2.5 units/injection site (maximum initial dose: 25 units/eye). Dose may be increased up to twice the previous dose if the response from the initial dose lasted &le;2 months; maximum dose per site: 5 units. Cumulative dose should not exceed 35 units/eye or 70 units/both eyes administered no more frequently than every 3 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cervical dystonia:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Initial total dose: 120 units (in clinical trials, similar efficacy was noted with initial total doses of 120 and 240 units and between treatment experienced and treatment na&iuml;ve patients). Dose and number of injection sites should be individualized based on prior treatment, response, duration of effect, adverse events, number/location of muscle(s) to be treated and disease severity. In clinical trials most patients received a total of 2-10 injections into treated muscles. Administer no more frequently than every 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Usual total dose: 200 units (maximum: 300 units; maximum dose per injection site: 50 units); administer no more frequently than every 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Reduction of glabellar lines:",
"     </b>",
"     I.M.: Inject 4 units into each of the 5 sites (2 injections in each corrugator muscle and 1 injection in the procerus muscle) for a total dose of 20 units per treatment session.  Administer no more frequently than every 3 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Spasticity of upper limb (poststroke):",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     I.M.: Individualize dose based on patient size, extent, and location of muscle involvement, degree of spasticity, local muscle weakness, and response to prior treatment. In clinical trials, total doses up to 400 units were administered as separate injections typically divided among selected muscles; may repeat therapy at &ge;3 months with appropriate dosage based upon the clinical condition of patient at time of retreatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Suggested guidelines for the treatment of stroke-related upper limb spasticity: Note: The lowest recommended starting dose should be used. Dosage and number of injection sites should be individualized. Multiple injections may minimize adverse effects. Dose listed is total dose administered to site:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Biceps: 80 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Brachialis: 50 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Brachioradialis: 60 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Flexor carpi radialis: 50 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Flexor carpi ulnaris: 40 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Flexor digitorum profundus: 40 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Flexor digitorum superficialis: 40 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adductor pollicis: 10 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Flexor pollicis brevis: 10 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Flexor pollicis longus: 20 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pronator quadratus 25 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pronator teres: 40 units",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10827175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Initiate therapy at lowest recommended dose.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10827171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10827170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10894930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xeomin&reg;: 50 units, 100 units [contains albumin (human), sucrose 4.7 mg]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F16124978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xeomin Cosmetic&trade;: 100 units [contains albumin (human), sucrose 4.7 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10826169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10826167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM222360.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM222360.pdf",
"     </a>",
"     must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10827176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     For I.M. injection only.",
"     <b>",
"      Note:",
"     </b>",
"     Do not inject through pen marks (if proposed injection sites are marked with a pen); permanent tattooing effect may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Blepharospasm: Use a 26- to 30-gauge (37 mm length) needle for superficial muscles and a 22-gauge (75 mm length) needle for deeper musculature; electromyography guidance is unnecessary.  Avoid injecting near the levator palpebrae superioris (may decrease ptosis); avoid medial lower lid injections (may decrease diplopia). Apply pressure at the injection site to prevent ecchymosis in the soft eyelid tissues.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cervical dystonia: Use a 26- to 30-gauge (37 mm length) needle for superficial muscles and a 22-gauge (75 mm length) needle for deeper musculature; electromyography or nerve stimulation techniques may help localize the involved muscles. Number of injections per treatment depends on size of muscle to be treated and volume to be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reduction of glabellar lines: Use a 30- to 33-gauge (13 mm length) needle.  To reduce ptosis, corrugator injections should be &ge;1 cm above the bony supraorbital ridge and injections near the levator palpebrae superioris should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spasticity of upper limb: Use a 26-gauge (37 mm length) needle for superficial muscles and a 22-gauge (75 mm length) needle for deeper musculature; electromyography or nerve stimulation may help localize the involved muscles.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10493111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Treatment of blepharospasm in patients previously treated with onabotulinumtoxinA (Botox&reg;); treatment of cervical dystonia in botulinum toxin-na&iuml;ve and previously treated patients; temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Xeomin&reg;: Treatment of hypertonicity disorders of the seventh nerve (eg, blepharospasm, hemifacial spasm); treatment of poststroke spasticity of upper limb(s); treatment of cervical dystonia (spasmodic torticollis)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     Xeomin Cosmetic&trade;: Temporary improvement in the appearance of moderate-to-severe glabellar lines",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10493106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Botulinum products are not interchangeable; potency differences may exist between the products.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10826879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dysphagia (cervical dystonia 13% to 18%), xerostomia (blepharospasm 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscular weakness (cervical dystonia 7% to 11%), neck pain (cervical dystonia 7% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Eyelid ptosis (blepharospasm 19%; reduction of glabellar lines &lt;1%), dry eye (blepharospasm 16%), vision impaired (blepharospasm 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (blepharospasm 7%; reduction of glabellar lines 5%, poststroke spasticity [Canadian labeling] 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (blepharospasm 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site pain (cervical dystonia 4% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Pain (cervical dystonia 4% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (blepharospasm 5%), nasopharyngitis (blepharospasm 5%), respiratory tract infection (blepharospasm 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Neutralizing antibody formation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Any indication: Abdominal distension, abnormal dreams, allergic dermatitis, allergic reactions, alopecia, anaphylaxis, asthma, aspiration pneumonia, blepharospasm, blurred vision, cardiovascular insufficiency, circulatory collapse, colitis, conjunctivitis, corneal perforation, cough, diaphoresis, diplopia, dysarthria, dysphonia, edema, erythema, eye edema, eye pain, eyelid ecchymosis, eyelid edema, facial pain, facial paresis, fatigue, herpes zoster, hypersensitivity, injection site hematoma, injection site inflammation, injection site reaction, lymphadenopathy, madarosis, muscle spasm, myalgia, nausea, paresthesia, peripheral edema, pruritus, rash, reduced blinking leading to corneal ulceration, respiratory failure, serum sickness, soft tissue edema, somnolence, tremor, trismus, urinary incontinence, urticaria, vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10826173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to botulinum toxin, or any component of the formulation; infection at the proposed injection site(s)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Generalized disorders of muscle activity (eg, myasthenia gravis, Lambert-Eaton syndrome)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10826174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions may occur; discontinue therapy immediately with signs/symptoms of hypersensitivity. Immediate medical treatment should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antibody formation: Higher doses, more frequent administration and/or onset of disease at a younger age may result in neutralizing antibody formation and loss of efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular events: Rarely, arrhythmia and myocardial infarction have been reported with use of another botulinum toxin product, sometimes in patients with preexisting cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dysphagia: Common when used for cervical dystonia; may occur within hours to weeks and persist for several months after administration. In severe cases, patients may require alternative feeding methods. Risk factors include smaller neck muscle mass and bilateral injections into the sternocleidomastoid muscle. Incidence of dysphagia may be reduced by limiting dose administered into sternocleidomastoid muscle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hematologic: Use with caution in patients with bleeding disorders and/or receiving anticoagulation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Systemic toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Distant spread of botulinum toxin beyond the site of injection has been reported; dysphagia and breathing difficulties have occurred and may be life threatening; other symptoms reported include blurred vision, diplopia, dysarthria, dysphonia, generalized muscle weakness, ptosis, and urinary incontinence which may develop within hours or weeks following injection.",
"     </b>",
"     The risk is likely greatest in children treated for the unapproved use of spasticity. Systemic effects have occurred following use in approved and unapproved uses, including low doses. Use caution in patients with underlying conditions which may predispose them to these symptoms. Immediate medical attention required if respiratory, speech, or swallowing difficulties appear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neuromuscular disease: Use with caution in patients with neuromuscular diseases such as myasthenia gravis or Lambert- Eaton syndrome (contraindicated in Canadian labeling) and neuropathic disorders (such as amyotrophic lateral sclerosis). Risk of adverse events including severe dysphagia and respiratory compromise may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular diseases: Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration when treating blepharospasm. Careful testing of corneal sensation, avoidance of lower lid injections to prevent ectropion, and treatment of epithelial defects are necessary. Therapeutic soft contact lenses, application of protective drops or ointment, or covering the affected eye may help. Gentle pressure at injection site may limit bruising of eyelid. Use caution in patients with angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Respiratory disease: Use extreme caution in patients with pre-existing respiratory disease; treatment of cervical dystonia using botulinum toxin may weaken accessory muscles that are necessary for these patients to maintain adequate ventilation. Risk of aspiration resulting from severe dysphagia is increased in patients with decreased respiratory function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neuromuscular transmission: Use with extreme caution in patients receiving other agents that may interfere with neuromuscular transmission (eg, aminoglycosides, neuromuscular-blocking agents)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Albumin: Product contains albumin and may carry a remote risk of virus transmission.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Product interchangeability: Botulinum products (incobotulinumtoxinA, abobotulinumtoxinA, onabotulinumtoxinA, rimabotulinumtoxinB) are not interchangeable; potency units are specific to each preparation and cannot be compared or converted to any other botulinum product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chronic therapy: Long-term effects of chronic therapy unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hazardous tasks: May impair ability to drive and/or operate machinery due to the intended effects of treatment; if loss of strength, muscle weakness, or impaired vision occur, patients should avoid driving or engaging in other hazardous activities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Injection site: Use with caution if there is excessive weakness or atrophy at the proposed injection site(s); use is contraindicated if infection is present.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10826170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10826171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased fetal body weight, delayed ossification, maternal toxicity, abortions, and fetal malformations were observed in animal reproduction studies. Use during pregnancy only if benefits outweigh potential risks to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10826172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Xeomin Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 unit (1): $255.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 unit (1): $510.00",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10827022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     IncobotulinumtoxinA is a neurotoxin produced from",
"     <i>",
"      Clostridium botulinum",
"     </i>",
"     that inhibits acetylcholine release from peripheral cholinergic nerve endings. Inhibition occurs sequentially via binding and internalization of the neurotoxin into presynaptic cholinergic nerve terminals, translocation to the nerve terminal cytosol, and enzymatic cleavage of SNAP25, a protein necessary for acetylcholine release. Inhibition of acetylcholine release at the neuromuscular junction produces a state of denervation. Muscle inactivation persists until new fibrils grow from the nerve and form junction plates on new areas of the muscle-cell walls.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10827164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action (improvement): ~4-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: ~3-4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Not expected to be present in peripheral blood at recommended doses following I.M. injection",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Benecke R, Jost WH, Kanovsky P, et al, &ldquo;A New Botulinum Toxin Type A Free of Complexing Proteins for Treatment of Dystonia,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2005, 64(11):1949-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/48/43781/abstract-text/15955951/pubmed\" id=\"15955951\" target=\"_blank\">",
"        15955951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jankovic J, &ldquo;Clinical Efficacy and Tolerability of Xeomin in the Treatment of Blepharospasm,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2009, 16 (Suppl 2):14-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/48/43781/abstract-text/20002742/pubmed\" id=\"20002742\" target=\"_blank\">",
"        20002742",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kanovsky P, Slawek J, Denes Z, et al, &ldquo;Efficacy and Safety of Botulinum Neurotoxin NT 201 in Poststroke Upper Limb Spasticity,&rdquo;",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 2009, 32(5):259-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/48/43781/abstract-text/19644361/pubmed\" id=\"19644361\" target=\"_blank\">",
"        19644361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15586 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-DB96A30595-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43781=[""].join("\n");
var outline_f42_48_43781=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10826166\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10894929\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10826168\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493109\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10827173\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10827175\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10827171\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10827170\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10894930\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16124978\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10826169\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10826167\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10827176\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493111\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493106\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10826879\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10826173\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10826174\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10826170\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10826171\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10826172\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322861\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10827022\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10827164\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15586\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15586|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/7/4213?source=related_link\">",
"      IncobotulinumtoxinA (botulinum toxin type A, Xeomin): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_48_43782="Anatomy choanal atresia";
var content_f42_48_43782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50816%7EPEDS%2F79734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50816%7EPEDS%2F79734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomic section of choanal atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomic section of bilateral choanal atresia, the obliteration or blockage of the posterior nasal aperture.",
"    <div class=\"footnotes\">",
"     *: choanae, u: uvula.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic view of choanal atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     mt: middle turbinate; it: inferior turbinate; ns: nasal septum; a: atresia \"plate\".",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43782=[""].join("\n");
var outline_f42_48_43782=null;
var title_f42_48_43783="Effect of antidepressants on suicide risk in adults";
var content_f42_48_43783=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Effect of antidepressants on suicide risk in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/48/43783/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/48/43783/contributors\">",
"     Gregory Simon, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/48/43783/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/48/43783/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/48/43783/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/48/43783/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/48/43783/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15733973\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants are efficacious for treating depressed patients, especially patients who are severely ill and may be at greater risk for suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, all antidepressants in the United States currently carry a warning that they are associated with an increased risk of suicidality in adults aged 18 to 24 years during initial treatment (generally the first one to two months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/4\">",
"     4",
"    </a>",
"    ]. Suicidality includes suicidal ideation, action to prepare for an attempt, attempt or nonfatal self-harm, or death. The warning also applies to children and adolescents.",
"   </p>",
"   <p>",
"    The warnings issued in the United States and other countries appear to have significantly reduced both rates of diagnosing depression and antidepressant treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/4-8\">",
"     4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews whether antidepressants affect the risk of suicidality in adults. The effect of antidepressants on suicide risk in children and adolescents, risk factors and management of suicidality in adults, and the pharmacology and use of antidepressants to treat depression are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15736?source=see_link\">",
"       \"Effect of antidepressants on suicide risk in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=see_link\">",
"       \"Suicidal ideation and behavior in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"       \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"       \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=see_link\">",
"       \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16005408\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1990, concerns were first raised about antidepressants precipitating suicidality (ie, suicidal ideation, action to prepare for an attempt, attempt or nonfatal self-harm, or death). At that time, case-reports described patients who developed intense suicidal ideation during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , a selective serotonin reuptake inhibitor (SSRI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/9\">",
"     9",
"    </a>",
"    ]. The manufacturer of fluoxetine subsequently performed a meta-analysis of 17 randomized trials (3065 patients with major depression) and found that the pooled incidence of the combined outcome of preparatory acts, non-fatal self harm, or death did not differ significantly between patients who received fluoxetine or placebo (0.3 versus 0.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, baseline suicidal ideation improved significantly more with fluoxetine than placebo (72 versus 55 percent).",
"   </p>",
"   <p>",
"    Concerns about antidepressants and suicidality re-emerged in 2003 when the US Food and Drug Administration (FDA) issued an advisory in response to numerous reports of suicidal ideation, suicide attempts, and suicide deaths in clinical trials of antidepressants in pediatric patients with unipolar major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. In 2004, the FDA re-examined data from pediatric randomized trials of the antidepressant drugs",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    . The analyses suggested an increased risk of suicidal ideation, preparatory acts for self-harm, or nonfatal self-harm occurring during the first weeks of treatment with an antidepressant, compared with placebo. As a result, the FDA elevated the advisory and issued a warning regarding emergence of suicidality in children and adolescents starting antidepressant treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/4,12\">",
"     4,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FDA issued an advisory in 2005 about suicidality in adults treated with antidepressant drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/4\">",
"     4",
"    </a>",
"    ]. In 2007, the FDA extended the 2004 warning about antidepressant drugs and suicidality to include adults aged 18 to 24 years and all antidepressant drugs. The warning issued in 2007 did not advise against the prescription of antidepressants for approved indications, including depressive and anxiety disorders. Instead, the warning emphasized that:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients 18 to 24 years of age should be informed about the risk of developing suicidality during initial antidepressant treatment (generally the first one to two months)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinicians should monitor patients closely during initial antidepressant treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depression and certain other serious psychiatric disorders are themselves associated with an increased risk of suicidality",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    FDA advisories and warnings (and regulatory agency warnings in other countries) appear to have significantly reduced rates of antidepressant treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Rates of antidepressant use increased steadily during the several years prior to these warnings. This trend reversed after the FDA advisory in 2003, and antidepressant prescription rates decreased from 2003 to 2007. As an example, analysis of a national database of 55 million patients from 1999 through 2007 found that prescriptions for SSRIs fell 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, rates of diagnosing depression also declined.",
"   </p>",
"   <p>",
"    Although the risk of suicidality posed by antidepressants remains in question, there is no doubt about the risk of suicidality in untreated depressed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/13\">",
"     13",
"    </a>",
"    ]. As an example, an observational study of 186 depressed patients followed for up to 38 years found that 14 percent committed suicide, which was 27 times greater than the rate in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, treatment with an antidepressant was associated with a significantly lower rate of suicide mortality.",
"   </p>",
"   <p>",
"    There is no evidence that more frequent contact between clinicians and depressed patients reduces the risk of suicide attempt or suicide death. However, there is evidence that symptoms of depression are significantly less in patients who receive follow-up care, compared with patients who do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/15\">",
"     15",
"    </a>",
"    ]. Unfortunately, advisories and warnings about the need for more frequent monitoring do not seem to have increased the low rate of follow-up care during antidepressant treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16005416\">",
"    <span class=\"h1\">",
"     EVIDENCE REVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear evidence that treatment of depressed patients with antidepressant drugs increases risk of suicidality (ie, suicidal ideation, action to prepare for an attempt, attempt or nonfatal self-harm, or death) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]. However, there may be an age-specific effect, such that antidepressants may raise the risk of suicide attempts (nonfatal self-harm) or preparatory acts in patients aged 18 to 24 years during the first several weeks of treatment, have no effect upon patients aged 25 to 30 years, and may lower the risk in patients 31 years and older. It is not known whether there are other sociodemographic or clinical factors associated with risk of suicidality in patients treated with antidepressants. In addition, it is not known whether specific antidepressant drugs differ in their risk of suicidality, or how polypharmacy affects the risk.",
"   </p>",
"   <p>",
"    Several methodologic issues make it difficult to answer the question of whether antidepressants cause suicidality. The associations between depression and use of antidepressants and between depression and suicidality potentially confound the results of studies that examine the association between antidepressants and suicidality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/18\">",
"     18",
"    </a>",
"    ]. Another issue is the reliability of classifying certain events or behavior as suicide attempts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three types of studies have examined the association between antidepressants and suicidality. In order of quality, these are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Randomized trials (including meta-analyses)",
"     </li>",
"     <li>",
"      Observational studies (including meta-analyses)",
"     </li>",
"     <li>",
"      Ecological studies (these use community-level, epidemiologic data rather than individual-level data) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16005453\">",
"    <span class=\"h2\">",
"     Randomized trials",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1290542\">",
"    <span class=\"h3\">",
"     Suicide deaths",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three independent analyses combined data from placebo-controlled efficacy trials of various antidepressants to examine risk of suicide death during antidepressant treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Each analysis found no evidence for higher or lower risk of suicide death during acute-phase treatment with antidepressants compared to risk during treatment with a placebo.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 342 randomized trials (40,826 patients) found no significant difference in suicide deaths for patients treated with an SSRI compared with patients treated with placebo (0.04 versus 0.04 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of 207 randomized trials (40,028 patients) found no significant difference in suicide deaths for patients treated with an antidepressant compared with patients treated with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A secondary analysis of 48,277 depressed patients found no significant difference in suicide deaths for patients treated with an SSRI, a non-SSRI antidepressant, or placebo (0.15 versus 0.20 versus 0.10 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that the data used in these analyses were often overlapping, rather than independent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22905832\">",
"    <span class=\"h3\">",
"     New onset of suicidal behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four analyses of data from randomized trials suggested that treatment with antidepressants was associated with an increased risk of nonfatal self-harm (attempt) or preparatory acts, compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/22,24-26\">",
"     22,24-26",
"    </a>",
"    ]. The increased risk appeared to reside primarily in patients under the age of 25 years.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two meta-analyses (40,826 and 36,445 patients) focused on SSRI antidepressants and found that the risk of nonfatal self-harm was 1.6 to 2.3 times higher during the first weeks of SSRI treatment compared to treatment with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/22,24\">",
"       22,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis (5433 patients) conducted by the manufacturer of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      found that nonfatal self-harm occurred in significantly more patients who received paroxetine compared with patients who received placebo (11 versus 1 patient) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/26\">",
"       26",
"      </a>",
"      ]. Of the 11 cases of nonfatal self-harm that occurred with paroxetine, 8 were in patients aged 18 to 30 years.",
"     </li>",
"     <li>",
"      A meta-analysis (372 trials, 99,231 patients) found the relative odds of nonfatal self-harm and preparatory acts varied by age. Compared to the risk during placebo treatment, the risk of nonfatal self-harm and preparatory acts during antidepressant treatment was [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/25\">",
"       25",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      More than twice as high in patients under age 25 years (absolute difference approximately 4 per 1000 patients)",
"     </li>",
"     <li>",
"      Approximately equal in patients aged 25 to 64 years",
"     </li>",
"     <li>",
"      Approximately half as high in those aged 65 or more years (absolute difference approximately 3 per 1000 patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the higher frequency of suicide attempts than suicide deaths, these analyses had adequate statistical power to detect effects of treatment with antidepressants overall or with a commonly used class of drugs (such as SSRIs). It appears that there is no difference in risk of suicide attempts among different classes of antidepressants. (See",
"    <a class=\"local\" href=\"#H1366246\">",
"     'Differences among antidepressant classes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The analyses did not have adequate power to either detect or exclude even relatively large effects of individual antidepressant drugs. In addition, data from these trials could not be used examine the effect of antidepressants on reducing baseline nonfatal self-harm or preparatory acts, because patients with such behavior were typically excluded from such trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86962249\">",
"    <span class=\"h4\">",
"     Suicidality and age",
"    </span>",
"    &nbsp;&mdash;&nbsp;New onset of suicidality (suicidal ideation, preparatory act, nonfatal self-harm or attempt, or death) was evaluated in separate meta-analyses of randomized trials in adults as well as children and adolescents. Taken together, the findings showed a convincing trend of increasing risk in younger age groups, and decreasing risk in older adults (",
"    <a class=\"graphic graphic_figure graphicRef63706 \" href=\"mobipreview.htm?29/15/29949\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]. The pattern is striking, though in itself does not constitute proof:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Children and adolescents: &nbsp; &nbsp;OR 2.22 (95% CI 1.40-3.60)",
"     </li>",
"     <li>",
"      18 to 24 years: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; OR 1.55 (0.91-2.70)",
"     </li>",
"     <li>",
"      25 to 30 years: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; OR 1.00 (0.60-1.69)",
"     </li>",
"     <li>",
"      31 to 64 years: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; OR 0.77 (0.60-1.00)",
"     </li>",
"     <li>",
"      &ge; 65 years: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;OR 0.39 (0.18-0.78)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of individual drugs show a similar trend of increasing risk with younger age. As an example, a meta-analysis of 61 randomized trials (14,911 adult patients with various psychiatric disorders) found that suicidality did not differ significantly between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    compared with placebo (0.9 versus 1.1 percent of patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/27\">",
"     27",
"    </a>",
"    ]. However, a separate analysis of adults aged 18 to 24 years found a non-significant, two-fold increase in suicidality with paroxetine compared with placebo (2.6 versus 1.3 percent of patients; OR 2.0, 95% CI 0.8-4.8). By contrast, the analysis of adults aged 25 to 64 years found a non-significant decrease in suicidality with paroxetine compared with placebo (0.8 versus 1.1 percent of patients; OR 0.7, 95% CI 0.5-1.0).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22905840\">",
"    <span class=\"h3\">",
"     Reduction of existing suicidal ideation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with suicidal ideation at the start of treatment, antidepressants may reduce thoughts of death or suicide. A meta-analysis of 16 randomized trials (8477 adults with major depression) found that suicidal thoughts and behavior decreased significantly more with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    , than with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/28\">",
"     28",
"    </a>",
"    ]. The effect appeared to be mediated by decreases in depressive symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25680582\">",
"    <span class=\"h3\">",
"     Methodologic issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence available for examining whether antidepressants cause suicidality is imperfect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/20\">",
"     20",
"    </a>",
"    ]. The highest quality of existing evidence consists of meta-analyses of data from secondary analyses of randomized efficacy trials.",
"   </p>",
"   <p>",
"    The question about whether antidepressants precipitate suicidality should ideally be answered with placebo-controlled trials specifically designed to address this issue. However, no such trials exist and it would not be feasible to assign depressed patients to a long-term placebo arm. Instead, we must rely upon secondary analyses of trials designed to evaluate clinical efficacy and medical adverse events. Our ability to answer the question with these analyses is restricted by certain factors. First, patients at high risk for suicide attempts are typically excluded from such trials (limiting external validity or generalizability) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, data from such trials are limited in their capacity to detect change in suicidality and in addition, cannot address the patients about whom we are most concerned. A second limitation of existing trials is that assessments were not designed to identify emergence or worsening of suicidal ideation. Consequently, re-analyses of those data depend on post-hoc classification of measurements intended for a different purpose. Third, although most trials involved patients with depression, some trials involved other psychiatric illnesses, such as anxiety disorders. Fourth, trials were short-term in duration, lasting approximately six to eight weeks.",
"   </p>",
"   <p>",
"    Suicide deaths are relatively rare events in randomized trials, and there were typically fewer than 100 completed suicides for all drugs and placebo combined in the meta-analyses. Although the analyses included hundreds of trials and tens of thousands of patients, statistical power to detect differences in suicide mortality rates was modest. Thus, none of the analyses could rule out relatively large (ie, three- or fourfold) increases or decreases in risk of suicide mortality during antidepressant treatment compared with placebo. In addition, randomized trials will most likely never have sufficient statistical power to examine suicide mortality with specific antidepressant drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16005466\">",
"    <span class=\"h2\">",
"     Observational studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cohort and case-control (observational) studies suggest that treatment of depressed patients with an SSRI is associated with fewer suicide attempts or suicide deaths, compared with no treatment with an antidepressant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. In addition, symptom severity and the rate of suicide attempts appear to be higher during the time period preceding antidepressant treatment, compared with post-treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25680519\">",
"    <span class=\"h3\">",
"     Suicide death or attempt",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of eight observational studies (265,889 depressed patients treated with an SSRI) found that use of an SSRI was associated with a decreased risk of suicide death or attempt, compared with no antidepressant treatment in controls (OR 0.6, 95% CI 0.5-0.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/29\">",
"     29",
"    </a>",
"    ]. The protective effect was larger in patients aged 65 years or more (OR 0.5).",
"   </p>",
"   <p>",
"    Data from a health plan serving approximately 500,000 patients showed that suicide attempts were higher in the month before starting antidepressant medication and declined after starting medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The same pattern was observed in another cohort of more than 200,000 depressed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study followed 757 patients with major depressive disorder, bipolar disorder, or schizoaffective disorder for up to 27 years with annual assessments. Although treatment with antidepressants was significantly more likely when symptom severity was greater or worsening, antidepressant therapy was associated with a 20 percent reduction in risk of suicide attempts or suicide deaths (hazard ratio 0.80; 95% CI 0.68-0.95) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One cohort study including outpatients treated with various antidepressants or psychotherapy found a gradient of increasing risk of suicide attempt: lowest in patients treated with antidepressants in primary care, intermediate in patients treated with psychotherapy, and highest in patients treated with antidepressants in specialty mental health clinics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/30\">",
"     30",
"    </a>",
"    ]. This pattern suggests that differences in risk more likely reflect confounding by indication (ie, higher risk patients are more likely to receive specialty treatment) than a true effect of specific treatments on risk of suicide attempt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25680618\">",
"    <span class=\"h3\">",
"     Methodologic problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative strengths and weaknesses of large observational studies are opposite those of randomized trials. Data from large population-based samples increase statistical power and maximize generalizability. However, nonrandom assignment of treatments introduces bias and threatens internal validity, especially if treatment decisions (such as the decision to prescribe an antidepressant or the choice of specific antidepressant) are influenced by clinical characteristics related to risk of suicidality. As an example, SSRIs are safer in overdose than tricyclic antidepressants, and clinicians may thus be more likely to prescribe an SSRI to patients who present with suicidality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1290505\">",
"    <span class=\"h2\">",
"     Ecological studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ecological studies used community-level, epidemiologic data to examine whether variation in rates of antidepressant use (either between areas or over time) were associated with variation in suicide deaths. Most studies found that higher rates of antidepressant use were associated with lower rates of suicide death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cross-sectional analysis of county-level data from the United States found that use of either an SSRI or other antidepressant (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ) were each associated with lower suicide mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increase of antidepressant use by 161 percent over a seven year period in a district of Sweden was accompanied by a 36 percent decrease in the rate of suicide death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Analyses of time trends prior to the FDA warnings found that increasing rates of antidepressant use in England and Japan were accompanied by declines in suicide mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/35,36\">",
"       35,36",
"      </a>",
"      ] .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These ecological studies cannot determine whether differences in suicide deaths are the direct result of differences in antidepressant use or whether differences in antidepressant use are simply a marker for other &ldquo;true&rdquo; causes of lower suicide rates (such as better recognition and treatment of depression).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1366246\">",
"    <span class=\"h2\">",
"     Differences among antidepressant classes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern about antidepressants and suicidality were first raised in regard to the SSRI",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/9\">",
"     9",
"    </a>",
"    ], and the FDA warning about antidepressants and suicidality initially focused upon SSRIs and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/12\">",
"     12",
"    </a>",
"    ]. However, most randomized trials and observational studies suggest that there is no difference in risk of suicidality among different classes of antidepressants, including SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), and other antidepressants (bupropion, mirtazapine, and nefazodone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/10,21\">",
"     10,21",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of randomized trials found that the risk of nonfatal self-harm was comparable for SSRIs and tricyclic antidepressants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple observational studies from different countries have found a similar risk of suicide deaths and attempts associated with different classes of antidepressants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43783/abstract/38-42\">",
"       38-42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16005424\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The FDA issued a warning in 2007 that patients aged 18 to 24 years should be informed about the risk of becoming suicidal during initial treatment with any antidepressant drug, that clinicians should monitor patients closely during initial antidepressant treatment, and that depression and certain other serious psychiatric disorders are themselves associated with an increased risk of suicide. The warning does not advise against the use of antidepressants for approved indications, including depressive and anxiety disorders. (See",
"      <a class=\"local\" href=\"#H16005408\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no clear evidence that antidepressant treatment of depressed patients increases the risk of suicidality (suicidal ideation, action to prepare for an attempt, attempt or nonfatal self-harm, or death). Randomized trials suggest that antidepressants may possibly reduce suicidality; observational and ecological studies show an association between greater antidepressant use and decreased suicide attempts and suicide deaths. (See",
"      <a class=\"local\" href=\"#H16005416\">",
"       'Evidence review'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Available evidence strongly suggests an age-specific effect of antidepressants and risk of suicidality. Among young adults (and children and adolescents), onset of suicidality is significantly greater compared with placebo, during at least the first few weeks of antidepressant treatment. The absolute difference is approximately four patients per 1000. However, the same evidence shows no detectable effect of antidepressant treatment on suicidality in middle-aged adults, and suggests a protective effect (lower risk of suicidality with antidepressant medication than with placebo) among older adults. (See",
"      <a class=\"local\" href=\"#H86962249\">",
"       'Suicidality and age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The small risk of suicidality in young adults associated with antidepressants needs to be balanced against the clear risk of suicidality associated with depressive syndromes. (See",
"      <a class=\"local\" href=\"#H16005408\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials and most observational studies suggest there is no difference in risk of suicidality among different classes of antidepressants, including SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), and other antidepressants. Available evidence is not adequate to determine the risk associated with a specific antidepressant drug. (See",
"      <a class=\"local\" href=\"#H1366246\">",
"       'Differences among antidepressant classes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based upon our review of the evidence and our clinical experience, we believe it is prudent for clinicians to warn young depressed adults starting any antidepressant about the possible emergence of suicidality, to encourage all patients to quickly contact their clinician if they suffer new onset or worsening suicidality, and to evaluate any patient with suicidality every one or two weeks. In addition, all patients initiating antidepressant therapy should receive follow-up within two to four weeks. (See",
"      <a class=\"local\" href=\"#H16005408\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/1\">",
"      Williams JW Jr, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/2\">",
"      Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/3\">",
"      Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008; 149:734.",
"     </a>",
"    </li>",
"    <li>",
"     Antidepressant Use in Children, Adolescents, and Adults file://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm096273.htm (Accessed on October 05, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/5\">",
"      Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009; 66:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/6\">",
"      Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/7\">",
"      Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008; 178:1005.",
"     </a>",
"    </li>",
"    <li>",
"     MHRA (2004). Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants file://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf (Accessed on October 06, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/9\">",
"      Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/10\">",
"      Beasley CM Jr, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303:685.",
"     </a>",
"    </li>",
"    <li>",
"     Reports of Suicidality in Pediatric Patients Being Treated with Antidepressant Medications for Major Depressive Disorder (MDD)",
"October 27, 2003 ",
" file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm168828.htm (Accessed on October 05, 2010).",
"    </li>",
"    <li>",
"     Worsening Depression and Suicidality in Patients Being Treated With Antidepressants",
"March 22, 2004",
" file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161696.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/13\">",
"      Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med 2007; 356:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/14\">",
"      Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/15\">",
"      Gilbody S, Bower P, Fletcher J, et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med 2006; 166:2314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/16\">",
"      Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008; 165:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/17\">",
"      Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. Am J Psychiatry 2007; 164:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/18\">",
"      Wessely S, Kerwin R. Suicide risk and the SSRIs. JAMA 2004; 292:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/19\">",
"      Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007; 164:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/20\">",
"      Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003; 72:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/21\">",
"      Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/22\">",
"      Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005; 330:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/23\">",
"      Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006; 26:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/24\">",
"      Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/25\">",
"      Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009; 339:b2880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/26\">",
"      Kraus JE, Horrigan JP, Carpenter DJ, et al. Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. J Affect Disord 2010; 120:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/27\">",
"      Carpenter DJ, Fong R, Kraus JE, et al. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. J Clin Psychiatry 2011; 72:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/28\">",
"      Gibbons RD, Brown CH, Hur K, et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/29\">",
"      Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 2009; 180:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/30\">",
"      Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 2007; 164:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/31\">",
"      Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/32\">",
"      Gibbons RD, Brown CH, Hur K, et al. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry 2007; 164:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/33\">",
"      Leon AC, Solomon DA, Li C, et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry 2011; 72:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/34\">",
"      Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/35\">",
"      Morgan OW, Griffiths C, Majeed A. Association between mortality from suicide in England and antidepressant prescribing: an ecological study. BMC Public Health 2004; 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/36\">",
"      Nakagawa A, Grunebaum MF, Ellis SP, et al. Association of suicide and antidepressant prescription rates in Japan, 1999-2003. J Clin Psychiatry 2007; 68:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/37\">",
"      Henriksson S, Isacsson G. Increased antidepressant use and fewer suicides in J&auml;mtland county, Sweden, after a primary care educational programme on the treatment of depression. Acta Psychiatr Scand 2006; 114:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/38\">",
"      Schneeweiss S, Patrick AR, Solomon DH, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry 2010; 67:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/39\">",
"      S&oslash;nderg&aring;rd L, Lopez AG, Andersen PK, Kessing LV. Continued antidepressant treatment and suicide in patients with depressive disorder. Arch Suicide Res 2007; 11:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/40\">",
"      Tiihonen J, L&ouml;nnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006; 63:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/41\">",
"      Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43783/abstract/42\">",
"      Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292:338.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14672 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7EC3A6EE76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43783=[""].join("\n");
var outline_f42_48_43783=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16005424\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15733973\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16005408\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16005416\">",
"      EVIDENCE REVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16005453\">",
"      Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1290542\">",
"      - Suicide deaths",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22905832\">",
"      - New onset of suicidal behavior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H86962249\">",
"      Suicidality and age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22905840\">",
"      - Reduction of existing suicidal ideation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25680582\">",
"      - Methodologic issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16005466\">",
"      Observational studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25680519\">",
"      - Suicide death or attempt",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25680618\">",
"      - Methodologic problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1290505\">",
"      Ecological studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1366246\">",
"      Differences among antidepressant classes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16005424\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14672\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14672|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/15/29949\" title=\"figure 1\">",
"      Age-specific odds ratios for suicidal ideation and behavior",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15736?source=related_link\">",
"      Effect of antidepressants on suicide risk in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_48_43784="Modes of mechanical ventilation";
var content_f42_48_43784=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Modes of mechanical ventilation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/48/43784/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/48/43784/contributors\">",
"     Robert C Hyzy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/48/43784/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/48/43784/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/48/43784/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/48/43784/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/48/43784/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous decisions need to be made once it is determined that a patient requires mechanical ventilation, including the mode of mechanical ventilation. The mode refers to the method of inspiratory support. Its selection is generally based on clinician familiarity and institutional preferences since there is a paucity of evidence indicating that the mode affects clinical outcome.",
"   </p>",
"   <p>",
"    Common modes of mechanical ventilation are described in this topic review (",
"    <a class=\"graphic graphic_table graphicRef77391 \" href=\"mobipreview.htm?19/30/19949\">",
"     table 1",
"    </a>",
"    ). Other aspects of initiating mechanical ventilation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VOLUME-LIMITED VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume-limited ventilation (also called volume-controlled or volume-cycled ventilation) requires the clinician to set the peak flow rate, flow pattern, tidal volume, respiratory rate, positive end-expiratory pressure (applied PEEP), and fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ). Inspiration ends after delivery of the set tidal volume.",
"   </p>",
"   <p>",
"    The inspiratory time and inspiratory to expiratory (I:E) ratio are determined by the peak inspiratory flow rate. Increasing the peak inspiratory flow rate will decrease inspiratory time, increase expiratory time, and decrease the I:E ratio.",
"   </p>",
"   <p>",
"    Airway pressures (peak, plateau, and mean) depend on both the ventilator settings and patient-related variables (eg, compliance, airway resistance). High airway pressures may be a consequence of large tidal volumes, a high peak flow, poor compliance (eg, acute respiratory distress syndrome, minimal sedation), or increased airway resistance (",
"    <a class=\"graphic graphic_figure graphicRef50556 \" href=\"mobipreview.htm?17/43/18110\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef75686 \" href=\"mobipreview.htm?29/53/30557\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Modes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume-limited ventilation can be delivered via several modes, including controlled mechanical ventilation (CMV), assist control (AC), intermittent mandatory ventilation (IMV), and synchronized intermittent mandatory ventilation (SIMV) (",
"    <a class=\"graphic graphic_table graphicRef77391 \" href=\"mobipreview.htm?19/30/19949\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     CMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;During CMV, the minute ventilation is determined entirely by the set respiratory rate and tidal volume. The patient does not initiate additional minute ventilation above that set on the ventilator. This may be due to pharmacologic paralysis, heavy sedation, coma, or lack of incentive to increase the minute ventilation because the set minute ventilation meets or exceeds physiologic need. CMV does not require any patient work.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     AC",
"    </span>",
"    &nbsp;&mdash;&nbsp;During AC, the clinician determines the minimal minute ventilation by setting the respiratory rate and tidal volume. The patient can increase the minute ventilation by triggering additional breaths. Each patient-initiated breath receives the set tidal volume from the ventilator.",
"   </p>",
"   <p>",
"    Consider the following example. If the clinician sets the respiratory rate to 20 breaths per minute and the tidal volume to 500 mL, the lowest possible minute ventilation is 10 L per minute (20 breaths per minute times 500 mL per breath). If the patient triggers an additional 5 breaths beyond the preset 20 breaths, the ventilator will deliver 500 mL for each additional breath and the minute ventilation will be 12.5 L per minute (25 breaths per minute times 500 mL per breath).",
"   </p>",
"   <p>",
"    Pressure regulated volume control (PRVC) is similar to AC. The main difference is that the ventilator is able to autoregulate the inspiratory time and flow so that the tidal volume generates a smaller rise in the plateau airway pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     IMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;IMV is similar to AC in two ways: the clinician determines the minimal minute ventilation (by setting the respiratory rate and tidal volume) and the patient is able to increase the minute ventilation. However, IMV differs from AC in the way that the minute ventilation is increased. Specifically, patients increase the minute ventilation by spontaneous breathing, rather than patient-initiated ventilator breaths.",
"   </p>",
"   <p>",
"    Consider the following example. If the clinician sets the respiratory rate to 10 breaths per minute and the tidal volume to 500 mL per breath, the lowest possible minute ventilation is 5 L per minute (10 breaths per minute times 500 mL per breath). If the patient initiates an additional 5 breaths beyond the preset 10 breaths, the tidal volume for each additional breath will be whatever size the patient is able to generate and the minute ventilation will be some amount greater than 5 L per minute. The precise minute ventilation depends on the size of the tidal volume for each spontaneous breath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     SIMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;SIMV is a variation of IMV, in which the ventilator breaths are synchronized with patient inspiratory effort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. SIMV (or IMV) can be used to titrate the level of ventilatory support over a wide range (",
"    <a class=\"graphic graphic_figure graphicRef64325 \" href=\"mobipreview.htm?9/53/10078\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/3\">",
"     3",
"    </a>",
"    ]. This is an advantage unique to these modes. Ventilatory support can range from full support (set respiratory rate is high enough that the patient does not overbreathe) to no ventilatory support (set respiratory rate is zero).",
"   </p>",
"   <p>",
"    The level of support may need to be modified if hemodynamic consequences of positive pressure ventilation develop. In one study, cardiac output, mean blood pressure, pulmonary capillary wedge pressure, and oxygen consumption were all better when the level of support provided by SIMV was less than 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26119?source=see_link&amp;anchor=H17#H17\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\", section on 'Hemodynamics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Comparisons",
"    </span>",
"    &nbsp;&mdash;&nbsp;SIMV and AC are the most frequently used forms of volume-limited mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/5\">",
"     5",
"    </a>",
"    ]. Possible advantages of SIMV compared to AC include better patient-ventilator synchrony, better preservation of respiratory muscle function, lower mean airway pressures, and greater control over the level of support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, auto-PEEP may be less likely with SIMV. In contrast, AC may be better suited for critically ill patients who require a constant tidal volume or full or near-maximal ventilatory support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PRESSURE-LIMITED VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure-limited ventilation (also called pressure-cycled ventilation) requires the clinician to set the inspiratory pressure level, I:E ratio, respiratory rate, applied PEEP, and FiO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Inspiration ends after delivery of the set inspiratory pressure.",
"   </p>",
"   <p>",
"    The tidal volume is variable during pressure-limited ventilation. It is related to inspiratory pressure level, compliance, airway resistance, and tubing resistance. Specifically, tidal volumes will be larger when the set inspiratory pressure level is high or there is good compliance, little airway resistance, or little resistance from the ventilator tubing.",
"   </p>",
"   <p>",
"    In contrast, the peak airway pressure is constant during pressure-limited ventilation. It is equal to the sum of the set inspiratory pressure level and the applied PEEP. As an example, a patient with a set inspiratory pressure level of 20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and an applied PEEP of 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O will have a peak airway pressure of 30 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O.",
"   </p>",
"   <p>",
"    Pressure-limited ventilation can be delivered using the same modes of ventilation that deliver volume-limited ventilation (",
"    <a class=\"graphic graphic_table graphicRef77391 \" href=\"mobipreview.htm?19/30/19949\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During pressure-limited CMV (also called pressure control ventilation), the minute ventilation is determined entirely by the set respiratory rate and inspiratory pressure level. The patient does not initiate additional minute ventilation above that set on the ventilator.",
"     </li>",
"     <li>",
"      During pressure-limited AC, the set respiratory rate and inspiratory pressure level determine the minimum minute ventilation. The patient is able to increase the minute ventilation by triggering additional ventilator-assisted, pressure-limited breaths.",
"     </li>",
"     <li>",
"      During pressure-limited IMV or SIMV, the set respiratory rate and inspiratory pressure level determine the minimum minute ventilation. The patient is able to increase the minute ventilation by initiating spontaneous breaths.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     VOLUME-LIMITED VERSUS PRESSURE-LIMITED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure-limited ventilation was compared to volume-limited ventilation in a randomized trial and several observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no statistically significant differences in mortality, oxygenation, or work of breathing",
"     </li>",
"     <li>",
"      Favoring pressure-limited ventilation, it was associated with lower peak airway pressures, a more homogeneous gas distribution (less regional alveolar overdistension), improved patient-ventilator synchrony, and earlier liberation from mechanical ventilation than volume-limited ventilation",
"     </li>",
"     <li>",
"      Favoring volume-limited ventilation, only it can guarantee a constant tidal volume, ensuring a minimum minute ventilation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies comparing pressure-limited and volume-limited ventilation used a square wave (constant flow) pattern for both modes. When volume-limited mechanical ventilation with a ramp wave (decelerating flow) pattern was compared to pressure-limited ventilation, lower peak airway pressures were no longer an advantage of pressure-limited ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PRESSURE SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure support ventilation (PSV) is a flow-limited mode of ventilation that delivers inspiratory pressure until the inspiratory flow decreases to a predetermined percentage of its peak value. This is usually 25 percent (",
"    <a class=\"graphic graphic_figure graphicRef67019 \" href=\"mobipreview.htm?41/14/42221\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For PSV, the clinician sets the pressure support level (inspiratory pressure level), applied PEEP, and FiO",
"    <sub>",
"     2",
"    </sub>",
"    . The patient must trigger each breath because there is no set respiratory rate. The tidal volume, respiratory rate, and minute ventilation are dependent on multiple factors, including the ventilator settings and patient-related variables (eg, compliance, sedation). In general, a high pressure support level results in large tidal volumes and a low respiratory rate.",
"   </p>",
"   <p>",
"    The work of breathing is inversely proportional to the pressure support level, provided that inspiratory flow is sufficient to meet patient demand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In other words, increasing the level of pressure support decreases the work of breathing. The work of breathing is also inversely proportional to the inspiratory flow rate. Increasing the inspiratory flow rate shortens the time until the maximal airway pressures are achieved, which decreases the work of breathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Potential uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSV seems particularly well suited for weaning from mechanical ventilation because it tends to be a comfortable mode, giving the patient greater control over the inspiratory flow rate and respiratory rate. However, clinical studies have failed to show that PSV improves weaning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14423?source=see_link&amp;anchor=H17990496#H17990496\">",
"     \"Methods of weaning from mechanical ventilation\", section on 'Choosing a weaning method'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PSV is frequently combined with SIMV. The ventilator delivers the set respiratory rate using SIMV, but patient-initiated breaths beyond the set respiratory rate are delivered using PSV. The purpose of adding PSV for patient-initiated breaths is to overcome the resistance of the endotracheal tube and ventilator circuit. The necessary level of pressure support is unknown and generally estimated. Resistance of the endotracheal tube is related to the tube diameter and inspiratory flow rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/16\">",
"     16",
"    </a>",
"    ]. With small endotracheal tubes (eg, &lt;7 mm), a pressure support level &ge;10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O may be needed to overcome the resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Levels of pressure support higher than that required to overcome resistance will augment tidal volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSV is poorly suited to provide full or near-full ventilatory support. The following characteristics of PSV are disadvantages in that setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each breath must be initiated by the patient. Central apnea may occur if the respiratory drive is depressed due to sedatives, critical illness, or hypocapnia due to excessive ventilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An adequate minute ventilation cannot be guaranteed because tidal volume and respiratory rate are variable.",
"     </li>",
"     <li>",
"      Ventilator asynchrony can occur when PSV is employed for full ventilatory support, potentially prolonging the duration of mechanical ventilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PSV is associated with poorer sleep than AC. Specifically, there is greater sleep fragmentation, less stage 1 and 2 non-rapid eye movement (NREM) sleep, more wakefulness during the first part of the night, and less stage 3 and 4 NREM sleep during the second part of the night [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Relatively high levels of pressure support (eg, &gt;20 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O) are required during full ventilatory support to prevent alveolar collapse (which can lead to cyclic atelectasis and ventilator-associated lung injury) and to attain a stable breathing pattern [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Such high levels of pressure support are not as comfortable as moderate levels (eg, 10 to 15 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16182?source=see_link\">",
"       \"Ventilator-associated lung injury\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While PSV is poorly suited to provide full or nearly full ventilatory support in general, it is a particularly poor choice for patients who also have increased airway resistance (eg, COPD or asthma exacerbation). Minute ventilation is more likely to be insufficient when airway resistance is high, which may be related to decreased airflow causing inspiration to be terminated after a smaller than optimal tidal volume has been delivered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In addition, PSV does little to decrease auto-PEEP, which can increase patient work and worsen respiratory muscle fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/28\">",
"     28",
"    </a>",
"    ]. Choosing a higher percentage of the peak inspiratory flow as the trigger to end inspiration may improve auto-PEEP slightly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/59/8120?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory failure complicating COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tube compensation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many ventilators can be set to a mode called automatic tube compensation. This mode is a type of PSV that applies a sufficient level of positive pressure to overcome the work of breathing imposed by the endotracheal tube, which can vary from breath to breath. Automatic tube compensation is often used for a spontaneous breathing trial. Patients who undergo a spontaneous breathing trial with automatic tube compensation are more likely to successfully tolerate their trial than those who receive continuous positive airway pressure alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, many ventilators have the option of combining automatic tube compensation with other modes, so that resistance of the endotracheal tube has no impact on ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CONTINUOUS POSITIVE AIRWAY PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous positive airway pressure (CPAP) refers to the delivery of a continuous level of positive airway pressure. It is functionally similar to PEEP. The ventilator does not cycle during CPAP, no additional pressure above the level of CPAP is provided, and patients must initiate all breaths.",
"   </p>",
"   <p>",
"    CPAP is most commonly used in the management of sleep related breathing disorders, cardiogenic pulmonary edema, and obesity hypoventilation syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=see_link\">",
"     \"Initiation of positive airway pressure therapy for obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link&amp;anchor=H16#H16\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'Cardiogenic pulmonary edema'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/5/12375?source=see_link\">",
"     \"Noninvasive positive pressure therapy of the obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     BILEVEL POSITIVE AIRWAY PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilevel positive airway pressure (BPAP) is a mode used during noninvasive positive pressure ventilation (NPPV). It delivers a preset inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). The tidal volume correlates with the difference between the IPAP and the EPAP. As an example, the tidal volume is greater using an IPAP of 15 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and an EPAP of 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (difference of 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O), than an IPAP of 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and an EPAP of 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (difference of 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O). Most BPAP devices also permit a backup respiratory rate to be set.",
"   </p>",
"   <p>",
"    The term \"BiPAP\" is often used incorrectly to refer to the BPAP mode. BiPAP is the name of a portable ventilator manufactured by Respironics Corporation; it is just one of many ventilators that can deliver BPAP. BPAP is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link&amp;anchor=H8#H8\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'Mode'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/5/12375?source=see_link&amp;anchor=H5#H5\">",
"     \"Noninvasive positive pressure therapy of the obesity hypoventilation syndrome\", section on 'Bilevel positive airway pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     AIRWAY PRESSURE RELEASE VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During airway pressure release ventilation (APRV), a high continuous positive airway pressure (P high) is delivered for a long duration (T high) and then falls to a lower pressure (P low) for a shorter duration (T low) (",
"    <a class=\"graphic graphic_figure graphicRef50395 \" href=\"mobipreview.htm?29/7/29822\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71401 \" href=\"mobipreview.htm?2/8/2190\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The transition from P high to P low deflates the lungs and eliminates carbon dioxide. Conversely, the transition from P low to P high inflates the lungs. Alveolar recruitment is maximized by the high continuous positive airway pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The difference between P high and P low is the driving pressure. Larger differences are associated with greater inflation and deflation, while smaller differences are associated with smaller inflation and deflation. The exact size of the tidal volume is related to both the driving pressure and the compliance.",
"   </p>",
"   <p>",
"    T high and T low determine the frequency of inflations and deflations. As an example, a patient whose T high is set to 12 seconds and whose T low is set to 3 seconds has an inflation-deflation cycle lasting 15 seconds. This allows four inflations and deflations to be completed each minute.",
"   </p>",
"   <p>",
"    Spontaneous breathing is possible at both P high and P low, although most spontaneous breathing occurs at P high because the time spent at P low is brief. This is a novel feature that distinguishes APRV from other types of inverse ratio ventilation (IRV). In a patient who is not spontaneously breathing, APRV is identical to PC-IRV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;APRV has not been shown to improve mortality. However, it may improve alternative important clinical outcomes compared to other modes of ventilation. In one trial, 30 patients being mechanically ventilated because of trauma were randomly assigned to receive APRV alone or pressure-limited ventilation for 72 hours followed by APRV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/33\">",
"     33",
"    </a>",
"    ]. The APRV alone group had a shorter duration of mechanical ventilation, a shorter ICU stay, and required less sedation and pharmacologic paralysis. Mortality did not differ between groups.",
"   </p>",
"   <p>",
"    Numerous observational studies suggest that APRV may decrease the peak airway pressure, improve alveolar recruitment, increase ventilation of the dependent lung zones and improve oxygenation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/34-39\">",
"     34-39",
"    </a>",
"    ]. However, such findings have not been universal. In one clinical trial, 58 patients being mechanically ventilated for acute lung injury were randomly assigned to receive either APRV or SIMV plus PSV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/40\">",
"     40",
"    </a>",
"    ]. There were no differences in physiologic or clinical outcomes.",
"   </p>",
"   <p>",
"    APRV is well tolerated hemodynamically. In a trial of 12 patients who were being mechanically ventilated for ARDS, the patients were switched from PC-IRV to APRV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/41\">",
"     41",
"    </a>",
"    ]. The initial P high was 75 percent of the peak airway pressure during PC-IRV. Following the change, there was significant improvement in the cardiac index and oxygen delivery, as well as a diminished need for vasopressors. Although much of the hemodynamic improvement in this trial was probably related to lower airway pressures during APRV compared to PC-IRV, spontaneous breathing also confers a hemodynamic advantage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no universally accepted indications. Use of APRV and its related modes &ndash; intermittent mandatory airway pressure release ventilation and biphasic intermittent positive airway pressure (described below) &ndash; has been best described in patients who have ARDS. In theory, APRV may recruit alveoli and improve oxygenation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;APRV and its related modes are infrequently used in patients with severe obstructive airways disease or a high ventilatory requirement because hyperinflation, high alveolar pressure, and pulmonary barotrauma may result. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Related modes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent mandatory airway pressure release ventilation (IMPRV) and biphasic intermittent positive airway pressure (herein called biphasic ventilation) are similar to APRV. Specifically, they allow spontaneous breathing and have cyclic inflations and deflations due to transitions between P high and P low.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During IMPRV, the cyclic inflations and deflations are synchronized to occur after every few spontaneous breaths [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The principal difference between biphasic ventilation and APRV is that T low is longer during biphasic ventilation, allowing more spontaneous breaths to occur at P low (",
"      <a class=\"graphic graphic_figure graphicRef73129 \" href=\"mobipreview.htm?14/58/15278\">",
"       figure 6",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. Another difference is that inverse ratio ventilation is more often performed using APRV than biphasic ventilation. Biphasic ventilation is also referred to as Bi-Vent, BiLevel, BiPhasic, and DuoPAP ventilation. It is different than bilevel positive airway pressure, a common type of noninvasive positive pressure ventilation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link\">",
"       \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     HIGH FREQUENCY VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;High frequency mechanical ventilation employs very high respiratory rates and small tidal volumes. It is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5591?source=see_link\">",
"     \"High-frequency ventilation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ADAPTIVE SUPPORT VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adaptive support ventilation (ASV) is a ventilatory mode in which respiratory mechanics dictate adjustments to the respiratory rate and inspiratory pressure that are necessary to achieve a desired minute ventilation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are unable to trigger the ventilator are given pressure-control breaths. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pressure-limited ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are able to trigger the ventilator are given pressure support for the triggered breaths, supplemented with pressure-control breaths as needed to achieve the desired respiratory rate. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pressure support'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Pressure-limited ventilation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The basis for the adjustments is an equation that determines the respiratory rate that minimizes the work of inspiration at a given minute ventilation. This equation relies on an expiratory time constant, which can be obtained from the expiratory limb of the flow volume loop on a breath by breath basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Patients who have a long expiratory time constant (eg, COPD) receive a higher tidal volume and a lower respiratory rate when ventilated by ASV than patients with stiff lungs (eg, ARDS) or chest wall stiffness (eg, kyphoscoliosis, morbid obesity, neuromuscular disorder) who expire quickly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The effect of ASV has not been directly compared to the effect of other modes of mechanical ventilation on important clinical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     INVERSE RATIO VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inverse ratio ventilation (IRV) is not a mode of mechanical ventilation, but rather a strategy employed during volume-limited or pressure-limited mechanical ventilation. The inspiratory time exceeds the expiratory time during IRV (the I:E ratio is inversed), increasing the mean airway pressure and potentially improving oxygenation. A trial of IRV may be warranted when a patient is severely hypoxemic despite optimal PEEP and FiO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"   </p>",
"   <p>",
"    IRV has never been shown to improve important clinical outcomes, such as mortality, duration of mechanical ventilation, or duration of ICU stay. The preponderance of evidence suggests that IRV improves oxygenation, although the evidence is weak and characterized by low quality, conflicting studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/50-61\">",
"     50-61",
"    </a>",
"    ]. The following studies are illustrative of the data that exist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study of 31 patients undergoing pressure control ventilation, initiation of IRV was followed by a significant increase in the mean airway pressure and the PaO",
"      <sub>",
"       2",
"      </sub>",
"      (from 69 to 80 mmHg), despite reduction of the PEEP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A crossover trial randomly assigned 16 patients with ARDS to received IRV or no IRV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/51\">",
"       51",
"      </a>",
"      ]. IRV increased the mean airway pressure, but the improvement in the PaO",
"      <sub>",
"       2",
"      </sub>",
"      did not reach statistical significance (93 versus 86 mmHg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IRV generally requires heavy sedation or neuromuscular paralysis because the inverse I:E ratio is unnatural and uncomfortable. It is usually well tolerated hemodynamically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/56,62\">",
"     56,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Types",
"    </span>",
"    &nbsp;&mdash;&nbsp;IRV can be performed during pressure-limited ventilation (PL-IRV) or volume-limited ventilation (VL-IRV). Neither is clearly superior to the other. In a multicenter, randomized trial that compared PC-IRV to VC-IRV in patients with ARDS, the type of IRV did not affect mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Pressure-limited",
"    </span>",
"    &nbsp;&mdash;&nbsp;During pressure-limited ventilation, IRV is initiated by increasing the I:E ratio until the inspiratory time exceeds the expiratory time. The primary advantage of PC-IRV is the ability to guarantee that a maximal plateau airway pressure will not be exceeded. This may limit the risk of pulmonary barotrauma or ventilator-associated lung injury. In addition, many clinicians believe that clinically significant auto-PEEP is less likely with PC-IRV than VC-IRV, although this is unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16182?source=see_link\">",
"     \"Ventilator-associated lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Volume-limited",
"    </span>",
"    &nbsp;&mdash;&nbsp;During volume-limited ventilation, IRV can be initiated using a ramp wave (decelerating flow) or a square wave (constant flow) flow pattern:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the ramp wave, the peak inspiratory flow rate is initially set at least four times higher than the minute ventilation and then slowly decreased until the inspiratory time exceeds the expiratory time",
"     </li>",
"     <li>",
"      With the square wave, an end-inspiratory pause is added (0.2 sec works well) and then slowly lengthened until the inspiratory time exceeds the expiratory time",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shorter expiratory time during IRV increases the risk of auto-PEEP and its adverse sequelae (eg, pulmonary barotrauma, hypotension) (",
"    <a class=\"graphic graphic_figure graphicRef55132 \" href=\"mobipreview.htm?30/47/31486\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/59\">",
"     59",
"    </a>",
"    ]. IRV also appears to increase the risk of pulmonary barotrauma independent of auto-PEEP. In a study of 14 patients undergoing mechanical ventilation with PC-IRV, the incidence of pneumothorax was 29 percent despite the lack of measurable auto-PEEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43784/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mode of mechanical ventilation refers to the method of inspiratory support. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During volume-limited ventilation, inspiration ends after delivery of the set tidal volume. During pressure-limited ventilation, inspiration ends after delivery of the set inspiratory pressure. Each has unique advantages and disadvantages. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Volume-limited ventilation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Pressure-limited ventilation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Volume-limited versus pressure-limited'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pressure support ventilation (PSV) is neither volume-limited nor pressure-limited. Once a breath is triggered by the patient, inspiratory pressure is delivered until the inspiratory flow decreases to a predetermined percentage of its peak value. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pressure support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continuous positive airway pressure (CPAP) refers to the delivery of a continuous level of positive airway pressure. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Continuous positive airway pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bilevel positive airway pressure (BPAP) is a mode used during noninvasive positive pressure ventilation. It delivers a preset inspiratory positive airway pressure (IPAP) and an expiratory positive airway pressure (EPAP). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Bilevel positive airway pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Airway pressure release ventilation (APRV) cycles between a high continuous positive airway pressure (P high) and a low continuous positive airway pressure (P low). Spontaneous breathing can occur during APRV. Variants include intermittent mandatory airway pressure release ventilation and biphasic intermittent positive airway pressure. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Airway pressure release ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inverse ratio ventilation (IRV) is not a mode of mechanical ventilation, but rather a strategy employed during volume-limited or pressure-limited mechanical ventilation. The inspiratory time exceeds the expiratory time during IRV (the I:E ratio is inversed), increasing the mean airway pressure and potentially improving oxygenation. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Inverse ratio ventilation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/1\">",
"      Christopher KL, Neff TA, Bowman JL, et al. Demand and continuous flow intermittent mandatory ventilation systems. Chest 1985; 87:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/2\">",
"      Sassoon CS, Del Rosario N, Fei R, et al. Influence of pressure- and flow-triggered synchronous intermittent mandatory ventilation on inspiratory muscle work. Crit Care Med 1994; 22:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/3\">",
"      Marini JJ, Smith TC, Lamb VJ. External work output and force generation during synchronized intermittent mechanical ventilation. Effect of machine assistance on breathing effort. Am Rev Respir Dis 1988; 138:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/4\">",
"      Groeger JS, Levinson MR, Carlon GC. Assist control versus synchronized intermittent mandatory ventilation during acute respiratory failure. Crit Care Med 1989; 17:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/5\">",
"      Esteban A, Anzueto A, Al&iacute;a I, et al. How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am J Respir Crit Care Med 2000; 161:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/6\">",
"      Weisman IM, Rinaldo JE, Rogers RM, Sanders MH. Intermittent mandatory ventilation. Am Rev Respir Dis 1983; 127:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/7\">",
"      MacIntyre NR. Pressure-limited versus volume-cycled breath delivery strategies. Crit Care Med 1994; 22:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/8\">",
"      Abraham E, Yoshihara G. Cardiorespiratory effects of pressure controlled ventilation in severe respiratory failure. Chest 1990; 98:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/9\">",
"      Rappaport SH, Shpiner R, Yoshihara G, et al. Randomized, prospective trial of pressure-limited versus volume-controlled ventilation in severe respiratory failure. Crit Care Med 1994; 22:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/10\">",
"      Prella M, Feihl F, Domenighetti G. Effects of short-term pressure-controlled ventilation on gas exchange, airway pressures, and gas distribution in patients with acute lung injury/ARDS: comparison with volume-controlled ventilation. Chest 2002; 122:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/11\">",
"      Chiumello D, Pelosi P, Calvi E, et al. Different modes of assisted ventilation in patients with acute respiratory failure. Eur Respir J 2002; 20:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/12\">",
"      Mu&ntilde;oz J, Guerrero JE, Escalante JL, et al. Pressure-controlled ventilation versus controlled mechanical ventilation with decelerating inspiratory flow. Crit Care Med 1993; 21:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/13\">",
"      MacIntyre NR. Respiratory function during pressure support ventilation. Chest 1986; 89:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/14\">",
"      MacIntyre NR, McConnell R, Cheng KC, Sane A. Patient-ventilator flow dyssynchrony: flow-limited versus pressure-limited breaths. Crit Care Med 1997; 25:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/15\">",
"      Chiumello D, Pelosi P, Taccone P, et al. Effect of different inspiratory rise time and cycling off criteria during pressure support ventilation in patients recovering from acute lung injury. Crit Care Med 2003; 31:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/16\">",
"      Fiastro JF, Habib MP, Quan SF. Pressure support compensation for inspiratory work due to endotracheal tubes and demand continuous positive airway pressure. Chest 1988; 93:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/17\">",
"      Banner MJ, Kirby RR, Blanch PB, Layon AJ. Decreasing imposed work of the breathing apparatus to zero using pressure-support ventilation. Crit Care Med 1993; 21:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/18\">",
"      Brochard L, Rua F, Lorino H, et al. Inspiratory pressure support compensates for the additional work of breathing caused by the endotracheal tube. Anesthesiology 1991; 75:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/19\">",
"      Parthasarathy S, Tobin MJ. Effect of ventilator mode on sleep quality in critically ill patients. Am J Respir Crit Care Med 2002; 166:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/20\">",
"      Fabry B, Guttmann J, Eberhard L, et al. An analysis of desynchronization between the spontaneously breathing patient and ventilator during inspiratory pressure support. Chest 1995; 107:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/21\">",
"      Thille AW, Rodriguez P, Cabello B, et al. Patient-ventilator asynchrony during assisted mechanical ventilation. Intensive Care Med 2006; 32:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/22\">",
"      Toublanc B, Rose D, Gl&eacute;rant JC, et al. Assist-control ventilation vs. low levels of pressure support ventilation on sleep quality in intubated ICU patients. Intensive Care Med 2007; 33:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/23\">",
"      Zeravik J, Borg U, Pfeiffer UJ. Efficacy of pressure support ventilation dependent on extravascular lung water. Chest 1990; 97:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/24\">",
"      Tokioka H, Saito S, Kosaka F. Comparison of pressure support ventilation and assist control ventilation in patients with acute respiratory failure. Intensive Care Med 1989; 15:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/25\">",
"      Vitacca M, Bianchi L, Zanotti E, et al. Assessment of physiologic variables and subjective comfort under different levels of pressure support ventilation. Chest 2004; 126:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/26\">",
"      Slutsky AS. Mechanical ventilation. American College of Chest Physicians' Consensus Conference. Chest 1993; 104:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/27\">",
"      Marini, JJ, Crooke, PS, Truwit, JD. Determinants of pressure-preset ventilation: A mathematical model of pressure control. J Appl Physiol 1989; 67:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/28\">",
"      Jubran A, Van de Graaff WB, Tobin MJ. Variability of patient-ventilator interaction with pressure support ventilation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/29\">",
"      Chiumello D, Polli F, Tallarini F, et al. Effect of different cycling-off criteria and positive end-expiratory pressure during pressure support ventilation in patients with chronic obstructive pulmonary disease. Crit Care Med 2007; 35:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/30\">",
"      Cohen JD, Shapiro M, Grozovski E, et al. Extubation outcome following a spontaneous breathing trial with automatic tube compensation versus continuous positive airway pressure. Crit Care Med 2006; 34:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/31\">",
"      Downs JB, Stock MC. Airway pressure release ventilation: a new concept in ventilatory support. Crit Care Med 1987; 15:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/32\">",
"      Stock MC, Downs JB, Frolicher DA. Airway pressure release ventilation. Crit Care Med 1987; 15:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/33\">",
"      Putensen C, Zech S, Wrigge H, et al. Long-term effects of spontaneous breathing during ventilatory support in patients with acute lung injury. Am J Respir Crit Care Med 2001; 164:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/34\">",
"      Putensen C, Mutz NJ, Putensen-Himmer G, Zinserling J. Spontaneous breathing during ventilatory support improves ventilation-perfusion distributions in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 159:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/35\">",
"      Neumann P, Golisch W, Strohmeyer A, et al. Influence of different release times on spontaneous breathing pattern during airway pressure release ventilation. Intensive Care Med 2002; 28:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/36\">",
"      Dart BW 4th, Maxwell RA, Richart CM, et al. Preliminary experience with airway pressure release ventilation in a trauma/surgical intensive care unit. J Trauma 2005; 59:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/37\">",
"      Bugedo G, Bruhn A, Hern&aacute;ndez G, et al. Lung computed tomography during a lung recruitment maneuver in patients with acute lung injury. Intensive Care Med 2003; 29:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/38\">",
"      R&auml;s&auml;nen J, Cane RD, Downs JB, et al. Airway pressure release ventilation during acute lung injury: a prospective multicenter trial. Crit Care Med 1991; 19:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/39\">",
"      Valente Barbas CS. Lung recruitment maneuvers in acute respiratory distress syndrome and facilitating resolution. Crit Care Med 2003; 31:S265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/40\">",
"      Varpula T, Valta P, Niemi R, et al. Airway pressure release ventilation as a primary ventilatory mode in acute respiratory distress syndrome. Acta Anaesthesiol Scand 2004; 48:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/41\">",
"      Kaplan LJ, Bailey H, Formosa V. Airway pressure release ventilation increases cardiac performance in patients with acute lung injury/adult respiratory distress syndrome. Crit Care 2001; 5:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/42\">",
"      Hering R, Peters D, Zinserling J, et al. Effects of spontaneous breathing during airway pressure release ventilation on renal perfusion and function in patients with acute lung injury. Intensive Care Med 2002; 28:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/43\">",
"      Rouby JJ, Ben Ameur M, Jawish D, et al. Continuous positive airway pressure (CPAP) vs. intermittent mandatory pressure release ventilation (IMPRV) in patients with acute respiratory failure. Intensive Care Med 1992; 18:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/44\">",
"      Seymour CW, Frazer M, Reilly PM, Fuchs BD. Airway pressure release and biphasic intermittent positive airway pressure ventilation: are they ready for prime time? J Trauma 2007; 62:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/45\">",
"      Rose L, Hawkins M. Airway pressure release ventilation and biphasic positive airway pressure: a systematic review of definitional criteria. Intensive Care Med 2008; 34:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/46\">",
"      Brunner JX, Laubscher TP, Banner MJ, et al. Simple method to measure total expiratory time constant based on the passive expiratory flow-volume curve. Crit Care Med 1995; 23:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/47\">",
"      Lourens MS, van den Berg B, Aerts JG, et al. Expiratory time constants in mechanically ventilated patients with and without COPD. Intensive Care Med 2000; 26:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/48\">",
"      Belliato M, Palo A, Pasero D, et al. Evaluation of adaptive support ventilation in paralysed patients and in a physical lung model. Int J Artif Organs 2004; 27:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/49\">",
"      Arnal JM, Wysocki M, Nafati C, et al. Automatic selection of breathing pattern using adaptive support ventilation. Intensive Care Med 2008; 34:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/50\">",
"      Mercat A, Gra&iuml;ni L, Teboul JL, et al. Cardiorespiratory effects of pressure-controlled ventilation with and without inverse ratio in the adult respiratory distress syndrome. Chest 1993; 104:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/51\">",
"      Mercat A, Diehl JL, Michard F, et al. Extending inspiratory time in acute respiratory distress syndrome. Crit Care Med 2001; 29:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/52\">",
"      Shanholtz C, Brower R. Should inverse ratio ventilation be used in adult respiratory distress syndrome? Am J Respir Crit Care Med 1994; 149:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/53\">",
"      Mercat A, Titiriga M, Anguel N, et al. Inverse ratio ventilation (I/E = 2/1) in acute respiratory distress syndrome: a six-hour controlled study. Am J Respir Crit Care Med 1997; 155:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/54\">",
"      Wang SH, Wei TS. The outcome of early pressure-controlled inverse ratio ventilation on patients with severe acute respiratory distress syndrome in surgical intensive care unit. Am J Surg 2002; 183:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/55\">",
"      Sydow M, Burchardi H, Ephraim E, et al. Long-term effects of two different ventilatory modes on oxygenation in acute lung injury. Comparison of airway pressure release ventilation and volume-controlled inverse ratio ventilation. Am J Respir Crit Care Med 1994; 149:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/56\">",
"      Abraham E, Yoshihara G. Cardiorespiratory effects of pressure controlled inverse ratio ventilation in severe respiratory failure. Chest 1989; 96:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/57\">",
"      Amato MB, Barbas CS, Medeiros DM, et al. Beneficial effects of the \"open lung approach\" with low distending pressures in acute respiratory distress syndrome. A prospective randomized study on mechanical ventilation. Am J Respir Crit Care Med 1995; 152:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/58\">",
"      Gurevitch MJ, Van Dyke J, Young ES, Jackson K. Improved oxygenation and lower peak airway pressure in severe adult respiratory distress syndrome. Treatment with inverse ratio ventilation. Chest 1986; 89:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/59\">",
"      Tharratt RS, Allen RP, Albertson TE. Pressure controlled inverse ratio ventilation in severe adult respiratory failure. Chest 1988; 94:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/60\">",
"      Papadakos PJ, Halloran W, Hessney JI, et al. The use of pressure-controlled inverse ratio ventilation in the surgical intensive care unit. J Trauma 1991; 31:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/61\">",
"      Lain DC, DiBenedetto R, Morris SL, et al. Pressure control inverse ratio ventilation as a method to reduce peak inspiratory pressure and provide adequate ventilation and oxygenation. Chest 1989; 95:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/62\">",
"      Chan K, Abraham E. Effects of inverse ratio ventilation on cardiorespiratory parameters in severe respiratory failure. Chest 1992; 102:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/63\">",
"      Esteban A, Al&iacute;a I, Gordo F, et al. Prospective randomized trial comparing pressure-controlled ventilation and volume-controlled ventilation in ARDS. For the Spanish Lung Failure Collaborative Group. Chest 2000; 117:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/64\">",
"      Lachmann B. Open up the lung and keep the lung open. Intensive Care Med 1992; 18:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43784/abstract/65\">",
"      Armstrong BW Jr, MacIntyre NR. Pressure-controlled, inverse ratio ventilation that avoids air trapping in the adult respiratory distress syndrome. Crit Care Med 1995; 23:279.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1651 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43784=[""].join("\n");
var outline_f42_48_43784=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VOLUME-LIMITED VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Modes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - CMV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - AC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - IMV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - SIMV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Comparisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRESSURE-LIMITED VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      VOLUME-LIMITED VERSUS PRESSURE-LIMITED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PRESSURE SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Potential uses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tube compensation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CONTINUOUS POSITIVE AIRWAY PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      BILEVEL POSITIVE AIRWAY PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      AIRWAY PRESSURE RELEASE VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Related modes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HIGH FREQUENCY VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ADAPTIVE SUPPORT VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      INVERSE RATIO VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Types",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Pressure-limited",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Volume-limited",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1651\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1651|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/43/18110\" title=\"figure 1\">",
"      Waveforms volume cycle vent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/53/10078\" title=\"figure 2\">",
"      Decreased SIMV support in ARDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/14/42221\" title=\"figure 3\">",
"      Pressure support ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/7/29822\" title=\"figure 4\">",
"      APR ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/8/2190\" title=\"figure 5\">",
"      APRV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/58/15278\" title=\"figure 6\">",
"      Biphasic positive pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/47/31486\" title=\"figure 7\">",
"      Pressure controlled IRV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1651|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/30/19949\" title=\"table 1\">",
"      Modes of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1651|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?29/53/30557\" title=\"waveform 1\">",
"      Airway pressure mechanical vent",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5591?source=related_link\">",
"      High-frequency ventilation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=related_link\">",
"      Initiation of positive airway pressure therapy for obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/59/8120?source=related_link\">",
"      Mechanical ventilation in acute respiratory failure complicating COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14423?source=related_link\">",
"      Methods of weaning from mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/5/12375?source=related_link\">",
"      Noninvasive positive pressure therapy of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26119?source=related_link\">",
"      Physiologic and pathophysiologic consequences of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16182?source=related_link\">",
"      Ventilator-associated lung injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_48_43785="Erythema multiforme acral";
var content_f42_48_43785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62370%7EDERM%2F57894%7EDERM%2F51037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62370%7EDERM%2F57894%7EDERM%2F51037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WpKWkFUAV7h8H9J8jTBNIMNJ8x4rxfT7c3V9BCP42AP0719G+FoxbadEMbRgVE5WR1YWN5XOtnmCWwUHA61Da3qWVwGJIRjlhnr71UubhWkIBygGBms3W8XG1FHJUdPWuVzaldHr2urM9f8AD13bu6SWzqxA+6DzXR6jIPsgwSC2ODXzjaf2vYshgaSNt2FOc/hWzP4o8UxRLG6NLER8sikkH1HtXdHEXtKUXocM8NeWkj0nVvL2szMqkHgniubspYHvJV85WZwBkD5Rz0z61y6a3fXyEzRGKdeqklsj1qXTmm+1gnKjJZgOM1E8QpTTsdMISUbXMz4mEebYqCOJ9+M9cZrHRN4yp+f+dTeN5xNrljCw4ClvpT7eJnKmPAYdzXLVleRT00J7RsiJLiPCqePx68068tY3Lw3Fuzn/AJZs3BIznj8KmtYpR/Dkddy1NZ29wshdoo5FbIILEYJHr2rSm7mEtEQ23h6NPMZYZJGjG9CsrLkAc5HermlaETB+8vrt1YbjFnasee3v9KIJJ4IJBeLIAibY2ALKufUj+daWmTlbaPy/MmJTA5Uj8utdEbdUY8r7kMumwwSKsVqFkY4QkEkEdSSaqSQrHPKHyP3ZMa5wOvX+daySGSILKVjm5G0Ngmsy4hO6RpCxKRkoWPvWEmr3RstjkICsviQJjKxx5I9ea1Lm9mSWJAPvHcDnqKxNIkDeIbve23Hyhvwq1Bbt5wkaQyeWwxjsK57XZtSdjsdEjuZZzjMgRSzDHGT3rU0XVYjcpZ3JWKUHC5BGfaq/g++htrtZp22JICjZ/nWdIj6hr99LaoXjUFQzsFx7j8K60lGKaeonJybUkdTetth3hl8hGKI2OrVmW82N+6UNgMMjqapJc3UmnxssYit1YhZB85bsMD0rMtpzvUFm25wTjB96yr73Q6L0aE10j+z7tSx27cDvXncMoiZlB5PA9Sfau512Rn028ZFLZh3EDnn0HrWDong/XtTjSZNOeJeqGZgufw61jClKekFcVWrGEtWRRFTFtbh26+9FlaIl350YYMo5x3q3qmh6ppUBF5Zyqo/5aqNy/mKqWc6uVUE7sc89amUXB2kjanUTV0bumTnIGCCSTz2rfs7g7GabPt2FcvbYDh9xAIxx3rVsZi2PlGBwfWoZV7nQWAVckvxyQe/NakDcksT/AI1gRTbJdpx61q2kqyoU3EnPLelEXbQcld3NO3Yyk8sMDg9+tTSTMpBbHPTB6VAhESqAeBwT60yaQeU/zfKAPzrfm01BJE7z7omyDg/r9KqSlHgYhtvIGM8fn3przmWBQ7bNq8HOSBUSt5gQkHH8A6fiazk02NRM3ULJLmGcSAFGRlyy5wcdq81NpPo120EoCgfOpJ6qa9Yk3ldsbZZecmuc1nSI7uNFeNVJIOQPm+pNOM1sxTpOWqMyxujsBwVHcYPy10FjNbvgkqSD0x+tcqYLuCVYwxlQkjjqfwp32i4VRIUZNp2srHkH3qlBPVMwldfEjt3ubeFNpfaijaW/iGT2rkdft7C8nWKxTckahTIVwWPXp29Kw768v7iVo0TYqfxdc1o6JFJsQzOS2ckU22lYcYxkVj4Rt1lCtGA4PIGP1xV+70CKO3hKQou1cScH5j6j04rq7UFnHyFFZApIPJ9a6TTbS3Fq5uIY3LZAD+pGOv8AWqiruyHOEYxvY8f0VH0s+XEw8rqYz1FdJb6iWQMNpwMgHpXUa/4bt5Eae22/JwGAwW/2T6ketYI0jYV+Rh2Axj61pNuDszBQ5tijcXnyrwGZupBqKCwa+eSSQltowATwK1odCeSfaBtGQdx4C812CaOtraxoPljKgZxgk/8A66h801poUqaT1dz5r8VeGSuqRuqFAxwR261t+GPC3nfZxLCQrFhux9416T4g0qJwWcZGcgkZ6d65uHWbrTY10wzBbKSTzdpAwHHoe1P2ja95kewUHzIi1HwnbQLkx5LZU7en50zQIbmxuIx1QcAegroTfLNEGJ3Z4BJ61D5kUWcHPrWLb2NFBLU3WuXeAJIwx9awL8i4vIrZTnc+D7io7zUHX5VzyOwrQ8O6cZY/t05JDsUAxyCKaTWo0uZ2R8t5opKK7jwjofBFv5+uRnGQgz+Ne62QP2Uhjjb0A7mvJPhpa7pZpmHBIANerO21UIJCKe3rXPiHayPQwaJ380dDgcbjW5Z26bLeSZ02EsGI5I71zN/fD7M8cL7mZgv1FamnX7z2qwXIhaFQPlJ2O59jWVK19TvqN2OluUkini3SmO0mXCsyrkODnj61kvDNDqVwsZkZZV3Zbna3qB2qrf6k93bW9pEswkgkAUOuGb0zVrXnld1ZMxFkAZF5OD/I13OV02uhzLcisLe4MLTThBIWxweTzzV+KLypXOednNMSN2FogKx7Bh/mJLHr/Ko727Uw3TLgEEBR7Z5/pXPKNjaDurHE+IGEni8gf8soFB/GteyO1F2k8Hg1zHm/afEN/MRz5gQc+gwa67TFIZTg+WBn1rmk9Stzat43SMnCtzuUHjH40sTPtz9mRpAw3R7uT71Zt4w+zBYNjI46irZt8MpMSsUA5UYNaU79DKVkQR3SrHj7LPEDjlvnGO4OKlNvbuPNIEfoy8ECrEUygPGsm0N/Cw5FSTiSON92xh2PSui7tdkW7GTOg3SME4jIIfOS3vWNqU48qR4yfmG3PtW1KzIkj42bjtwOcn0rl9WmdbOZwvG0nH4Vg2aNWRymklp725lj+XdIwAFa0IO0KysCzYZt3TB5OKzvBkZkU5wCzBlB7H/CukurRnvJ7jekTONwZR9/J5GKzW4k7JNFjT7OeV2czeZEi72eNQWUe4NaCQpFpd0yzyKWI2gFdzDODnjOOe1Qi21TyyLae2wDnPk53DvuPepYdH1VLgpPrCRKcjy4oV+8e+D0z7elddOKWpnKbfU0LmVxbwWYhjhazAdjK5GeOCPXOa5JrmWW5csSGJ2sfUV0Vxp32e5E95qVzNOAWeV8NgjsBismdGuLneq/OwyXNY1tdDakjU0lVTUtP8zDR5ycDO7k8V6dZSO3+qhVR2ya860eAfaNOO4sU+8PTk8V6Vp88aDp8o4J7V6OBjPlaRx4hx5k5Ed0rbmSeFWX0FeJ/EfRo9J1NNS05CtrIcSxD+BvXFe/3SK2OhBHBrltW0+GW7jM8KSxNlGRlyGB9aeJhzpJlUGt46Hien3hl+7ywGQQMitGGRt+SwTNZWs6c2ja7c2wBWIMWQL/AHT0H9K0LeWNYcHKyFhgseMen1ryJRtoztT10LUbvNMiIxHfPrXV6UnkW6r/ABMed3OawLGPdJ5hIbn05roIJuQCNo7Vl1N73NJpwEfoCBgVmtMZM7TgBuM8ZNQXlzsmIB4IqvG5iiYqST/nk1EpXZaWhpIw53NgjhRjioRcbDtwSTyaoG6ZW5J4Hy+9NSdifmbGew6mlcqxpo6iMZc8nkdsVFLIIySpJ3HrVdW258x8r39RVeW4jUH5WJJwD7U4q5SkkJMAVwxAx90Dg/WqjsHjw4BzkEt3+tOnlL5CckcY/wDr1Snm2QjcdzA8ketaxZlOaYgiAc8oc8g9eKlgG1SFJ3A5+gqnLdEqA2Qe2RxTIrs70ULyfX+dVfoYcyTOs0zAVUQlixDBieB6112mOuAinkHC4/i/ziuD0+4Z1YBjhe5HA+ldJbXwJEK+WMkfOcjHvj0q6UuV3CWqNnUZvLZDtbAbdtI6f/WqCJbXyre4BUTszF4/c8d6zbq5mUlZpRIUBG7rn6VPa3cTxRqJELuOcLlhj3rVVPedyZRsjcWcImdgVTwwXofb61Snvk8so5zgY3Z5A9xSKrTWjpG2GUnJJ24X1rm5fPtLmZJ5Y5VAzuQ8EfjTqVHHZaFQgmrj9WkDcgAjd0HOOPSuG8S2CXoMf3ZFOQR1zXV3l4gYnaYyxwCw4yKwLxXMplDfNnGfauZS1HJaWMOOyu4YoUwWB5y2Vzz+taMK30ke1I4xjO4E9h6e9WEdlcFmyAMfWtTT2TeGjA2nrnsat1WtiYUVLdlXS9OYTxzXDsVBBGVyPyrqLO3ijWLy2KDjcvY+9QBdxG0D8KnhIibA3D29aydRvdnRypLQ+QKUUlKOTgV6R8wen/DyHytPVyoIYZJ9K6m9vvLBCAlT1xWF4WiMVtChJChM89MYq7fB5Y1bI2Z6dK5K0tT1cNHQtQyTMSUQLuPAx0rp9LsJUi+03Vl9pjU/xMR+vSsfQ7i0R186J5iQMIvf8a20122ht5Y5Ib2EpIAjNgqMdQ3Y4qqUFa7Z0Tk3pYparO9neRTQiRIn/eKueD9K1rXXHuUW4nsQFEm4PuBb6bc8isie8glRJUIDeY2AM4K4/h9s+tWLCOMWU/l3FqisRIrOQzMCv3R7iri2tmYNJ77mv5v2rUIJraU5G4NxggYzyKyb2faLhgR5aRlmP41PYQukbyozZDYIAyDjBPP41h+LJjDp184yC4wwzjJPSlUd7Di+W5keHF+0tJcY/wBbIWAPua7qwwFAwCe/tXJ+FbfZZwZUjAFdlaoWX5AOD1zXM1dm0Hpc2IE+QE4cL0weTV6GVn2/KDgc4ODVAI0UY5GWG4YNWxJHblmBB4/i4P1rogkjKWpaSNCUD71bqdwBBqG6SWBhg/u2HKrk1PaTCVPMJMZHOB3+lMc7HbO14+OnXGPStH8N0SrozLx2KNtAwBnJ4rjfFEjQaRcyHnMZ57jIrsb0KUbLbj2/+vXCeNNyaJdEN6Lj15rneho9jN8Ix/uYWLYGBXaLbI7xK6JhRkfSue8HwhbKIHqAOK7vTUMkZGCQpJwe1ZwTbLatFMW222wEkFsGQ/K8fmcH3HGRVhioEE/kTxoFGXKhgWz7H8OavWcRXD20m04IwVyMVZ8qZSNogfIGcDbg12wu0YtK5g3SRlP3Ji2ct8wIYN75rLv4gxQRtuCryVGM+tdHcWv7xnaJcdfWsu6QeYNiKD09K5qzu9TemrLQrg+TPasAWV3jTjtkgZ/WvZrOyiSBdwASPH6V41An2q8hBO5QoYgdjXounXV21pHDJMWiGOo5P416OEvKnyp21ODFUnN3RvzLZz3QUtIrN1PRT+dc7fbBIoPIV8fka3tY2S2qMBh+DwK5yUlSCOxrSXwIMNC12eZfFq1Eer2d4i4jkyhA7ntXLW0m4A5GQeh5r0b4s2/2jw60wBDQsJAAOeK8v0wN94ElWPf0rzq6tJ2Omm72R1emStEucBverjTsqFmIC46VjwSgDZk5A4pkkpkcc+3Ncj3OuLSNJ5AThepyTjtTgxYbOcAcnNVbZhGxywLnqRT/ADGGAzA5PNZ2ZfMTOgUZQ8niouiN90AHrSy3O1MKrMexHSqLThwynjuwHAo5Re0L0ci7Du2gHuaqXMi787mU9jjNQvcoYgoPHQKeM1myNG0bRoTvz95j0rSKM5TLhnJIDStgHqvakZvKK/8APQnOfWsS6c2xQiZ9+7nK/Kw9KgW7Zy2JXzk8HtV2aMOdmxcOqSLJITuaoYbppJj8qqucgg9PrWJJdONwjcyAHGDzUsMd3JKjhCCBgj2/rSsK7k9DqbC7EZHmSbQDwygEMfx6V09lLGBlrmFpTxhjyR6DtXnyxzglvmXgYA6A+9SCe4i+aXOMZH1oTNFdHoE1y7M5nkwQNoyuAasW8scUOI22sT1UjJrz8a7MXw3zr29qkGukhthcAD5V2/mKVne5TkluenpqCRW7xSbNz8lj78CszVbqJo8iVcg7VPO38u9cJFrzqW82XP8ACVz0pzax5rAF/k64Hp9apzlJWZKdndGpcSyB8YTac9sZ96z7yfc+wsvup4NU7rUMkeXKGQAjmqE1+m3a7YPvStqKUzQW6BkPOATjn0+tXY7ohv8AZHQgcViRS71/d7cnqg5/GrkUcjukjHc+Oh/h/DvVOxMZtHT2d6SoHmEj19KvLOWCHBLDtmuZjfBBEhI6nkcVoJOCMhgFPQ1jKNtTojO58yVa02Lzr6BOuWGaq1teF4TJqG7so/nXrLufPRV3Y9KsBtsQqgb16GtFY1njC7RvHrVGyjKxtkZwfzFba2its2JkdcZ6V51R8zuezRVh1raokSiQEOpOSOMV0lvYva2H+lRzeVJ+8iw/yS9uFPf6Vl2KF5ykkbMp6gEZB9RniuqcWT2KEW13HNFHvCxMBn3Xnj8q2oJNajqs5aCwEl2HSIQ5c/whjkDuKmTQYGvPOELLGx27ujKQeuBWw9rNujMYd3Q+YFKgkfy55q6LZikf2l2jkfDFSu3I9citVojHqV7uJBbhIzhMcd8AfeP415945mQpDCvLyMA3Poc9K9HvQY7GQxHETnYnHQZryzxBi88UQw7spEM5x1PSsqjbkNLQ6LRY9sSqW+cDBwf6V09jHsWPZyCerVz9rtjjC/xAVrWpbPXhcEjPeoii7tRNRXmVN+xF44O7tUyTyNndAXB6BGzmsW4umTYHhDruz8rc4P1pgu3KoyvhMnBQ45rfYm9zpEmVl+VPKK8FuwPT86naQNEWixlQFwTnnHY1z0M90ryqW/dYDHI+9z2rRt7p2lUuQwKg8c44pqSaDlaY29AaDdkD1HTNee+PJcaXJGuPndcnPvXoOoMZocqRu/iHf8a8+8brvsovlUZkUYH1PWueW5e5c8NErDESdwCgfhXbQxuE3Ry+WRzx0Psa5Pw1GDYRsi5bOOa6+23fxDKYBYjkVnBO5r0LVlv87fIJWwPlQHbWir3EWJA8pGeRkEelVoUJYOrSMOqsBzjvV6VnEW4iQqRhWAyD7kV1wTSMHuU3YNhfMbcPwArOuiHJRcjv071pzZcbsjcODxgVUcK5Y/dcj196xrK5vDYxNLwdTXe+z5flz3x2r0PT3xEhHT1ry7UHMV5tXAAy35Vr2XiSe2hijSIuwHzHNb0MVCjpITpSqK8T1e7ctZg5BO0fhXPXUuzIPfge1Yya9f3MQxFsRhjzCM7RVdIroTl5pRIGwwI6VtVxScfcRFKi1pIseJovtmgXED8MYyM14vp8jLGEADMDjI7c4x7V7dcv5lu4cZOK8SuB9h1m9ixhFlboeMHoK5ZS52TKPKzThn2gscdcDvU0WQQx5NYdrOS4HQ56mtRJ96kRsFZetc8omimaAkDMoYe3/wCql+VXIB+QHkkH8hVWFpBliw2n15pZApTb5wUcnOQMU0mJzEluzLiNN+c8DGAfpTZWKR7S539flpofdCVQMVIxnHNIU8uIu8TAHgEHJaixPMyK5kYQkLEmOpJOcmsqe7dG2iNAoHHOTU0zSO7bypAAwnQ/Sm21jLcMxjVVTIwSMmkK1yi6PcqBsZm/KtLTfD01wjZ4HUqOn510lhp9uNqsVMvC/N0rRtpI4XV4lUsvO3+62ecj6Vok2axpJblTR/DcMM+yUKBtJ55y3p7d+a0HtbaCQOzqUIQKpAyFLdT+VWmkj8qU7S+/5sKMDk9qxr+V2na0hy0bIMFsAg5z/StlCKRrGLWg42XnbUjmiSN3KZc4wwY96s2ehTXTzLFET5Zxxg7hj3rLvWW9Nq9pG5ZV2XCMMqGJ5YVpeH7+RV2M+GT+PHXspx75/Sj2EL6jc3bQr3Hh+e3iMtxAAn3iRjgZx/OqEOnRsSYsZJ7H9K7v7UzyMt15THIJBJIJxnpj/OKuMI0tleKGNZJRsY7cAAn6cH3p/VE9Ysz9tZWa1PPzo9vsw6JuC5JYcn3FVoNCV8eXGzMTtKg4564NdpdzQQybDEAcDG7G0H0qtqN5H5UkqsDLJwJezY6j8qx9iluzWyf2Tk5vD6BcsrKSxG0jnPHaqt1oMRDFCu5ASeM4+tdTfy/avLmhYmfO3gfMMdPyrNuLZYIyZgzSBCWRiQCT3yKn2dtg5I21Rxd3YTW0ZeLceeDjg0+wvnWQb8BwOUOa3447kTIhTgDLI3RcjNZmp6fFMjS25wzDOCMUvU5qlFrVBDco92CSixn7wx+taiSMpKx4APQdsVxSXM8VwuUDY+8GPBroLS6M8yq0WxegwcgihxsjKMjwuur8HRkI8n+0MVyld54St/Lsom7kZruk7RbR5lL40dlYhjwBlgchfaujtt/ykbQ3qT/OsPTxhgVG5sc+ma1rZXkRHJUEn7vevOkz14G1AG81DGpyg5YLuGPcdxXQxq0dmE+yCUbtyfvBt2keh5FUdKsD5DO1uzTjncsmMfhV8NNBHt86KRgcCKU7WHurDrXRSXKtSZ2Y2UCLaI7Z4JUbO4Ngfn3p5jaaNSySK4yeZNwB/wD1VLAyfOm2TzOrKWDdvyqRE2DnaflydpwDV31JsZt+AkGQzARj7p6Zxx+teV2Si58QXlw2Wwdg49P/AK9el+I5hHZO/HQlvfHevPvClsTam6YjMrls56c9azerC1lc2JJGjVN/y7jgn1NT2svmI7o+XOCASF4B6fjWPqMpuplt8EjJBYnaPbFSaakxm2N5WVAGSx59qpK25NzZmN00gQqivvHJflR9aLeS6VVLRyFGbBYfOqj6CmwyhJxIwiO3O4AkD9etaVnOGdQECgfMBIMqPUg1cdXYNtTc022gu4DJKTvRc4Ax+lZk0ohZ/LySvIdcjAPap11C4890Vt2WyrRENx3yOCayJ5xLPI00bRuM5GCAPQY96qpZJJFU31ZdupmgeNXEh6APnKn1rj/FwZip3cM44PYV1cJM9uElUBH/AIeuQelcprsahUALMqSBcH+dc0tijofD8ZFtFFG2MA8Y5PSuks4yDgfdxzk8/iK5jw/KJGAYckjaB2rqYRbRsfNAxIcEFj19qcEnqW5aGpaKyyM9vKyhCCSoz29D3qwpuYn814t6tn5kOM59jWZClp5q7XMQyeFlIrUM8saKiX0bg8jftYDr1IrrVra/mZNu9kU5LsO7R+XycnDDGRVSQpjIxyOPrTb0vI5DKrNjqp6e4qu6n7OMsOOOBmuKbbdjeG1zFudrawu7ocj8cVtWen7yAUXf93B71g3ZKarA2DwfSuvhl5wgw5wctwOlTFJvU0jJxWhp2FvDHax+XuL5ww7DHtUUqEPnYAAOgqWxSR7mUM7GPaucDaMnvU00caqgz5bZIZweDxXbJXhdGKlaWpmNzG2D8xrxvxgrW/iCfK48wA49TXr2+VVZXRCVLY2nPFeW/EYJ/atuznYWBXPPPvXHGXvWLq7XMSEu0nykBl/SrnlyBCZGwvUnOSaz7UlSR0XPXB5q/u8yZQwO1BnOMVTRzXNe02lOFZePukYAqw9qpjIdUw3P3etVobeML5kzHc2BgtitSCEMU5PsBg4oSLbKZiwVCxhWXpzgVLyWJKknrjtmrIhjbJKnKfNnPWoL2YIVJKgY5A70mNK5UuLXc/zbXHfAyasJJGUaGMBWI2jPQH61SkumlYhTtHYD2oh+XiTdtbgn/ChK50QikaMAUbQinbjk45BqxJ+8UFB+8kTcAp4yDz/Wslp/KbKcHHXPWp7C6XK5++DuBP8AKtOZLQuJtWDebcpGjgFgzOckgADt71JZW8VyrNcuPPD4KrxznIPHtVTR22SyOMNgbAWOMZ7/AK1qWd2kToHweeAOMHPr+tbU5K1zSSZR1OyVVXy8AbysZOAwPQr/AFqfT7IPZSSQvE7qqkA9cA557/jWpIbe7AdwPM3E5AzjntSRqqzNGzBeqjAC5GP8au+pkw8pkulYzvLhQ52YI5Xt61qBnmlt9j71A3nvkDpWBeSmGbBPAQJ8vOcCrmn3YN2T5qwsQBknge4ohNRdhThdXHanYvl5EUMXXCgDG7B681FdaIt5pLyb4IZIojJsk+Xcw4OD61r298LkSRllwBgsT78YNY+qLBdB45pCUVQCQcZPU/maqahvvcKcpLTsYXhs+bbzLtJlVvlUckH1zVO6E32+SKRWQjjk5qxr03/COaEt1boSzNuEaEKQo75rg/D/AMRrQXLRavE88MtwJgz/AH14wRn0qfZKMEpGdTFL2r5fuO0tSpZ45W69COucYqN7Rykk7qqqv93knt0rLXU4L2586wc+S74wRyp6/wAq6GeRBbPEgO1hkljzjP8AOuecOUvnU9UcdqlklwDJEP3i8lc1UtGJYIFYDPGwnIP410V0ioySqu1RkNznJqnLaorGTGVZQRnsajTY5qsbO6R4NXpPhxT9kRVHRQOvevOEG51Hqa9L0NRsUZ2gYrpqaRPMofEdRYL5eD95x0QdzXRaVEjuhPOOx6/gKwbJ1DbQMn1xya6Kykt0Ik2bSq9cZ+Y9641G8rHorQ6MXHlxkxmJnKhFDIVPXufWq8l66LteLYGBUsp8wdeo71RmuAQhBZsk9CQetVjqiiVgss/mAbULLnjHfitmx3OjsLqGR98PkkKNpjZQGcdK05UDRHaQCvVelcraXkUqCJLiGYBx8rLyCfQ1rxyyKgRN2U6p14+tVrbURgeMHWLTLtmLL+7PA7CuT8NMY7ONcjau3k9PXFdH45m83SLrkBhGcqe4rkLAudNhEX3hjK5wPas4LUVSXQ0IJ1k1Oed1VcscDrj0rVs/JaTzAgGACzdPwxWBYyFtQDYCK5+VRziuiis5mIiWVoyBn51AHrk5p6tkrzOjt0XyY1eONgBnH3jzntVPUNJs/LElu7PKEAypIWNj79M+1UVjvIZ2VkLAfM3lnGauR6gksKiApGjFcxEYVuevua2WmjQNX2FurC4hI+z3Czqy4i3cMpPXBHcVn6o93EvmTO7BSB8wBPPHUda6PV7KWyZHLRAuu5AyhS2e3Bx0rKkmLSSeZHtUqPlxwcHpSmrOzFF6XRJpMbTO6TLgxqdrY7VzfiiH99ESDsMgxzz9a3rYStcucttxtKlsEZ6H+lYWruC6JO21kDEEdAfT6VlPsXF3NSyjWKAMh3luCq8Fcc5rTgMktzbxhwiN/F1wT3rmLOaURARkkPjadtdDaGGK2jYXU0U4Ofm459hjHNKCLc7I6F0nhlaONvMIBywkGGx04NMe7T5TdwBMDc7PFgE9AARwaovLcBmxeF8KG+dMD6ZFSw6g+3Y4aMyAZYsCv69q6HbYzvfUSWWIs0sAV4ucjdyMdx602GV8MUA5HVvSsy/W3VWyyqMfMyHADE9PpUkDOY4trAuy8MBxnvXJPc3jLQoalKFkRi2DkZ4610enTh4oXaOUlTtf0I9RXK3W6a4QNjLnB/xrpNCSHyYzM4QqGRt7cbh0qYpuSLvozobSeVZpoP3yDaNpC5JXtmpbRHaWeV3Uqh2nfkmql1qq201rKZ4hgGMsrZOMdc/WnLfWz24S6uoVEx3H5hnJNdaSvy3uY83UhvZ8K4QEk9CnTFeV/Ea4EiwsygOH+U+xr1G71Ozjd4I2Mo2EKFTocV5p8RofM0x5VUq6kELj3rmatO5tJ3jqctYNN5e8gEgYA6jNa9vgyrE7s3APA4J9KxNOkMm0biBjOAOPzretMo+8kFmXAyen5Vbtc5UdDBsijDyc8dT2+npUN5fQW6ZSQ7iQTWPe3Z8tw2QeijNZF3cuAULqB14NTHUbZ1E+qRFUwzqmMHK9RWW9w0sx5JzwB7Vjw3AZhuY471fidRk55Ayvsarl1NIy0NWHCopTc4yD+lOaQIgaPgdz1FY0Vy3nE/MSOcg96uW83nOFIzH3xwc1TVylJsnuJQyKcBVzkbelVvPaPGW+UnArQSOOT5flRiMfMODTWsMQt8qlM8p2+uaXJc1UrF/S7lJMtKcA988Vo37eWqvFkjuVFcmoks2wiu8RH3Twy1f/ALftms2jnlVZRxg9auMHazNfbqyNXT75luHdSRnjGa0Bd7pGLAAY5I7157a68sF7L5vyRtkq5P8AP0rYsdYhuYQ6zx7uRjdg1NmgdRNnRXUxKkKw6cZqtFdMoJCg5GMe9ZzXtuVy84VhxtzWTb63LBL5THcA3AUZ49alq2rH7VbI7Oxv2RWL4wc57YokuvPfbGypuIzjgCuUbVBIMAEn1Ixj8KItejjA2xhnUnc2eKamtrkzbtobfiXw4NV1S3+2agwhhj4gDBQw6kkntXini1I4fEDqU80JKVCoQodc8AYH6133iPxfJcsEt1nkdVIQRkEE46nIrD8N6Nm8F5qGy4uCDhOTszzknpmuz2iT5keTVpSm1A3PCmmLbaZbMGdXkIlbdxj/AGfyrqBcHzP72e7dKzTvUDzBtUfgaswBnG8AY965asuY9ClDlSRavoFMSsSfNIyEXGAPU1jwPid4piNhGBn61qrMY4nAI5/M/j6VhXG8z72wBntWTVyp66M8Vs13XUSgZ+YV6XoYMYBGMnqcZ4rznS/+P+HAyc16VpkggiXpubuegrrqfCjxqHU6W35kRImZSepPT2qyb+BZJBI0ZUYXLEn8qyoJYpCWdnfaMBz8oBqRPKZg4cNz0SPJx+ArmWjOzcuXd4fKKxSMoPAUZ5Hp9KfDp4aIS3FxIGPIUEk49OtU7yRJJlEpdQexTB//AFVs2scN8IpFlbBAXHr/AIVfK2y00kVIFj89NrMOcK7g/KRXT6PdHmKR1DqAC/Qsf8Kx9Q0Y6ZKskFyZY5V3Be6//WqzbgPAGZXZx95umfpRG8ZWYSs1cZ4wKyaPOGOT5bAcdBiuD0w7bGASsVBwWweSMcY/Cu91fy30mUNux5Zxnkk4rzewJ+xRls7R2x/KiPUzqaWOg06MzXKMgLRE4O7jBrpfNurYf6NdJMueY5EIJPoDXOaPMPtYQFjFje/H3a6S8tQfL+coZCDuzuXqP4fX2pxT6ClJFeDWpQ8rXFpPLvO59hwSRzg4HQU+41xLm4eSWwnhZ1xGkY+VOM5x359KVLRw0ktozyJuIOw7OOetbum2jExu0piRztwT6DgBsZ+taWbVmxGGs5kt0zFNvAKkytggdcgGnC6keOaPMx+b93kjJ6dcdua3LpPNkhYIh2jaGBHP0qr9nijiclYwx4wB2x0+vvUO9zQZY7VS7iZdsjbYznksCeuf89K53XcPelXkVchn3Bcjjpx74rpYJfLSWRAFl2n5xzt9BzXIaoSNTSN4g8mzqvqamWqRHNa5f8O3ltuKyq28D7pPUE8flXRQWkd/KhE0hAO0KvysAOnNcX4fYGSVpWy2NqkrwuDyPavR7WK0S3hWa3XexwTnaFz0+Yc5yelVFcysNvS5l3NpMVto/tUqtlgVYbyvPp3pn2TUoyNklpPHjbh4+a0p7qbTbx5owJCoaMF8ncfVcelK2waXDcSbwqjKhT/EeSx+p6elU9BrUyNXhUoySWIikcAfK/OeucelMWVraCBR80R+43IKnvV+5ke7kiS8UtIeN7MBn0OfWqExXzoomcsp6KRt+orF6u/Q0S0sypdkvdKhIwG7Guj0+2kuGO5RJzwehz71ytyQssKhcKDjGa7PRFIVd7AKwBzms38SRpFuxLNoltJGsgtWKE4KhiOf8aZb6ZZrJslhjCseC5LAelah2RMrx3RVifm3thQPWoxNGGcvdR7+ScKG3enPpWr0sSrplt9OggiRoY8pjJODgj1zXG+PNLW80qXaQCEIGOh7/jXd2hma2MKZMPBwcYB9axvEEIe3ZWHVTnBzRUSdpIuPZng+lKPIGcBwO54rWibdIAMlfes6RTbaleRj+CQgDFW4+fLJLLjnmol3MCy0kaeYz5Z1+hzWTPbm6Zntyu48hW4/KuhhhikyZ9r8dAKitbMPOypt2nvzwKdNrm12JnFtaHLeXd2Nz/pNvIqKwVn6qCc4BI78HitOB1nb90R24rrdUsUksWCQQs8oXqdoXB67e7deTXNiyW0vYZCnmIG3Og+62D0zW8lBy0CnCo9GiP7KRKwDrn1BzV60R0jO4hWHB9DXVXK2UTpPBaqlmRuLINxBIztOeciqF3qX2uBjbJCix8kKvLH61b9jHd6m9OlOTuQW0ZkjJXLkAkjrVd9X+zhlMixxr0Urmp7C4mF3G0oaKORSDtOOMd6eLWGS8F5bSRYiPyxSplW+tJSpv4XZm8qc1eyuYks76oQIxcykcDyYj1qXTvBGp6xMPMP2aMH71wfn/Kuuj8YzWJCtpcLRgfeSXAP6UqeO9KudTge7iktxGOcfMAT9K3UaD+KRyzeNs+Wlp95Y074T6YsY+13c90T1AOwfkK0W+GHhYROn2OVpCvyss7AqfXrXQ6f4q8PXKAR6nAOACCdtbZktZ7Um2ljkB5yhzXXGhh91ZnlyqVr+/dHltn8MLOS8mimhlit1x5TrMfnXHOTWk/ws0p41jtXu7dVGC6zZJ+uRXpdtEjwqrde9EtuEDeW2P1pLC0WthPEVe55e3wdgKSOur3WQMplVx+NcH4j8FXWjW01wLtZLdTukZhg49a96glmmuJYiwCDAOOpqLU9CsLvT5oLuJrkSAAhjgY79KcsJSmrRQLE1Y/FLQ+XfLNreo1ypkRxncDwwI7YrpNBw8P7hQAvJwQK6Pxh4AttOtLibTpJPLiBkEMhzt9QD6e1cRpN7bSgxMWjkHXBIP4151ShKjL3kexh61OvH3XqdbKqyH96+5cfePB+lRySBABFxjpVQTsI13Nv7dhTHldmCpGc4POc1jKNzV3iTicYLTSAc8DvVaWUSfT0qi5kXLOSqjqxFMNyAGG/a23OOpNZqNzGdQ8v0Uf6ehGOMnmu/s5PKgRyCAAACehPeuC0PP2wAdxXd2GJFywDGMbgu7rjrXVPZHm0OpsCZWDM2X5+7jg1r6VcQ7QJDJEqc4wRkVhvJmePYysXJIQHhK6nTGiWDdcSuwTJMakAA9q51udnQivDbyCV1uMBlBKhi5x06etWNBhuLd91lbTSRlvvsMD8s0tpBFOgEloElmcsHXkFcdfXOa7XT1jW3tGid1kz5bjoMVaeujNFHTUxrnUlmUI0AinHAA5Vv8DWbPLKdRRUHlRZyGYdSe1db4jjtFhOwIGDDDL3P19a45ixuEdmZk3c7V+6SarmctyGkvhLeqMo019gO8Ic4PfFeeaDIZbUwfNySMAfy/Gu31K4VLScjIdQwx6+9cT4fYCyDlNo3naxPHOKiC1uRV6GpbELMQmVHtxn3zW8PNS2hxMxcfMgKEH8x1rKjjMx2ADevO1h/Wtu2tkWIFZnhxyVboD7e1VezbZKXYr/bbi2me1kV/Ln6KqliD159/atmyv0nUrJOu0DJMh5B6HApuIJExLNIQwyCmRhj0ye9SPBGmA80jiIbGzgr0xx+NNuxaix9viNUIZ2WPIV8DGM9x/WmXa4t5HYSEMwBye/t9acLcLAskscnlA5zKdo9Dhe9Tssfm7A2+UZZm4woPYD8azvcqxSjdAkkTKcbMnAwD7VyaMX8Stklog3lZzjBwf1rs7+2KxvgBFDh1Hc/jXnNpcSXN1qLPtRfM8zJ4OenHvninG91czqeR02gwxmFXcbRuKhf7w759/51u3crNbm2tTKBJyoZv3a+h+vFc1ZxXEiGPKNGrZHO0knrg9K3vsEqQA6ffXFjcAF9kmJFcdCPY01rsU3ZaiPZq0EYnubppnXKyCX92oIycEd/amWelw3Wn5iku2BUEx+YcfiKzfsmohkiub6FR5iqPkycHuB0GKv6ZDfxQv5Oot5hznCjYq5/XPpVNXd2SpWRZudPgs9giln8xV6M+4A+lNuJk822Zizu7B2YH8+tJC01tcI0gkufl6nBxnpx2qpcqj6lGsjGMs/TO5VFZ7GvNdWGXqotxE4BAY4IJrsNDWRIU3ENEeR7Vx90A+ooCBkux45xXa6aoa3QZCsO4PGfesZfEaU37ptW8ixFd3lnOSMjOKVWSVtqKshY8qqgE/jUEUapv/5Z/wB75sgZ74p7xSSOsRETjcDlcEfnWsW7WKSTJxKqSlEE0ZXj52qpq6tPEWPBx0AGasalYLDGj78Ej1PSqUMhMUkbjK9mBzUzvF2Zairc0Tw/xKnk+I7ngneMj1JxikjPyrnqB1JqXxvEY/GDqzfKUyD6mmRN5f3lAJ6ZpPVHM9HY17Wd5GULlU29sc1r2pQEbUAOw4ZRWJZcyrsO0Yxx1NaskjxHaHBTuV/lWctdjWBPDfxuD5ykj7q8bSPqao3yKko8tlTdzkD+VQ3csM8BJDBR05/nVGV2QRuGyEGATVQlY6qT94v3lxBDAYJBLtdcE9y3qa2dE02W609baI28aF/MDsuXJxjjHPTtXPQkXmXZg7Hnn1qxoOqT2huzny4Y1CtNg/LjoFHqTWkkm7y2LlCTi+Q1JoIgrWkOwPg7pZvlU4+vf2rPhSKNMIysBwSTWbEl3cuGtSXlckNk5x7muij0nZYxLCsjSqxErsAc8dPrmsYU5z95LRG8H7KNm73MG7/fNiNRs7N61CNCluJU+RUznBLVvPaKXSOUNHuAOCu04+lWY51tYpo3jby3UqrYJB+lYyb5rS2NViZR0iY8Phm8WJovssIIGQ6vtYj+RqE6ZqOnENBezI3UGNiv6V0Szz2yKUfIx0fkiqlyxu5syThP77uTgD1o5lH4bpg06vxWaEsvGHiWwXbHqEc4TqtxHn9a17D4lasC/wBvs7aWM9DE20g0R6SsE8UVvdW86SruA3Z3qehGarTafbLKyyeUuCQSD9010xxFel9o4p4KhU+yWk+JPkNI8enF3Y5w0mMfpVS++LWohSINNt1OeC7E1mXdhaod0b5xyT1xWbqSRTqF37GGAScYqnmNS1kxwyvDac0bk134o1vxBG0cjQLHJ8rJEvJB9zVG18MrHcEyKFm/iGcml0jT4Gk/cyYYnBAfA+tWJre+UE28zLIh4DgMrCp+tTkrzdy3haNB/uopF2XS/OukE1xMioAARHnjsMVbXQ7aZvMiuJV4wVxg8eoHSsxp7lArZRJWB3Mn9RVvSHWfULdJpRBKzAB3J8s9cgn8qarSk+VGTSlq2JcaIFtZZvMVY0byixcHJ9MVzusaDPC6wgzQCNf3vnAL8+TwvfGMda9T1uzF/oEFra3MNmkDMZldcKzn+IEA89RiuS8Rzy6hcwxGR5nggSJ7gDCzkEk5HXHIGfat0qqaWh58482p4RofM/HXB/lXdaK0al2kQswI+hz2NcRocaks56jNdxp/lnT5ByJGZTnHQD3rWpqkcNF2TJrOMmdD91jyq4+8PSuktrS+Qk/ZvMeVuXi6r/SuYsjLJc7Bl16DA6H+ldlp8lz86rFtXZ/f6+ox6f1rnUddTtT0C01S5t7kvPZeapOCFJHA/hB5xWtPrhnSJLO0uYFRg213yoPoDWc6jENqylWk4SRNw4z9xgR29afFbzQ+W8k20xSkL1MasD19zVWkP2ttC4980z7sMWVskdvpSXOyEfaDlXDcxkZGMdBUMr7julCNuJJZM5xnr/hT2SFocSFyirtXPXeTjP609tjLmb3MjX52i0eeUKOYTtB549q5fwkvm6enPyng56AkV0HxIJsvD0kSkMqxFcZ5XoK53whueyjWQMU4BPT6U4Q3InLVHTWLTebHKsZZx8uzb9411GlyRyRsCJWUrglccexrnoHP25/LB2AjBXOVbHT8a3LaRFjM8EkcEuAWx/F/hQrLcpF/zIS0qW8sGwt8wmj25I9D606a5htVSNbuJMgFzHHkk49fapYb2YRGSaAsneYIGHJolvXkVhFGqRKf44wevcCk7f0i47lIt586KlxJMr5zhtx47egrRso4oo1Ds6lvvZ5IPf61XtI2ZZHzgZ+dguGHoBWtbNLKuUQKCpADdT/hUbFvc5/xRcGC0lUZVYl57ke9eV6cpmSeUSHDsxjLdyTXpXxAn8jR53VFG2NsnqMkV5r4eO61j3Bs4IGOg46U07oyl8SOo0K582MBlZBEu8qQc8f0rs0ikFvCYJQ7/fCyKDtzyec/pXH6VAk7JHvLFV2qykjJPPX1HvXV2qSNb5vLEybACHh6qc98VVNNCbuQai7yZjkhPnsCm9Ux9M/571c0W5tpt3nwIr7VQNLMFKY4yPpU9ulpPHuF5MpKhAX+YE55yD2P9KkFkksODcwTBWOMxjnHvmtddwir6FK+aMSY+VccLtPEhBFU71Y2lRpUJLjIaMYABPep54oonAUo0jLztHXnPB/SoRGkJZZj85PLZ4+n1rGWt7l6lGZUa/t/JOQmeB169Diu3sZohaoQm3aOQeprkLNfN1V3QgMcAHpxXURTwQwjeSB13delc0371zeC900ZJYVCsLWc5wAQuc01L628v5rSeNlOCTDwfxFUI9VtTId0z4XlgWxmrUN7FdFYYZstn77TAfh0rWEk9mU423GzajbMSgZ1HUFkI/CpoQjxExSBh3xSzWW0b2jdgT/CwYD+VZzt9ivVXBCsOD71nVhNO7NVJNWR558SrZo9es7gLy2UH86oQx7kWQjdkkD3NdH8U0DWNtKoDSJIAT259K5OzkO1dhyc9af2Tke5vQwR7wQBuxniryxqVYoRnHzA96z7TLJlSM9Mn1rRt5MFS3QcH3qGaR2KF/B5i7Vk4Azx61jPIfMKEfJjiupuADGfLwoB6nv61gTxKkhyVJIPBGMUIqMrFXTpjBO24fuya1Z7WCaMSsSMtkop4b61kqF27SRxyRVyOLbg/MeM4JrSMujPRpSUtUzTsrqG2AWJQNp5GOtbtpqRvWaJsbM5Vc4APtXOWkYC5wSG71cjXymE0fDKOvbNUqzVkdioQkmupr6F4dafVZEkmAgkBPzElw3bFbFzpE1hJBFHDtZTyzkcMOhGeufSqFjLc+dbSyYQMQwOOa2tUjczxPfM7jOVBJGc9s+nvXRam4Npann4inU5029DA1GFp7wzSKkbH7+1ePTNY+qQLAyJEwkRjglTx+vevVrnRDLYW95OAnmoNiBcgcdTjt0rjL7RLqISFbfJUkfMvGfb61wYnBzWq1RlQxVuuxzctqHG0I0S4wNrVHcSBXRI23qRtO4d61GtJoyFkilRscgjG3ipItFub0Si3gllC7QzKpP8q5aVKc3ZI7o1lu2cxPlFJKkdhj19x6VUzh28xPnJGOc5rs4LS2lDQRW/nS5KpGysGY+4HNYuq+CtWlvXnhgeBI1PyMcEY9utbPCyteKKWISdpaHP+UguW2OyYJGRnt2re0i3unj3SLuTG8E8EL71B4f0maS9ZSPMYHIyOR/tY710ureVFJDAEMAjUiVcnDk9x7V0UaOnNLYipN1HyRMDVbaAW/nWTE7gOP4kPfIxyPesUiSYCGRsbDuUr65rcm3Qr8gODnp0NZj3KROkhhRyjBtrdH9jWnLG90ZzoOnpudvouq6svh/TI7Ge0h+eRZ1lmRWfng/N2xWLr+sXlrdodUaK4uSmP3bow2ZPHy8ZBzWRca9Cdp/sDSTg7gSjf41Sursaneb47G3tEC4MUAIUnJOee9W6rsec4csveR5l4cRTBOHHVcg9wa6+zTzYFSPhueveuX8NIGiJkwoK8H1INdbYxCOeN+QCc/Qg1vUPLor3R+jIsdxKssZyV+Vgf1967MJhYmM0qEDgIBwPxrnbO0AZ2Jy+eGHp9K3rNmDhi0bbSAM9D6E1judKHyW7vKsjSXD5z96UL+lJDbTQJmQzQtjfgkPuz3xViONnmLSSFCxySoHcYPtVlLdXUKwZVQbXJwB65znmncVru5HDCZYSY1G5MZ3MCAT9Ov0qSyUKo8wlEhJJL5Ic54PtSSzFi4MmVPIVBtUnsR/9anvCpheZ2BjwAyjueflUVN7A0eefFC4KaM28t5s8gVSTjcvXpUGhMV0yMRF2UsMhj6DmqHxauzJdWdrwduWwPwH+Nafh7c1rHyRCq+n8XT/6/wCFax0RzttybZ1di6jyni2i5fsDgHHetRIPLuJZUlVY87QrLjOevSuVVRGTKGA+X64P/wBetqyne3LC4ZMtgxOBjbxyPes5OzudNNHUQ2kbWOY0QgtjAcgA9c4pkUVsjBWmYJ1J5/LJq34agFxZmV5H8pQMsCemakuJ7C3uXww5Byd27NX7O6ubK17DYRGioyykgFvvjGSP51e2ZY+W/wA64xWZ9otfMjGFAU/xHgZqza+Wl0ckAP8AMSOM1lKOpdktTm/iQFHha+yfm8o/KD2rz3QI/Iit4nQjKAnJ6nsPyNdr8ULiGPw1eTk4dlCDPfJFcVoqq0UW4OXC7sZI4Appe6zkqP30zrdOttk8kaDG5QySE5xxnkCuosbq5S3AUIcEYnhOfwYGuZs5CscSyZdeTtB59cg/Wun01d9qr27hmb5miJAJPrWsEuoncka8UCS3EkDMMYEwIIPqMjvTzHHswttbIx7q3y59qR3jnkXzZ0SRTj7md34VK8cRhdYjbxknJZVyVHaiXkaRXUixvcvIsS9gYiP8+1U7qIQgk4dQvQ/wj3q+EEUSiEbic5duOc8cVlXrsEcn5h90+3rmsZbFkOiStLeXDxYyxPPZKnkuI94ij8ySLqewLVX0dG/sfUJI0LrHG7gqew9a1/DVtHJAsuFVnXox4FYOm5OyN6ckldhBeBIVRrJVUHIJfv8AlV+xHDFEtZAx/wBVImAfbcOtLYStcMbdXELK3JKBuPUH0qfUPDd39nSaS/zETkN/D3IraFCdrrX8BSqRvbYjW8u44WXzEIjOFQMTkemT/Wsm6eV3a4mdgoOCCOB9DUUtncwzNEk7nHJDDNNubiRbLEyg44DA9PqKwlKTdmW1y6oo+OV+0eGJ2IOVUMD9Oa4TS3QxpvHJHc4r0PXwJPDUyE/K9vu/nXl2mkiOMp0xwMVS2OaW519sy7VC7VJ/WtSNVeMuAN49K52ykJUK3Uc4xxitNZ2Z9qqwQYPFSzSJbyZFK4DY69jWa9gI3kfDHcORnt7elXZZgrFg2SOciozOjP1B9Tmhbg9THnj8t26g5zmrNmzSN15zg+1WJ4o5lK5zGvQ4x+lY5k+yT8scc8Y6H3q+XTQqlVcHY6SB0z93GTxWpZxx+WFYq2TurmrW6Vvutk9cVrWc2CCemKhxPXo1uZHRwiRyi7iApyAT0Fa0Ui3kBWckunPXrjpWBYXGxiWHB6GtNJCDmLJJ61dKpZ6m8oqasdPo/iFrKy+wyEsoUqpcZ2qfStOPXtOit1eVJLiYAqyFsZJ6n0rirsqzDcuWPU1V2bV2Kp3HNdEa04aJnnzy2E3zbHTXviGCS/a4a2jj3JgjhgwAqTQNS/fTCxUQx3BVmKN0wMcHtXLM6WkwEkRkQfrWjp10JXASMRxZ6DjitIVLO8mVLARUWkjq7S1jhu2kmuBtHIPcfjWR4pWW5mNzZyBCiYXIzk4qCWLcp2yvtPQBqD5scIC/MSeCTya2liIyXLYSwqU1O+voYGmWU+mwNPKIjMed5Ubkz6HrWLqu6aYyuDtxjJ71093GzIVkbAB+YZrF1IRqgVCCQOlcNSppyxO+mowfN1Me4+aEIc47YrDuUx8q/MCcg1qXcgydrE47CsC6u1SI5YcfzrOCuc2JqqK3ILmOaZ40hikkZn2KEUnJ9B7+1bMdtBZ2ywyW95BfKAZxMw+bk9FxkDHvWp4Z1FP7Jhmzcm4sEmKwpCWVnf7spYdMDI5p+rzwr9kijeW4eC2Eck8qlWc5Jzg84GcCnJWPGlUdSR4/4fCraISCQQOP6108ELI8asGITLBzwCDzXOaMwWwiVATIVIyecDrn+ddRYukj4AfCqB83QNjkfTvXXUOCjojZ0xR5W4gEAkgd8H3rQMQ8xcoxQ9COv04rO05hHu242nOB13VvRSbcbIY5FHPX+VYo6UQhQ0xiWLYjHpI2APfNXTBsMagb25G0fMB+ZqzHbswI+yxRjAOCxYL37etRRQqsu6ZkKjJ2IvJHpV2sJ3QsMTzsXdQWOI8Y4jHpmrd/C1vC4DKzLnG0fKM+g9qjtrx5HLBDvC4SMdB7tUVy7TWzjzGwvy5U5Jb0H8z9KnS4m2eI+OJxP41iiwrxRBFC9hnk/wA66LTUjitFcknY2zA9+Rn9a5DWF+0+OblUDPGku3K9gOM12+kxvJDNGF+ZVXaD2IOM/ka2tdHNF3bNdIUHyMdguOVbHUhuPwpYHdpw+Mx7ypUnIB6flTliPmWbNGWHkmRVJxkjOeaLCB0V/JxtYh1Vx1BHOD655rGotTsos7jSSh0vNq0iBeJFB6tWNquWkkzJszzGAozn+h5q/o95st2h1G3Y4OBNtxvGMDpTdQithGhZ2YFsrGnp75rTmThuaq6kZen75LhfMAcAgYUYAPfmt23dp3aQYxGnI6DJ4H41kWpCuxskDTk9znrWtZ25gjP3WmAO5mJxn/62awk76FydjgfikJZNBZVYyKsicHtzWd4diV4YdjliVx0yVOe/tWp8SUcaXkEtGr5KjjdjqaqeGYo5YcwPtkwsgXH54rSKXKcVRtzN+CSR7WCEhGljyqHGAw9PrWtaWUs7qWJVzgFkYgrn1HQ9KxE8xZWSJAmOSCPukc5/GtywuJcZaYssiAtuGRj2IpQ3uzaOxcaS6g3CaLzXGcOvysB9OhFXw/n20cX+sYHJIwPzqpayxTK1uZHWROdsmMAY7etOii82ZgSSEwdwbAJq5NdAj5k80TLFH/GoOWQtmsvUI0SEryeCQB61tmNNivC4ZuoGMc1jayz+QWkVfl67eM1jIsyvDbl9Pu9PLfNKjKnzYyD0+tS6dqN7YoIgyZByGZfTt7EEVQ8OyiWN1JG9W+RvYH9DWlFHiaUsBJGWLMOcqfXFZt2Y46oni1JryZDLYyvJkjfC3LljyMelWDruqLHNHJaXH2cErnHTGcfrUc2keYkM1gpkmXG5QwIPGRg9/pSXT6pdaaqwxwPEXLFUJV1bvwa2u7asTavoTW7XAHmaml1C0qg7sfePvVXULaWKylmVpow2Sof+IVas9VnuMx3NjK7RKEjj3YCsOhNN1MtNFm5dUcceUDk/n0rHkS1NOe+hUc/aPDbFC5VImVmfpnB4FeW6TuEaruC88DNeowKf7Du94Cp84wPXbmvLtPI5KDn0quhl9o3IJdoIHDd60Elcgljxjt1rNs2YdQQcd6vKMtnKqQMjJ61mxx0Lcb5DHrntUbxE/MWC46+tReaVOVGCPTpSvIJgPvD1296SZaZE1zkbsbmUcVBLKkigYzu68VZ8ldwIJweB71VlthnK4BPHWrjJGcoszpZHtnxFKHxyP8K0bXWFUqlxmN8cg9qzZ7UgMjkjHQ46ms+QyqH+TPIXL+la8qkKFedM9Csr+NkDJID9DW5p96yRKfMzn9K8Zi1G5tj8mVXOelbFp4waLakqH6gVk6bR6VLMItJM9bivGkyZSAo6CrMN9HsDEjPSvLYfF9q/ymYox9eMVox+JLR4yEnjx3+ap95HbHFU5dTubq7hmfIHYZOetOgn2t8hxk4HNcSmu27LiOZcexFW4NXQgMswI6kZou+pusRC1kzukvHjADNxjFE16wUASYxz6VyDavkfK4wRUFxrKFPmkCkD16079DOVWG51N3fx7M78561zWo3i7uuWrEuvEEKgkMGAGRgE1i3WsmSXbH8nOCxPSnGm29EclXG04LQ1tQvERm+br271lkefMHY4Uc9Op96qo+WBzvkIJJJxVuLLKzAkk81ry8qPJq4h1Xoei+FJ4Z9Fit4ru3hIhuEnhklEe9mHyNz94Y49qx/E06Sy2UAuUuLi2t1innRsh2yeM98DAzVnTo518NafJpmkWeoSl5BPI9qJWjOflUjr05zV/XIIJdNu1m06zs5ILSOZ2gQIYpy2PLJHXcOcdqzepnF8p4tp0QSFBk/d28V02iMAERgenJ/ka57SlfzYhtPOTwenHNb1kH3CWHbwvGT1/wA4rslsc8VqdBBGyDan33GWcHGcdqtsZBG23AdSM9g3PeodOyNsrdWJLLjjp6VYjVJYgVJIzgZPQ1gdUXZm0msRJoj2qxjznfcz5547VBZkzFz5jbX4UDjjvmqDQGBOHHlk427ckGrmnqhcySozEHIUjaG9vetE29yZtLY041AhCq6xQYAYBcFh9fequpyNFC6geWwBwgH3c8Z/KnggzNLM6nadzFDjLdlUd8Vl6zJGv2gGYNI52nLZ78j2oeuiMW9LnjmiRTP4r1AxBs/vCVU/eXOT/Ku9svMe5d1KwhrZZFXjkjt+n6Vznh9DF4ruZID5YE7Rjac8YPA9q6ogwRxnKt8jxtjkA7/5cmteljFIcssgjuZtmWgTylGD0c559Ku6TIiTtA8xmjB3Yxnb0wAfxrOnM0NrIUkfzZiqsg6syMP0NFjcBb2fgYaXaVIzlT3zXPU0Z10tjtrSCN4XCmRXUndk8AfSqslpDLMNu915PzNwD9BVy3Ltp6p5TkxnCt0BH1qIK63BTASTB+6e9ZSOhXsWNPskhZXUeUF5+bPJrUQEKPnVgCS/pkDJqtEyI8eWLlDnBPtTpWz5m5st5QwB0BY9adrIhtt3ZxnjbBsXWWPKSYVdvYk8E1geEXJLI6ALGPLYkYMZBwCP0rqPFAjjht/ODOPkZsH8hiuT0WX7Pr0iyI3k7DKe2cmuiMfcOWUvfOqlCwBbsN86nB259ecg+3SprJI0usTSMbZgSidF+b3HSprkBriSNcGGeISFV7EDH+feodHeFnkhk2dgG67mHp6Gs2rGsfM1Hj+z24Lbtuep5Ib6+lW7UOqKHVs4wVPTFVlDKAkrsiLghsYBrSjCqw8uUZ2E7TzUyfVGqJCUEIjI2jbztHQVkamTHC0SnchXAJFbTBliDBRnBHArIuWK7lL5w3Q88fWpQ3qcX4ezHPcJM+xTKcDrzmuj8hLqdWmke1mBysq8hzWFZqj6heRSOAVwY8L0/wAa2UmJTyyDyAdjDjNRLSQQV9h073mnM3lRSygjd5kY7jvj9DV/TtRs7qMF41guQQS5DZJJ6jtmtLTLCaOEXZ2SW2MqN+0r9Pz6VWk09o3M1s8oG4lQhDYz3wa25Xa6FtoWrWIiS6uIHAjGAcr2OeOe9VLqJZFVgS0irkD+6e9Nn+1t8k8sgXqCsRGT781IoUwxJCryy7SJGJxj8ayauzSFjNvZHj0C5jbAGHcAeuOa8o08fLv6Fhg16vrp8vQrlVG0iI5Puf8A61eSWZLPHz8pp9DN6SNuM4UbcselWoiDkfKuBkE1XRQpG09OcZq5AA7cj8PesmxkgTKEkg5529qkiBUEg4z1qVVG/EanaR368U+KEb8jO0enQ1JaRE0mVA2557jFOjTht5B7fSrJtxtBwQSec9qeLJJVKHNFy1G5SS180p5ZyN3zZFI+lISweNS/TJHSt7S9PhtmC4Ijz0PJHHetO3sA0m0yHaBkr2Jz61STtoxOC6nGf8Iut0AmCpYZUKM5x1p0Hw/M7ZVSm3IVcglj1r1GxtYoE3BDvJxnAwWHYf41rG2jMsQt1Kg4JVjkjHUD1ropwurtmclbSx44vw0hmOBIiliQvP3iOo+tRXHwnYJJhiCMkEcivanEUcsu2NlBBG3GGDZpjqqwEfMjv1DZPHXp3+tdUacTB3seCv8ADK7RmKuEhVdwfrk/SsyXwVqkOUiebGchgTivoeTE0W2SH90OCT3P09KhksQlv5jBgchFUc7c9z+FRKmlqikmfPB0DVoiP3s6sQcqSelRSaLexKDI8vXhjzXul3YCbfNO5CoVRWLfMw9KwtRs4ySwhUqcgAHGP9og1hJuJpGFzyuHQ5xli7HHbmrI0xosMykZXHT0rvfs0ccbFIzuPRhVKayXyvmDKcc5rH20g9gjm7e0A+Z+QAOO5q0kSjDKMKOCM4q08WFJHPYGqsqByQx5pObe4ciR2Xhy3sI7WzdoLma7vY55BJHO0QzHnCfL1JxXL+MJYkbTpdPga3t7uATiN5C7b9zAls9+OvpWxYNaafodjPcXep/vZnliS0ZQsLKduST/ABEH8qwPFGoQ6nqCXMU19MDHtJu9m4EdgFAAFUmZSRzWmqFbIYgjv6mt22iEP7rI2nOOelY9rbeYVw2078kentWpY7QSGJ3Kdi/U9a7ZbGEdzZtHc2xDgmTAJYH/AMeFaqpG0RAwjYGGDfL+FZVo0rSESR+ybew7VrwR8sFjDLnGQuB09KxOhEjIjgYHmH+I5zgepqdZmlC7AxOcKfRe5xVVyQQnkpxyxHUj2xTllEhkTeY1Yctt59gKqJMhzXMkdurKgaOP5U7OT64rI1mR4rGd3iywIY89D71oEIkjN5h8vbgKOSNvf86z/ELr5cxUEEqWO/09TVrU521axyng2A3J+2KSGe63LxkD5j1rodSja3S9VXDo8mV2L3xmsz4fw+Vp9rM7Ahps7fYZJx781vXcRXVg0SMQX34zkAbjgGrW5KKdwxW1YsDu3Iy4PI+Xdx+NV7CXbeAOC4ADA5znjmrlxDDMYlUuZGGJMfwsvf8AQ1HA2+7+WImPceB/IVzVzrw71PTtP8q20JLh8yBwMjd09q5+7dbi53rkc5BA+vX8avrB9s0EFSrMpyFNZMam185rxkAfO0NnI+laVLcqN4aNmrpz+ZDJJNnccBQD71eL/vrjbtC7lXPoPf8AKsGwY/ZUVgcszYH93kGtFZ2Cy4G5VlBAHU1iiHuzl/GDL5ZZXDykLsA7DnjNc3ckLe2hdVWQwlSytjknIx/hXW65bx/Zp1Ls1yqDaMgYO7pn8a5a/QSwxyNbiOQncvsMYx9faulaROOXxHZgm9sre5VvNn3bV28HGOcj8az7aAQnzx8kysFZexHqPf3pdDU3GnWwhIjkZvlycjdjnPpWlJGp8pkx+9BZlPBUjjg1jK5vTLLOPs4dAxRzl426gdv/ANdaCsAqhCqnsQM9v/1Viw3DyTp5qqMNsY9wuK10MabDHLtYrk5Xjdnpn6VMmrGyRcjCyIkcjHcN3JPBOKqzoAWUbHVBuyBjrxzT42Z5FDElQclsYGcVLAoDcEMpj5CnrUx1ehMnZM5C8gMWvSCDYHkUMjBcbuPu1ozWy3tkJYUfzk+b3A7g/wBKdrZFprMJIR4h8vAJ5/8ArVGYLm1ummId4XXLeWeV9/pTqRSkRSm9y3pN0gaNBMwbJBUnaR+fFa4uZGMge3RQSAXKjgZ6j3rBvbX5UurOSO4R/vxsPmPuDVuzngntfLjmG4dEdeQfTmqTa0Zq5c2poyP5k4VkLOOnzZzSMh+V5QUjLbTtGPrTRcMsqgxqWGON2SP0qTBl2tIQGD/MAemTUyCBj+MAE0a628hgxA9gMD+deIWF3yAOOeO9e4eIh5tnKq8lt6+2K+doJ/IvJomJG1yAe/Wqpx5kzGtLlaZ3to3yAvgg+/WtC1xISAQD1+tcxpVwvLO4x6dq6DTpFSVXLZB4471hKPKap3RqpuU5KspGDgVeRdxO7GOvHWmKVbDINue2acrbefm29/UVm/I0Ro26Bj5aMOR3FSfZ9kgYfMw5qpBMFOeMDHIrRgmDuSByoyAwrORtAGYyKiBcEMOfb6VuWKRx3C7/AONecjHH1rMCiXYSgAHJ4q6rsI8AcNhdo59/woi2VoapmRVZl2ZU8pjggHkj1q+t0JyFSFlYMCPLOcL1zWFE4I2jcyqD99TjH+TTrW58idSqEcYBQdvx/lXRCrYlwudI80coLyozqCVO4/M46gr7iqU8gjui0aStIScCRf0OKhFwoTeFXc/Hbv8ATpVJ9SEYEbmUkDDFidoB/rXQ6y7mSpvY1Y58yB53AJXG0LhQfx/Oi7ikjVkIRnYZOQcjP045FUjdM0R3AJHnarhclvaqU87CEQlMlc7VjPDccsxz1p+2vow5UiS7XhSURQ+F2pnOcdc9ves/apdUDsVAITvk/wAzT0leQYgjYAkKGkJ+QKPqQBUgGGOScqv8P8OPc81zzfMVsUJkKA7lB2Z+ZuAe3FZt9IjZCL1GGJ4rQvo2corCXaPft1HFZU+wMUcnJz/nFZlLYyZ1LDcoGzGRisyZmXkAe/vW7II0hYuOfUdKwpn2XsbMiSopBZGzhh6GgykdRo092vhyyXTNU07TpRJIZopnTdISflY5B6DjFc74pa6fUIzqN/bX8qxABrYqVAyeDtA561oNrmmtknw7poxxu3P/AI1i65qEN3ciS3sLeyAXaUiJOT689/8ACtInOzOiUqqjGSQSMc+wrRjt9joU2s5bIzz+P1qFIZEDbONvzHP5Yp9tE8f+uf53OcgZx9K6mzKK6GvaB8ZVlKFcEEdDWnG+2F5AZC5PyjaVz65rPhQlU2BzE2NwHB49q1ZZdsarl5MHG1lx9azNr2QFmYosSFC45EfNTJBaiUCTZlBnawzz/WqapJL8oPlIMsXbOcdhU8MEUZA3eZjqAMEj61rFdzObB8q5W0jUOMdRxzn16Vy3jCUpp5VZhISmwuPx6etdLMjoSrmJABkKWLZz04Fcz4klgk32sEe+RkWPJGCORkjt7Vokc0maPguLydIthICwXHAH3eeoFWLhkZroZw7TIpx6bjxWlpyraW9vHI4OwI5A6tzgAfQVg3Mm9rjylKj5SynnPzEjr35oejGhksUv7yYtJ5m8J7BSDkGrFmrregugRyoOMYDCppYY982XPz/NhsAAnjP51IPmuI97gqgCrg8D1/CuatqdVDQ6Wxubm1jATbt/uBxwfYGsXUJZLybfKzkc4GP0rqIRZLZvMZYlmA5UqSG9x6Vz13MobIBIbcAcfzrNt2Orm6klpgHCGQMRkZI46frWkHZIisKoE+XOerEHmqWkET3O8gKgXcR6eo/Wr8toyo0cL4lU8Fh0FaxRhK5ka7aJs2u6mVjuBHQdeM1hT2q3tmqSE+ZGd6yA8KfQ/lXR61EiwJ5kLSBTg7c5PNZdxELWS5kj+aMhcg9fy/Gt5bWZydSLw9dF9OMny+ckhyyjDM3cY9KveZKhjRo8sw3KxPVT0IP1rL0O3Ae+j8tjCBuQBvlBP6mtG2jlaQQLKHjICjI4QfWpkk1c1g7OxZiAmh85wNzDB9atxsFTcfMXHOMcA4qGKBp7YrgowXORyOPT3qxDI7oTcKqoeNxHfHPFc7R1IesrLMyqTyOOeCSM1qaXhooTIMs67T9QT0rB3M0zK5ICcjjqf8ituzO6KFlI+/nHXGRkUqa1IqGX4vNxE1tJj/R1kyyjt2OaktIvtKJCtycFC67euO+Pam+PZUjsG7OMHB52DHJNV9FuGksoLiFoyigplG52nBwR2romveOeL6EVrLPZSplR5RfazD1+lXZbWGZGfdtuwQBIqkcc/h+dLq3+kQlVUtCPukEEg+xqravOJ1QSsybdpBwWA+ves3vY1jqXrYyrCrTbXZT/AAMM7f8APpWlAnnlAFKuDzuGAax7a4USZQHk4dewOewrYSRzKkkYwd4BB64+tTJG0UZ2ox5gWNu24nA9T/8AWr5q8TRG08RXiYwRKTX1Dd4kt5OPmOD79a+d/ijbfZvErMANsqZz6kHBqqDtLU58UvduU9K1ElgmBxxiun024JkPmYx6/wBK86tpDG25Tgg8j1ro9N1EPHmQgdutaVad1dGNGr0Z6fps6MgVAM9h61a5kfecBc4welctpd+DGig4x37kVtRTiQ+mMcGuJxaZ2xlc0UIVdwUrk9qnjlLljnPqc81lJKoSRn4XB71NHLD5Y8shSPzqGrlpnSW9xlAo5x+Qo81wzc7iOeapWrB48Kwyxwexq+VAwG2lVHUVGpspCxXr7zvUqTwfQCrn21XwyEgL8rbeM1lyAJGxDYAXGfc1XJEcSmRhtAJJ6HNWhuSNSW9UHMYVcNjPTNSNcMICQ+d4JOazEdWD7kG4plc+h4J+tVNQuAZ/JVySAGA9sfpTsZuaNn7XK2CzKsg53jPB6cCor29H2g+bGCPlZo1JXPv65rEa+2SfOwBRT19etaFvI08G+RnAOMsF/M+1Gq3C6ZorflpuAERR8qbuN30qPzgm9Sc7vVulUItkcjBSqFTtQbefqaZeXKIXbAO1duAMAkUNthc1bi6acbWLDB5BP3h61nXTI9wxjJyOOf4jVWC4dz5pQhyM9aieYxuDH97kbifaglyK2qgshCEbVznnrWLFIIpY5JY/ORWBaPdgsM8jPatK7kMhRGIHJyV71Rv4o4gwJLHH5UJX0M3JHU2enWup2bXFj4VZ4dx+ZtQKAkdcZ64rlfGtr9ivkhOnpp7eUrmEXHnHknkntwOlamnazFHpmkyXcF00Ns0trMyLmORJQc8/3x6d65zxxdQpd2tlELovYwCB5bmMpJJySPlPQAEAewrppxuc0pGhG4XLbUJwfl9PxpYpS9ztKbpCSOvANUZZyoEgPzkkY9MDir2jKzKHYjO7Oe9Wy4R1Z0VhZ3MkRGWiwO3zHFTSW0sWVMztngNnmtvw/cQ3UzoRmRRtwflP0qnqSGGd1QRxEk985qnDS5e+hm28dzEGHnuEHUuOf/1UksyO+XG5m+Y447c1I3pcNsXPJPBPtj0qMGOWVfLDSuehBwB+PtVRMZiXM8MUZCoIn2DCg/M2aw7GzDeRcyYbFwApzwMckk+pNat88VvEysVMir82B0+p/pVy1tVjCJEisR+9+ZuVdv0rbQ5txZAlulzDcNxEofJ75yR+tcvbzlhJDKqeeTxkcknnmp/Ft7Irfxb5pcAjoVXtVrw3aROjXMshMxyORzkjrWcnrZbmsI3V3sSXC4WfGQuVjK9S1V4b4x3RRh5bZ5A/wq/eboNPljKljEFJcDIBzxk0mjWW1GuriMuM5yOTWEk5SsjrppLU3tNlmmtSSsrr12qnUd+e30qrcPGYFLA7GOATyRWpY6za26qIkWYMCXRBhl5xyewpniix+zMLqLDCRdxHBUA9vf60502ldfM2STdtijpRRQxbOCpBGcZx/iK2dQGxI5fM39AQo48sjrn2rB01lWRcbVt3wyt/db0zWmCzyE26qqkbHB+YD3+hpQemhhNWeo51Plui8iIE4xnjFZk2nebGwQlHQZ81T1B7EfjWzEGJUjJUnt6Ed/yqFX3NNE8Y8uXqSMsD/SujeOpyvRnN2kRS0uJo2CIwLbD3wehPvVxHLZIHlFgMrjGP84qR4naFLWMD90hJdhjfyef61agSMLGVMioq/wAR68e9TLYunuWrULJCxlZQxXYdp5Deo/Ske2KsUZMSY3Egjn1x74xTrZGRACmHHAH17kd6I5TsZEUbnIPPXOOv0rDyOpEEaxmZgCVAwCefnHFXtPHlhW7ljgZ64Y//AKqzrhhIEO3yoyuSBzkeoq1YyuhbAPUMoHQZ7n8j+dNKxnLzIfFqtJZ3EkYw7REDjpn/APWa5jwFqMdxpElt5ZaZXZdxIXoMYrq9YkMkJBDNGhYkg4OewHsK8rhgfR/E8xw7QXC+YMttIbHIz3Oa3Ubq5yylyysemyzPLbBPLUBl4BA4HY59aookYWPCYdOrA/rUemysdODtE6qn8QfNDYnEjn73KkqvGP8AGonqbRZpKpfyfLkAPQ7hg8/zrcVzFEd65VCCSOh7VztrKsTx7mZW+XA5Ix3raeVJCEjAz6/3l61kbondP3Uh4wQF9++a8b+NWm/uYLxUx5bbSfY//Xr2SzDTQqAc5I5x161xvxF08ahoN/GF+bbkZ7EdKS0kiKseaLPnMGpoWAkGPlHrUBBBIPUUoPrXZF9zzDrNI1MQ481wT3Unr7VuWeoyNNlWwM8nOQorgopohIny5AIHI6e9advqRidoMdyNxP5VnUop6o3p1mtzu47jezbCGXb1/rWnbTxqXkdv3ZC8E88VxFrdiNkRZch/Q1ak1BDMsQbC9+eCa5XRZ1e1TO2tb/DFjzhskZ6Z6CtCO9WOBVDkr1IPr3rgLW/EbmQfPvPQ1dTVAbvaW3jI2L0575qHTNec7d7obFdnJ43Y9Aar3V15lnOCfmCg9KxEvYg+VcNgEdd2T9KtxXEEtlIA3zSjPqOn+NJQ7A5mlBcsZSHB3KMDavUf4VmQSM+uSysT5UgIQ4645x+tNOogzSJHxtTdgiqFncfbriWVUVQhYqR68c/SrUbbkOV9jVguQtx5hQM8jkYK54A6/wCfStSKeSQmNNw2HBx0PvWPZIst1vMquiJtz79/1qdL3a0mN2xRhvUEf1qWrlc6NGaZkSWZsbwM4I5IB71QBaQKJGH95h3yailuGmDqWUsD8/HQDmqcd6qyMc8Y656+9LlFzmhdTMhRQ4yiknBzkdqbHPyXLbVA4J7msmfUQQzZADY3P7elUbm9adXMXAJCqp/lT5GLnNe4uYyok3qpXnGfWsi6vjcyMV3EDcM+tQz3aqfJLDOPnbsMelZa6jJBOslq3lyRsHR+6kdDWsKZnKVjpo57TVvDljYT6idOksnkwkkTvFNuOd2VB+YcjmszxZew39xYW9vPLcJZWwgNxIpUzHcTnB5wM4GfSt3Srqa08P2V1d+JNTsRcySMtvbwCTd83zPksOCT+dWvEGhi7tft0et3Gp3EdqtwouIdm6AuR8pz2YnINb3UdjKzlucvdyZijZAPlwCfX3rqdBaOJFLsmSNzZ/pWBAiytEihWj27Cccgk1q2tqOFw/yHbgVlJnTDXQ7HTNSt7bcyLH5h7Y6iq0ktxdSMYohljy2OAKrWqeQwkkCKcAY3cmtSEPJA7rFKY0JBkJ2rmmpOWhc7R2M5kjtpWkmKtIMFl9fbmq8ku0l2LRoSMIvce1WLlUZ2EEZeU5y+cgfUnrWY2UceafMXYduezdeBVxdjCSuOnzNKiSr+6J3N8vRa1I5URfMVyFlJ9zsHf2rMtyzKxxIwJ+bIwFPpmrF0cZAVgxHLDsv+FaNnPytM5jxGf9Js1XOxNxPOSSxzmum8GTwWau00qu7DjPOKwtYiiaUzSBo4y208859qTSU8uVlk3HByrg8MfxrOcuSfMjekuaHKdFr9yZ4JQm1ImG7g8s3arlhdq+liIsUaRgMKefqKyW3XDMCpbZKpGOw6CtNYglxFiNNgBC5Pye/PUVk6j5rnVGCasacOiXFhCbgW7u44jKjOd/U/X2rT8UJBHoiRxo6kABiyhWz7ioNK1TU7O5gSdDcfZH4VfmyQOM/rU2sXUutXa3F5DKsRwVAU4J9c9PwrSVSHK0jVRlz3kzn3t3gjCqCf+Wqr6jHIx9KsRXbCPcp3Akj72D7DFX9ShKxyNC/mGDDBm4OB/hWKGD3bKGUROokBz91+eo/A1lDTcxqam9byRkghdwCnJBzn2ptxsjhwA+5/7p/Cs2Gco8UmcE5wvTv0xU05NwhVpCrHLbn7Y7flXUlpc4m9bFaZo2JU7gBySM8k8CrFrEGuIIlBaVMySBQeMf41mx3UcpErK2EckgDgL0/+vVtp5kZ57OcB2UMZM8H/AGT+lZN3epujWafzoGlhDrKHzhumOvX61BCdtjcXS7hMjbSx69OmO4qhHM3nqxZI0mjXnPHT5vxyK0okheG4jxkMuISRgn8fapi05aG62MTT7qWEeYArROu35jkBs/4ZGKtoRFfyoszpAyhhxziqdrZu8EtuXaOcvyCMgjPGKkZGF9ZpkiUEiTd2A6E05fCTNovaw32iErCFEu3zACehHvXC6raTyeW7hHgOd6544P3gfUZrsrhgLeVicIGGQACTnI/wrKvbOM2UkO7azMBHIxICH0GfXvXRT2POqfEiPS1EMJWKNNgwMlywII7H1q3BPtna2R8Kx5YEDk+tU7OLyLn7PNGomDEhAcZI7gd6smKNb2HzgwMgPzEY5+grGcktjemnpc1bc/v0Q5jVD5YYdCSM9avw7o4HIQHgYPp6mo7R4YbdoWkMkjMQSR3HTNWrQNEY4XVcYPzA5zjNYt62OtXLenMqKhRvk3AisrxEhNtODhwGOfetVF2q6qpCqoOMZ9sZrO1j/j1lXBErAAH1zUyG9j5l12wa21O4RVIUPkD2PNZhBB5616V4v07bq7hQMYFcfeWOCcDmuqEk0ebKnYxKXOetTzQlM1XIrTbYxaJ0maL7jE9h7VOl63lhS21h0NUamjiMkLvvQbMfKzYJz6DvQtQu0adtqQiC7jkgYA98dat29+bYhmZXZBvJzzk9hXOujIxDqVI6gjFISSec5osuxSmzrH1ZXZGUvvByxB+7x0q3Y6okf7pZFGXUuepA9q5CGSQlYtyIrfLlhgDPc0xMxnIcdex60ezj2K9rI725vXMkpidmkPyGReFK/j7VN9sitbIxwOY/l+Zj1fPYVxMF5PIdzyYSMDqCf8n61YkuWQrK77zgElx1Ppj0FDoJ6oPanb22r+TAsYAaYrlmzgKAOBVfSdSmuLG5mjdHMAMzlnGT0HHr16VxtzqSyLsUkL3K8E1A2oSCFYlJwvcd/Y0lSSeo/avod3/akSwLI8kvmuxd1AG3b0AznPXNZetauZrnEQ8pWADewFc3JqDSBERdpH90dTSW8zu4MiFlBydx5NV7KN7idWR0TXO5lDFizgDOe30oa9WLzEhXJ6YUdTWSkc15cH7GrCHGQNwLY98VuaZok0bFpG+dhyB2qHGMdWy4uUtitDFNIpyCf7zH1qaKzUSfvCSoHbvWx9nQL5aBi392kEaK+AOB1GKylUvsa8iOl8OKi6HANbfTP7OaR/siXUUkkmeN23YQQueueM1b166vbXzreRrJ0vII1imtUwotwThI/QZHIPORWbp99YTWFvaavYzzJbsxt5raUI4DHJUgjBGea0tdZ5GsMWyW9n9nUWsQfeQm5uWPqTk1lJ6FpXdjmrMsLpUkACrmTnjOa3tN2hcSS8kgkdOcVzkcgkmQOduPlGepNa8MjW63KuWVmYdexFEka01qdRpiPPIFjESAc72/hrXu4nhtUKvI6s5JD8IWxjpVPwXqtraA+cFK4OSeasXl5HqF28yEmMjBUNj6c+tWopRunqaPV2aMq+Z7ZGjRkd1x8iL0Of0rCuVlEvzAls4VdwOM+tdFMRFbvEIFB3YMgPA749zVeSBbeeWUHzEcZXcPmkyOoHUYPapIaK1vE6xLA8i7GJZuMYAqMHzZd7fMoH3QTgIB6Ulx886wRttDD94zHsPSmtGfs7FDhi+C2Mce1axfU55q7sUNWZpfLRVyHDOARzkciqkGfKEgBVyd5Tt6HFa2pWr+XbzCExq7bVJOcLnv6Gs4qywKQUdlUofbJwKUyoK2hesboiacE4XJbIOBx0FdAlxE9jBuClmjKsvQlf8AGuWE5jeYCP5y23BHUEc/y61u2jxlba2kjGwDAIPLbjgGsXI6Y7GvFKkskc0Tb0IVZEc7WwvTn3rRbUWMUfmO0LqW2oRhceo7GsKO6W0jMMqrI8TsqtnLgDoD2/GrMEhu4USViMDKrztAPXJ9fao30NbFmaZZLUSIrLAuSUzgtkVlFSl3OW+VVXI477eBVpZZXldGQyqWJ+XgZxjr24FR3b/umlKRq5chcDpjg/U80LczktB1msMhWWWQZ2Z2HqDT7qVgD5hLAEjAHT/IqjayAHG0krgDPc4zVuaRpYIiBvck5HbNdl7ROO2pRVrdJ2YOyoT5qJ7jrnNOlzDbqXXbFK+5l6Ad+vvxTLi3ASR2AKDDrjj8P/rU9oWZCqYYbcn5sqP9qsW7mqSGqqyXzR+eRGv70FOSue3PfNXiz3U8cflG2k28jGfM46geh9KpaYg810cblQgbskcDkfzq6b8Wdm7TEsc9NvzBweOetCSbNlJpNktu6RTN5joOPnZuPp+tZ84SPUi4Yt8hJcZ+YmsN2uNQurhnuVa4PSHPUjtnpW1obi2sPMmZXVl55yBnufcVaV3YiW1yWaWExyKNyKgO1jzuOAcfmKzNWYyxgQB5FUgszdRx2HTNWcmWFofKCytuZSTz69PcUy4dYoFuYk3IfvrkgnPGcnqRWy0icTj71zBinBuJDK3mIG/dOvT8fSuggnlS6DHzJFUD5iu/ANMXT18g3FukTtEfni7EY+8PfmrOkHy5pmtCXj2bcdSKxqK25tDcvpKstpNNIN5EgLMo6CtW0/eeU6nDRR7uOeDxzVFUieGVF2wsdq4Jwd2etW7RUJuS7qpx17YFYbM6lsa0mFk2DkyIxzjg4IrMvkMiDIz8mR64rSLeYsLtwXBGPasy6kZQX6YX8MHtRIRwHii3WTUgcbSy9RXI6hZAEkAFgefQ13HimPE0bI2fnP5VhzRiTJRckdvWiMrGDSZwl9aKBjbzmsSeDGSox7V32p2gf7q8965y5tcuSOCPauqE+5zzpnNlCOtG3jpWzJaDbuAHvVY25GcqcVpoZcpR+aRe5x3NCrkgE4XPPNStA+/5QSfalS2dpApyvGc7SafmTYjmfeR87OFGFz2HpUZOanMEzFtqFjjJxUtvah1JdXA/3cmnuK1ius8qwtCrkRsQxX1I6U+aTe64RYyABtBOOB7mtSPSDcxsySqmwfKH4Lf/AF6hGkyy3CRBlYtnJUdPanzWW41BszFyz4QbmPQAU3a3YHjrxXUReGyhDPvOSQNh9q29H0L7Mojuot0ZwwYLkYPb61i6qNFRZxNnYTzNuVCenT0rpbTTUnlitCUijLYLYwcd+a6Wy05rSIxAqqO2YpIYwx2jtnsa1rWyyGLRMEwWIkOGY/1rOVVvRGsaKW5TtdIs7VgsCfLCo28ZyT/WnmHaSDj1bmrhUW8YWECND1GMVSmcMewwc1lq3dm602IJNp2qp2EdWqKARG8iF08hg3DzDGBux7Z4zSTLkkNkcZyO9TadavcXEFtGpaSVlRQO5JxTJsdJCvhWEkxvrZ9OIjS6zcWd6bJNMjuBBawCEGcDcTuJ7cd6VNI0i1maCfW8zRkqRFas6K3cbs81Je6f/ZzwgTpPFOnmwyxjh1z6HkdOlRzMqK6nAb/mjD84JGR1resZJNwyFaTduPOcjHTFc1pv+kXUgclVBO0dceldTbxIhXdypHOOaqVy4s2rWxtpCUil2Soed+cMDzx6VoW00VsnlQoDPngkEk/iO1YVvPAsLCUuNqkqVOM/WrMNypRWSPbFjB2IePfmiKtqatvZl6ZcTB5njkcnIVfujPoKiug8atiNWdjw5znpycf1pTLvjdrVWSNF5fgkk9qjcNIBK5AcrhjnAVcdB6mixm2PaFVuzmVZNkYZ/m+9x93Pv6Vn36SuIsZAjPmZK8EnrV6CKMoUYbcYb5jjAHT8TQkYni2ZZlYngdQTnBrRSstTJx1uVLjUHvYYYJkEaxIykqv32x1rNcoJY8B2cMS6gdRnOf1rXvAZpEj34jAIVWHOcY5NZ48xXil24BbajZ6YGNpqb82o1uCLEJwXcYDn7w4IzwfwqzHGcLJA+JXJj2lslT1BH602ZnVN0QCknIXHCnvRbt86so3qARyejf05zUPQ1Wht2k0KystwGWBlLM64LZ/wJq1pzDyRJazGN8g73IGDmsWNPkDqpzgjLKMrV6JRiNREsj7cn58K3vxUq7ehqnYTUL0LJhWbcpyGVerHrionbbaqDHtVT8pbruI5psxYpksE3gYQNx6du1LDIjZ3jdKDgbuRjvxTUdSJDY3UqC6MM4ATptx1rVt4lacmPoOBnp0zx+FZwDBIztYTu/INaNtJGrYfd97cMcEn0rVvSxgldlfYS4XyxkAume5z0xVYRnyLiOTCydUP3QMnnn8elazoscUcknyhTuHbHqKyZQZSQBkOcgnovPWpSsX6BxI7qwC3CSZwDwOKlvp90CRswVnXaRxkYpGjIVJIQvCbWI5PHtVC9tWMvmsrlSAIwD0pPqapXRB/Z8sDsdha0J+ZEPzLkfezU7eXbNCuAbUOow2eMdzTgJk3B3UxjqcEnp0qW3jS7jlD7cDOMnBz/WtYO5jJ2H6fNBPd+YJMCFmyOnGamhie80tooWLSLIWXGOSc5GPcVTlgEAkc+WkacCIffLYOc/pTdLlkV98cWQcoR0xjvWt1HQxceZ3JreCXS7K7uLZswOQWRwDg46fhUfhws8E0oK+XK20oOp70t95t0Dtb7x2AL0//AF1EtsQ4ktztwdn7skcgck//AFqxnLmZrGHKblxK0961ywT5QcD+HPTipbVsSMqlizkZB5OMZrNCXSssbyL5RUhW24+UdaXz5CWlbAwu9SB68D+VYyNonRx3P76XkhBGTnPTjFRXbb0Krtwu1SapWkjPCqH+N1zz0AHNPlkBb5PmXOWINCVwkct4q3bFZOMNiscFi6sMA+3rW74qIKuUBIyuAfWsP/VSnepA757GnZI5+o24jFwCQAJO49a5++tu5AVlrp1DPwjDI6e9UtQgWSM7vlkHt1qk+qEzlJIv4sZ7kGmrbq+Tg59K1HjDIRgh89O1RLCc91OMj3q+a5PKjGnsgMNn7pBNXLa3B+Zhg4xkelXo4wkgEi9qsxWwLfuTnPODQ5aWBQ1uVYtKLSA8hMYBxzV+w0RwxMLDJOSFHB/wq3a7g6gkqwI4rpLARGTfjL9COgNZyk0Vyo599IdowFjCk9cjr+NT2/hwrHG0bbZM7t6qc++T3rsGmUPhIQI1HABBGaptKHcFmVVPUDP9KhzbKSRnQadMItglG4ewA54qWG2LQ+SZ5HdBtdAAcY96vG4jjiLs6oP7wUnFZct2C8hQOM9SON3vSuxpE6CO2jMSyy+U3LgsefbNQXFyjNvRzgD5uOaqm6jcExE7AcZc4Ofeod42jaDgnnBqkmJk10xDBiAiY4Hr9aoEM3zuQEHc96sXG1GBeTdn+Ec1Wdl3Ag5HpTERtGxZcZGegNWLNpYbqJ7Unz0cFHHXcDxSBd5zgjj1p1szCdJYy0bIQylTggj0NO66BY663nS4lM934bUzuSzvG0sas3rtHAz7U/UZJbqaF57YWyRIEjjClVRQTgAHk855rZabxJeQW9xFFqKSeWFfaxAcjo209M+1c7qdzdy3LR6jJM10nysJicr3xzUGkTyxJWgvHUnCvyCPWujs7pvKRmdlG3HHb1rnpoPtAIBAbrgcflTIZriNdpZinbI7V0yRjCTOzs7vdNsDb17Lxj8av26EMCxZwVII+6PpmuMsbjbKoaLJJwSSR+NdVE5MYUsAByVHOfrWLdtzdvXQ07ONZLmPdh0AIH8KjjrV+eFSgcqpUKG9ASD1qjFdloQgVI4SQfcH+tXshyAQ2AB9/jIpcw7XJraL7Qknm8LN+8ZsfMSOgB9KsW8SmMeTGVZjuVemQM4+lIi+aoLMW35UMB9wVO8IaDCN8m/l3PPTj+Rq1ruQ9HoZDKiXMrRB1kQhSrDrxnNVJY1kAJRiTyy9gfWnXt06SvAw2jqcdc54OevSt610oukbQsUSQHryrDuTRCPNsNxtuctcRyy23D7uNwGePofeoUQ/vAoKMQFK8cH1Oa1L5ZEmMAjWRUO0tnaGB6fQ1mSIBcbmcEHIIJ3bSOmfb3qJDvYvWvMfYhh95uowfStG0UOpRmcxsNpKkDHtk1n2EahVcK68YG7nr7/41qoJFdEYg8n5VQ4+tSmarYzLmLy/vAgHgDuamtYXdDMpXIOSB61YZdzIojXJIy7nP5dhT4rWVm2wkDkk88EeppxJkxjRlNroWVjnAz+tPBPm54xwevAFWG+eNsFWO7DbTz+FQLnCLsVFXr6t0q79zO2o+QF3dWzJGeODx0pYBG6qwfDRnIXH8OOv+fSpniCwk8hRjHPNVS/GNuw9s0LUo09Mtorl4ciPoQ6yHG70rM8RfZ7Z2it5I5fLYLlcqRz0+lSreRfJ9mQp2ABPHvmqK20styjMQu47iDz+NW37tkhtdSEAMd/R3JC9hjuBU1lDG6lwGe5J6E8AA8ECpp7UQquAzGNQcs3Ge9aFrAkkrNIeBglV4AJ7ULRmL11OevLR7idprgKqj5hznd9cVZgDGNp2YplgF2j7ox1qzqUXno4ikw4AyBxzxkU6KFY0AckIo7HGPxqNW7BYpSQMJWSVc8fKAcA+4Pr9aW0RmkzGxhUA844xjpx1zTIriG4E9qLiMF2HTovpg+laywvC4hlciPBK8DGB6+lKSdjWEdbMqAu8IjViNo2Ebfur3/EmowrGaZ26EhEAGAcDAq2u5t+UZeh2cjgd6ntogvzzHcoOeBkfhUa2KtrZEcERibypDgKu5j6j0/OnYXKBRyQCox2p1xOGdVP3n7H09KImDTLghsHB/kKa2M53Of8AE64tDnIYdazn2zEMQSHrZ8RREW8oHORwD3rKhn3WykgfKo5PrQ2ZrdkQXy2woBx0IHIouofMQ7lwcd+M1ZTZIpOATmlnhG04OVPJWhSsBzstsqIWGcniqs0eeMHpwK3JoEkU8lSPWqflkKd3P93HWrTBqxmCNV2llyMdM09P3J68dcVP5ZGX4z3B7ilYLhW2gr3A60CHpOxb+Anua1NPuNhCMAAeemRWRHJHIpCDaN3THNENx5MxX5sZ6dKLDR1sc5YDaiEAY+Wo2uSAqSbGyMAL/WsyKaIlWDOuRycdKk3QRKdkhBIyCR1NRysq4jkM7byFAYcA8Ukk0TjYrkYPLY4qncbNwZ/09aAWdiI0AC8nNCVhNiziJ/mSMF/727BpkECctK7ZHABfio3Lh8v0Y4AFPbGCSd2D1PTNUmIlCEfKMBfbvUZjUSnd0HQU7IA+9+dJt4zgCh+QrXHOQq5PJPQelaOjOIL62uJowyxSrIVPcA5qpbxxllMgJHX8K1dOMb6nbNdRAWiyKZPZM8/pUbDN6dbG81GW5j8QoBMxfE0cm9c9uOuOnFM11oJ3tBFJLcCCERefIuGlIJOfpzgZ9K0rm7P26az1vyJLKQ5hlhC/uFP3WUjtjGRUPieFYTpaNKkgiswu6M5V/mbkGky4ni1pIrrGJCODkHFS3FttlIzu9AvcVVtwFbHRTkCrscS7Vx97tg8/Su2Zzw1I4VYMpJByeBnP6V0Gm3KrkgN5hP3WGKxipYkMDu9QOPrV+BWIVgxY9vUVzzRvFnQ2dzvMaDaHLHJPGfTitRkzxJIjNgfdJP8AOuZtiykuZFAB5B4JrpLK4jEIBVM9VbGTWJoa9uXiiZgyonZF70sqlkWFABkbzjoPaoLWXKlAcgknLjj8BTpJUAMa4DcgtnGB61V7BuctrXmLfmRwSJG6r0PtV7SdVvEshZq26PcQgYZKfSrN7Ak4DOcIODkdfcVDZWYt386ECSJs7H8zDD6DuaceZbbA2mrMtFpZbcLKfmU7iGIBrNul2XJYAB+GyRnd6gitO/klwrbd2cMcndtHT65rKnJKADAZeeO/PWqYt9zSslBnXzOdwwNjDP0rZXyjAxBEZ6MAOfyNYOnyEgmTYRnGR1+tacIcQIzgP6FyD39KzNIkwUws4X5CSMtjOBSqyOhRZyduRv46/SmMzFWYFfOycljlV9vrSR28iYWMA5JwAvHP1px0CZalkiVtvyKCCNp5GfXiqEisW+bnC5BJxkfSrBP7rAizg8yNwWPt7VFOWEgO0DcOSMNn2FVdGdhtrJI42bgXOcZ5AFEqBQFzyMkuQefwqVIgEJbEfoXPQfSlkjVU2OVC4znufT8aYyi7FpUMgCDIC45Jq4CEOyNnCkYbb71TCkhd3DHkDOSB71chcSKMZJOBjHGPc00wepYUhi4mfbEg/EnAxx3qaFXZD5S7QpHmMf6UrZC7huzgsOBjHuPSnDYEBywXGDgf5z/Om1qZLQzbg78siKSCduB1xWTrQluNGZsGLa2MdzW5fkxuRGVPlr6YwT6etZdzHKjrHcrE8LDOHbofepTs9TWLOTs57dbmBI4SRGqnoSS2eprt5ZTOlv8AJudnA2gnp6Vj3en2m6OdZ48Lnd5Axj05ra0iNQInKs8mCERTyB6n0Jq5yVrFo0YIRK4bnYSc5Gcnv+Ao1m5isYSAwBY7APYdeKnsDII1LrsQEfj7CszV4Vu5isjqEX5nZeuPSohbdgrIqSyi5ezaIcsCzHHQd62LKJNnABAGcdwT61l20byXHzDbCo2rn0H8q6i3hRUXAOMbzj17CqbTRg3dnM+JISIyvBYfp7VytsN9ko6NyM+vNdj4iQmFyQoPJx/WuM0xgsBAJ4JGfxrEkS3TZMVJOR0FXoGO394mRnk5qEZ3llGd33s9qkgRw7ICCp5zQBDd2ihfMjJwTnbVQRlyeg9q1VLq+WwFAxtI5qM2rOwCkfNzn3pqTGzKeLDYXlO49DULQExAqDnPOa1GhVA6uNsmfXOailgyoVCxY9qtPQmxjm3z84AyDjA4qvK53HI2kevetwREnDDDAYyaiezBwGwfencaKNu7GMYfg09pnK8g5J4qz9kwSNucdhTIrVjMCV6n7pouBWwzZ28s3p2qVcoAhOT3b1q4lvhmUDAPQDtS/ZWzxjdU3AqwRPI+XJ2g9MVKIwoyAGz0HpVz7JJgbnyv8qkFrh0TdtxzuFFwKgiRiFCs2KVIxuKtwAe1XJUj2hVZiFbFTSIowuPm647VPMNbkcSL8gGVJPU1bTaAy5KjPYdagRwzAcfL1FaOk4XVLWeXiCGVXZevAPWpZpypalx9OjQmGa9gguAcmLazbT/tFRgEenaqF7BcQ3BgnUBhhgVwQwPcEdQfWurNsVvrBjcSRtbDAVIWfzOcl0KjDb885/GsfxO0LTxQFF3QxsHVTnbliwTI/uggUCT1PJZUAjdh1XGKjP3Vboc0UV3dDmRbU4APcH86uKoQEAk7cgZNFFYyLiTyEgqM53kZz3rc0xcqDk5AoorB7m8djRtxjdtJG1scHrmrOoK0entNHI6vheRjuaKKfUYkSbpBGWfa8ZLc9eM1RlYC4BKKQ5Hy4wBwOmKKKuOw5Fi6Gbfd0KjjHFZzcuWGEZUJyvf6+tFFDJRfthtQ4/h5Ge1X7P5powQCCoPQUUVl1NEXvKVYA4GD5h+n5VVuWZPlBJ3HJJ60UUwZJnaQ/wDERjPoPakT543zgEdx160UU0SQ3Q2tvBO8nk96VV/eRNk5Y8nPX2ooqnsIilOGMagBWBzgVWUsrjDNgdB2oopx2A2bWR5XhiZjhgQSOvHSi6neOaNF24245Ge9FFX0IkTTwws6SSRI7F15bJxxUN7aQLGrmMM7ZYk/y+lFFQxrczrK1hikykag78AkZwMVt6VBGPKfHzzMyufYelFFZlEsVw32SRtqZ6DjoPasa9YpEoXje3J/GiigfU1LWJPPmXaMAZrdUkQkjriiitIdTM5vxGP9Fl9sL+GK4bSwGSUEYw56UUVmJ7lyUkYHb+VPt5WMbjONvpRRTZJYVRIgLddpOar9EjOeSuTRRUlBc/vGJbkgCmRoMv1z60UVa2JBvmOD2qaCBHGCOp7GiipG9yKVQGbAxyRTXjVUV1GGxnNFFA0KqBzubk1IQMx8Dmiigb2Gklrjyz9zb0/GkAxKEH3c0UUC6Ekkaxqdo5yetNYbdpySSQMmiikiomhHGsYJVQD60xyfnHTjtRRUsoljvLqG2EcNzPHGeqpIQD+FQoihC2MnBPNFFVED/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple acrally distributed target lesions and mucosal erosions are present in this patient with erythema multiforme majus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple typical target lesions are present on this extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical target lesions in erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A larger lesion is surrounded by multiple, oval atypical target lesions of erythema multiforme. Note the presence of only two zones of color change.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43785=[""].join("\n");
var outline_f42_48_43785=null;
var title_f42_48_43786="Overview of the causes of venous thrombosis";
var content_f42_48_43786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the causes of venous thrombosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/48/43786/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/48/43786/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/48/43786/contributors\">",
"     Gregory YH Lip, MD, FRCPE, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/48/43786/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/48/43786/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/48/43786/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/48/43786/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/48/43786/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/48/43786/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presentations of venous thrombosis are deep vein thrombosis (DVT) of the lower extremity and pulmonary embolism. The causes of venous thrombosis can be divided into two groups: hereditary and acquired, and are often multiple in a given patient.",
"   </p>",
"   <p>",
"    The inherited and acquired causes of venous thrombosis will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"mobipreview.htm?1/6/1132\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The diagnostic approach to the patient with suspected venous thrombosis, the evaluation and treatment of patients with documented venous thrombosis, and the various causes of upper extremity venous thrombosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=see_link\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27754?source=see_link\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=see_link\">",
"     \"Brachial plexus syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIRCHOW'S TRIAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major theory delineating the pathogenesis of venous thromboembolism (VTE), often called Virchow's triad [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], proposes that VTE occurs as a result of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alterations in blood flow (ie, stasis)",
"     </li>",
"     <li>",
"      Vascular endothelial injury",
"     </li>",
"     <li>",
"      Alterations in the constituents of the blood (ie, inherited or acquired hypercoagulable state)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A risk factor for thrombosis can now be identified in over 80 percent of patients with venous thrombosis. Furthermore, there is often more than one factor at play in a given patient. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifty percent of thrombotic events in patients with inherited thrombophilia are associated with the additional presence of an acquired risk factor (eg, surgery, prolonged bed rest, pregnancy, oral contraceptives). Some patients have more than one form of inherited thrombophilia or more than one form of acquired thrombophilia and appear to be at even greater risk for thrombosis (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Multiple inherited thrombotic defects'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population-based study of the prevalence of venous thromboembolism (VTE), 56 percent of the patients had three or more of the following six risk factors present at the time of VTE: &gt;48 hours of immobility in the preceding month; hospital admission, surgery, malignancy, or infection in the past three months; or current hospitalization (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Multiple acquired risk factors'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, many patients with VTE fulfill most or all of Virchow's triad of stasis, endothelial injury, and hypercoagulability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUPERFICIAL VEIN THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial vein thrombosis (SVT), a less severe disorder than deep vein thrombosis, occurs in both inherited and acquired thrombophilic states and may progress to DVT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. In 63 patients presenting with ultrasonically-confirmed SVT of the lower extremities as a first thrombotic episode, and in whom DVT, varicose veins, malignancy, and autoimmune disorders were absent, the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty patients (32 percent) developed DVT at a median elapsed interval of four years.",
"     </li>",
"     <li>",
"      Fifteen patients (24 percent) had recurrent episodes of SVT.",
"     </li>",
"     <li>",
"      The odds ratios for the development of SVT in patients with factor V Leiden, the prothrombin G20210A mutation, or a deficiency of antithrombin, protein S or C were 6.1, 4.3, and 12.9, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/25/43417?source=see_link\">",
"     \"Superficial thrombophlebitis of the lower extremity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INHERITED THROMBOPHILIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Common inherited hypercoagulable states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia is a genetic tendency to venous thromboembolism. The most frequent causes of an inherited (primary) hypercoagulable state are the factor V Leiden mutation and the prothrombin gene mutation, which together account for 50 to 60 percent of cases. Defects in protein S, protein C, and antithrombin (formerly known as antithrombin) account for most of the remaining cases, while a rare cause is one of the dysfibrinogenemia (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"mobipreview.htm?1/6/1132\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each of these is discussed separately, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Factor V Leiden mutation &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prothrombin gene mutation &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20743?source=see_link\">",
"       \"Prothrombin gene mutation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Protein S deficiency &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13176?source=see_link\">",
"       \"Protein S deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Protein C deficiency &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=see_link\">",
"       \"Protein C deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antithrombin deficiency &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24136?source=see_link\">",
"       \"Antithrombin (ATIII) deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dysfibrinogenemia &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link\">",
"       \"Disorders of fibrinogen\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thrombotic risk associated with the inherited thrombophilias has been assessed in two ways: evaluation of patients with DVT (",
"    <a class=\"graphic graphic_table graphicRef56252 \" href=\"mobipreview.htm?21/4/21579\">",
"     table 2",
"    </a>",
"    ) and evaluation of families with thrombophilia. In a Spanish study of 2132 consecutive unselected patients with venous thromboembolism, for example, 12.9 percent had an anticoagulant protein deficiency (7.3 percent with protein S, 3.2 percent with protein C, and 0.5 percent with antithrombin). An additional 4.1 percent had antiphospholipid antibodies (aPL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were noted in a series of 277 Dutch outpatients with deep vein thrombosis: 8.3 percent had an isolated deficiency of antithrombin, protein C, protein S, or plasminogen compared with 2.2 percent of controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/19\">",
"     19",
"    </a>",
"    ]. The prevalence of a protein deficiency was only modestly greater in \"high risk\" patients with recurrent, familial, or juvenile onset deep vein thrombosis (9, 16, and 12 percent respectively). A higher frequency of inherited thrombophilia has also been noted in patients with thrombosis of visceral or cerebral vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall 8 to 13 percent prevalence of an isolated anticoagulant protein deficiency in patients with deep vein thrombosis does not include the contribution of factor V Leiden or the prothrombin gene mutation, now considered to be the most common causes of inherited thrombophilia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Physicians' Health Study and the Leiden Thrombophilia Study found a 12 to 19 percent prevalence of heterozygosity for the factor V Leiden mutation in patients with a first DVT (or pulmonary embolism in the Physicians' Health Study) compared with 3 to 6 percent in controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. The prevalence reached 26 percent in the Physicians' Health Study in 31 men over the age of 60 with no identifiable precipitating factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prevalence of the prothrombin gene mutation is approximately 6 to 8 percent in patients with deep vein thrombosis compared with 2 to 2.5 percent in controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/16,23\">",
"       16,23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20743?source=see_link\">",
"       \"Prothrombin gene mutation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the total prevalence of an inherited thrombophilia in subjects with a deep vein thrombosis ranges from 24 to 37 percent overall compared with about 10 percent in controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Thrombotic risk in families",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute risk of thrombosis among patients with inherited thrombophilia was evaluated in a report of 150 pedigrees, which compared the risk for thrombosis in individuals with inherited thrombophilia due to factor V Leiden or to antithrombin, protein C, or protein S deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/12\">",
"     12",
"    </a>",
"    ]. The lifetime probability of developing thrombosis compared with those with no defect was 8.5 times higher for carriers of protein S deficiency, 8.1 for antithrombin deficiency, 7.3 for protein C deficiency, and 2.2 for factor V Leiden. The thrombosis risk in affected women was also increased during pregnancy and the use of oral contraceptives (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Pregnancy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Multiple inherited thrombotic defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second thrombotic defect can occur among patients with any of the causes of familial thrombophilia, particularly factor V Leiden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link&amp;anchor=H16#H16\">",
"     \"Activated protein C resistance and factor V Leiden\", section on 'Combined inherited defects'",
"    </a>",
"    .) In one series, factor V Leiden was present in 4 of 14 patients with protein S deficiency and 6 of 15 with protein C deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/25\">",
"     25",
"    </a>",
"    ]. Carriers of two (or more) defects seem to be at a higher risk for thrombosis than their relatives with a single defect. In one review of four studies, approximately 75 percent of the family members who were carriers of two defects had experienced thrombosis compared with 10 to 30 percent of the carriers of a single defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inherited thrombophilia also may interact to increase the risk of venous thrombosis in patients with acquired causes of hypercoagulability, such as oral contraceptive use (",
"    <a class=\"graphic graphic_table graphicRef56252 \" href=\"mobipreview.htm?21/4/21579\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/28\">",
"     28",
"    </a>",
"    ] and pregnancy (see",
"    <a class=\"local\" href=\"#H23407368\">",
"     'Acquired plus inherited thrombophilic defects'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    However, not all carriers of two thrombotic defects have an increased incidence of clinical thrombosis. In a large thrombophilic protein C deficient kindred, with the G20210A prothrombin variant present in 13 percent (prevalence in a normal Caucasian population: approximately 2 percent), neither the presence of the prothrombin variant nor an elevated plasma concentration of prothrombin was associated with increased thrombotic risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical characteristics and diagnosis of the five major causes of inherited thrombophilia: the factor V Leiden mutation, antithrombin deficiency, protein S and protein C deficiency, and the prothrombin gene mutation, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24136?source=see_link\">",
"     \"Antithrombin (ATIII) deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13176?source=see_link\">",
"     \"Protein S deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20743?source=see_link\">",
"     \"Prothrombin gene mutation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4518697\">",
"    <span class=\"h2\">",
"     Other alleged inherited thrombophilias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The remainder of this section will briefly review other alleged causes of inherited thrombophilia. As will be seen, it remains unclear whether some of these disorders are actually associated with an increased risk of venous thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Heparin cofactor II deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    cofactor II (antithrombin is heparin cofactor I) is a heparin-dependent glycoprotein that acts as a thrombin inhibitor. Several families have been described with quantitative deficiency in this protein inherited as an autosomal dominant trait. Heterozygous individuals have plasma heparin cofactor II concentrations that are approximately 50 percent of normal values.",
"   </p>",
"   <p>",
"    It is not clear if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor II deficiency is a significant risk factor for thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In one series of 305 patients with juvenile thromboembolic episodes, two patients had heparin cofactor II deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/31\">",
"     31",
"    </a>",
"    ]. However, each of these patients had a second defect: the factor V Leiden mutation and protein C deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Plasminogen deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital plasminogen deficiency is usually inherited as an autosomal dominant trait. There are both quantitative defects (type I, hypoplasminogenemia in the heterozygote and aplasminogenemia in the homozygote) and functional defects (type 2, dysplasminogenemia). Venous thrombosis has been reported in some patients identified with plasminogen deficiency, but a familial predisposition is usually absent.",
"   </p>",
"   <p>",
"    The development of ligneous conjunctivitis, hyperviscosity of tracheobronchial and nasopharyngeal secretions, impaired wound healing, and hydrocephalus soon after birth have been reported in a patient with homozygous plasminogen deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/32\">",
"     32",
"    </a>",
"    ]. Replacement therapy with lysine-conjugated plasminogen resulted in marked clinical improvement. There have also been adults identified with moderately severe type I plasminogen deficiency secondary to homozygous or doubly heterozygous mutations in the plasminogen gene. The most common findings are ligneous conjunctivitis and ligneous gingivitis; less common manifestations include ligneous vaginitis, involvement of the respiratory tract, ears, or the gastrointestinal tract.",
"   </p>",
"   <p>",
"    Despite the association of severe hypoplasminogenemia with ligneous deposits in multiple organs, the clinical importance of plasminogen deficiency as a risk factor for thrombosis is uncertain. In the Spanish study of 2132 consecutive patients with thrombosis noted above, plasminogen deficiency was seen in 0.75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/15\">",
"     15",
"    </a>",
"    ]. However, this prevalence may not be significantly higher than that seen in the general population. In a cohort of 9611 blood donors, for example, 0.29 percent had asymptomatic familial plasminogen deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other rare fibrinolytic defects such as impaired tissue plasminogen activator release or increased plasminogen activator inhibitor levels have been linked to thrombosis in isolated families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/34\">",
"     34",
"    </a>",
"    ], and may increase the risk of venous thrombosis in subjects with other thrombophilic defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/35\">",
"     35",
"    </a>",
"    ]. In one of these kindreds, six of the seven subjects with a history of thrombosis were also deficient in total and free protein S [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/36\">",
"     36",
"    </a>",
"    ]. Once again, the pathogenetic importance of these defects is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=see_link\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dysfibrinogenemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with dysfibrinogenemia have structural defects that cause alterations in the conversion of fibrinogen to fibrin. Approximately 300 abnormal fibrinogens have been reported, and more than 80 structural defects have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The most common structural defects involve the fibrinopeptides and their cleavage sites, and the second most common involves the gamma-chain polymerization region. Approximately one-half of the mutants are clinically silent, whereas hemorrhage and thrombosis occur in almost equal numbers of symptomatic patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link\">",
"     \"Disorders of fibrinogen\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Factor XII deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor XII, Hageman factor, is the zymogen of a serine protease that initiates the contact activation reactions and intrinsic blood coagulation in vitro. Severe factor XII deficiency (factor XII activity less than 1 percent of normal) is inherited as an autosomal recessive trait; affected patients have marked prolongation in the activated partial thromboplastin time (aPTT) but do not exhibit a bleeding diathesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/39\">",
"     39",
"    </a>",
"    ]. To the contrary, venous thromboembolism and myocardial infarction have been reported in a number of factor XII-deficient patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/40\">",
"     40",
"    </a>",
"    ], including John Hageman, the initial patient described with this abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/41\">",
"     41",
"    </a>",
"    ]. This thrombophilic tendency has been attributed to reduced plasma fibrinolytic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency with which severe factor XII deficiency leads to thrombosis is uncertain. One review found that 8 percent had a history of thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/40\">",
"     40",
"    </a>",
"    ]. However, interpretation of this type of data is difficult, since patients with complications are more likely to be reported than those who are asymptomatic.",
"   </p>",
"   <p>",
"    This concern has led some groups to perform cross-sectional analyses of thromboembolic events in larger numbers of unselected families with factor XII deficiency. In a study of 14 Swiss families with factor XII deficiency, 2 of 18 homozygous or doubly heterozygous patients had sustained deep venous thrombosis; however, each episode occurred at a time when other predisposing thrombotic risk factors were present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/43\">",
"     43",
"    </a>",
"    ]. Only one of 45 heterozygotes in these families had a possible history of venous thrombosis. However, other groups have found a more pronounced association with thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Thus, it remains unproven if factor XII deficiency is associated with an increased risk of thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4518711\">",
"    <span class=\"h1\">",
"     ANATOMIC RISK FACTORS FOR DEEP VENOUS THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following section will briefly review several anatomic risk factors for the development for deep venous thrombosis in the upper or lower extremities; these are not known to be inherited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Paget-Schroetter syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paget-Schroetter syndrome, also referred to as spontaneous upper extremity venous thrombosis, is usually due to an underlying compressive anomaly at the thoracic outlet. This is frequently due to compression of the vein either between the first rib and a hypertrophied scalene or subclavius tendon or between these tendons themselves. Compression between the clavicle and a cervical rib as well as partial occlusion of the vein by a congenital web have also been reported. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27754?source=see_link\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=see_link&amp;anchor=H24#H24\">",
"     \"Brachial plexus syndromes\", section on 'Thoracic outlet syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     May-Thurner syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamically significant compression of the left common iliac vein between the overlying right common iliac artery and the underlying vertebral body (May-Thurner syndrome, iliac vein compression syndrome) is a common anatomic pattern in normal subjects, which has been associated with unprovoked left iliofemoral DVT or chronic venous insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/46\">",
"     46",
"    </a>",
"    ]. However, visualization of a clot this high in the pelvis may be difficult to detect using ultrasonography, and, if DVT is strongly suspected, further testing should be performed using contrast venography, magnetic resonance imaging, or intravascular ultrasound imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\", section on 'Contrast venography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    May-Thurner syndrome is most commonly seen in women between the ages of 20 and 50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/48,49\">",
"     48,49",
"    </a>",
"    ] and may be more common in those with reduced left common iliac vein diameters",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe degrees of iliac vein compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Episodes of DVT may be recurrent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poorly responsive to treatment with anticoagulation alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], and may require catheter-directed thrombolysis, venous angioplasty",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intravascular stenting, especially in those with limb-threatening thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that compression of the left common iliac vein by the right common iliac artery is the only plausible explanation for the clear predominance of left-sided over right-sided DVT in the general population, which was left-sided in 55.9 percent (95% CI 54.0 to 57.8) in one study of 2576 subjects with unilateral DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Inferior vena cava abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital venous malformations of the inferior vena cava (IVC), including agenesis, hypoplasia, or malformation, may lead to DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. In such cases, DVT primarily occurs in young patients and may be bilateral or recurrent, a clinical picture similar to that of the inherited thrombophilias.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 97 consecutive patients presenting with confirmed DVT of the lower extremities, 5 of the 31 with thrombotic occlusion of the iliac veins had an anomaly of the IVC; thrombosis was bilateral in one and recurrent in two. Average age was 25 and 53 years in the groups with or without IVC anomalies, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one report of 10 cases of IVC agenesis-associated DVT (8 men, two women; mean age 25 years), DVT followed intense and unusual physical activity in eight, was bilateral in six, and was localized to iliofemoral veins in nine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/60\">",
"     60",
"    </a>",
"    ]. None had symptoms of pulmonary embolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic testing and screening for the bona fide inherited thrombophilic disorders (Factor V Leiden and prothrombin G20210A mutations, deficiencies of antithrombin, protein C and protein S), including the timing of such tests as well as the possible interferences from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef76966 \" href=\"mobipreview.htm?43/22/44396\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ELEVATED CLOTTING FACTORS AND CHEMOKINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated levels of some clotting factors and chemokines, including factors VIII, IX, XI, thrombin-activatable fibrinolysis inhibitor (TAFI), and interleukin 8 have been associated with an increased thrombotic risk (",
"    <a class=\"graphic graphic_table graphicRef62182 \" href=\"mobipreview.htm?41/60/42955\">",
"     table 4",
"    </a>",
"    ). These measurements in patients with venous thrombosis have generally been made following a thrombotic event, so that a post-thrombotic phenomenon cannot be entirely excluded.",
"   </p>",
"   <p>",
"    The basis for the elevated levels of these factors has not yet been proven to be genetic, although one gain-of-function mutation in factor IX (factor IX Padua) has been described. Factor IX Padua has a specific activity 5 to 10 times as high as that of recombinant wild-type factor IX, and was associated with an episode of proximal DVT in a previously healthy 23-year-old male [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Factor VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated plasma factor VIII coagulant activity (VIII:C) is now accepted as an independent marker of increased thrombotic risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/62-67\">",
"     62-67",
"    </a>",
"    ]. In a population-based case control study performed in the Netherlands, patients with factor VIII:C levels greater than 150 percent of normal had an adjusted odds ratio of 4.8 for a first episode of venous thrombosis event compared with individuals with levels under 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/62\">",
"     62",
"    </a>",
"    ]. In both this study and an English series of patients referred for evaluation of unexplained thrombosis, the prevalence of elevated factor VIII:C levels was approximately 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/63\">",
"     63",
"    </a>",
"    ]. The risk appears to be additive to that of oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/68\">",
"     68",
"    </a>",
"    ] in contrast to the supra-additive risk observed for the hereditary thrombophilias (Factor V Leiden and prothrombin G20210A mutations, deficiencies of antithrombin, protein C, and protein S).",
"   </p>",
"   <p>",
"    Asymptomatic subjects with elevated factor VIII:C levels and a positive family history of VTE or arterial events before the age of 50 appear to have a high annual incidence of first VTE and arterial vascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An elevated factor VIII level may also be a strong thrombotic risk factor in the black population. In a United Kingdom study of 100 black patients of African or Caribbean origin with venous thrombosis, only 9 percent had an underlying genetic cause (eg, protein C or S deficiency, antithrombin deficiency), while 34 percent had VIII:C levels higher than the 90th percentile for normal black subjects (odds ratio 4.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High factor VIII levels persist over time and are not associated with increased levels of acute phase reactants (eg, C-reactive protein, fibrinogen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/63,71,72\">",
"     63,71,72",
"    </a>",
"    ]. Thus, elevated factor VIII levels appear to be constitutional with a heritable contribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]; the genetic determinant responsible for elevated factor VIII levels has not yet been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/76-79\">",
"     76-79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other plasma components",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a single, large, population-based case control study performed in the Netherlands, a two to threefold increased risk for a first episode of venous thrombosis was found for altered levels of a number of plasma components, coagulant factors, anticoagulant factors, and inflammatory chemokines (",
"    <a class=\"graphic graphic_table graphicRef62182 \" href=\"mobipreview.htm?41/60/42955\">",
"     table 4",
"    </a>",
"    ). Others have since been added to this list, as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2575893\">",
"    <span class=\"h3\">",
"     Elevated levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plasma factor IX antigen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/61,80-82\">",
"       61,80-82",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Plasma factor XI antigen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Thrombin activatable fibrinolysis inhibitor (TAFI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/85-89\">",
"       85-89",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Plasminogen activator inhibitor-1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/89\">",
"       89",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interleukin 8 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/90,91\">",
"       90,91",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Factor VII levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/75\">",
"       75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Plasma fibronectin levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/92\">",
"       92",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Von Willebrand factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/75,93-95\">",
"       75,93-95",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fibrinogen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/72,96,97\">",
"       72,96,97",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link&amp;anchor=H11#H11\">",
"       \"Disorders of fibrinogen\", section on 'Thrombotic variants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Altered fibrin clot structure and function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/98\">",
"       98",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link&amp;anchor=H7#H7\">",
"       \"Disorders of fibrinogen\", section on 'Fibrin crosslinking'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2575901\">",
"    <span class=\"h3\">",
"     Reduced levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tissue factor pathway inhibitor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/99\">",
"       99",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Plasma fibrinolytic activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/89,100\">",
"       89,100",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Thrombomodulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/101\">",
"       101",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While inherited",
"    <strong>",
"     deficiencies",
"    </strong>",
"    of antithrombin, protein C, and protein S are risk factors for VTE, subjects with borderline low values for these proteins also appear to be at increased risk for VTE, with a dose response effect on the risk of VTE for all three of these anticoagulant proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/102\">",
"     102",
"    </a>",
"    ]. In addition, the risk of unprovoked VTE in carriers of factor V Leiden or prothrombin G20210A appears to be increased two to threefold when levels of antithrombin or protein S are borderline low. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Multiple inherited thrombotic defects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Assays for some of these proteins are not widely available and the clinical utility of these measurements, or that of a shortened activated partial thromboplastin time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/103\">",
"     103",
"    </a>",
"    ] or an elevated endogenous thrombin potential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/104,105\">",
"     104,105",
"    </a>",
"    ], which might reflect such procoagulant imbalances, is currently uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical use of coagulation tests\", section on 'Shortened clotting times'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Single nucleotide polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single nucleotide polymorphisms (SNPs, variations of the nucleotide sequence in the genome occurring in at least 1 percent of the population) and other genetic variations are currently being investigated as potential genetic contributors to the risk of a number of conditions, including sickle cell anemia and VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/101,106-111\">",
"     101,106-111",
"    </a>",
"    ]. The majority of SNPs are missense (69 percent) with another 24 percent located in transcription factor binding sites or in untranslated regions of mRNA, which could affect mRNA expression or stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=see_link\">",
"     \"Clinical variability in sickle cell anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21097?source=see_link&amp;anchor=H1497124#H1497124\">",
"     \"Basic principles of genetic disease\", section on 'Genetic variation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The databases of the Leiden Thrombophilia Study and the Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis study (MEGA-1 and MEGA-2) were used to identify SNPs associated with an increased risk for a first DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/106\">",
"     106",
"    </a>",
"    ]. A number of such SNPs were identified, including two within the factor XI gene locus, a contribution explained at least in part by an association with elevated factor XI levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. A risk score based upon 31 such SNPs yielded odds ratios for development of venous thrombosis ranging from 0.37 for those with no risk alleles to 7.48 for those with six or more risk alleles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/114\">",
"     114",
"    </a>",
"    ]. Interestingly, the genetic risk score based on the five most strongly associated SNPs, which have an association with the functionality of coagulation proteins (factor V Leiden, prothrombin G20210A, ABO blood group, one SNP in the fibrinogen gamma gene, and one in the factor XI gene) performed similarly to the one based on all 31 SNPs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27898?source=see_link&amp;anchor=H10#H10\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Thrombotic risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26581288\">",
"    <span class=\"h3\">",
"     Non-O blood type",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the ABO blood group of the patient is a known risk factor for VTE, in that persons with the non-O blood group (ie, groups A, B, and AB) have been shown to have a significantly higher VTE risk than those with blood group O in two studies (odds ratios of 1.79 and 1.84) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. This may be related to associated differences in VWF and factor VIII levels between subjects with O and non-O blood groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17049?source=see_link&amp;anchor=H5#H5\">",
"     \"Biology and normal function of von Willebrand factor\", section on 'Plasma VWF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ACQUIRED THROMBOPHILIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired risk factors or predisposing conditions for thrombosis include a prior thrombotic event, recent major surgery, presence of a central venous catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/117,118\">",
"     117,118",
"    </a>",
"    ], trauma, immobilization, malignancy, pregnancy, the use of oral contraceptives or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , myeloproliferative disorders, antiphospholipid syndrome (APS), and a number of other major medical illnesses (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"mobipreview.htm?1/6/1132\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/2,119-123\">",
"     2,119-123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link&amp;anchor=H5138262#H5138262\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'VTE risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While upper extremity DVT is less common than lower extremity DVT, some of the same risk factors are present. As an example, in a study of 512 patients with acute symptomatic upper extremity DVT with or without pulmonary embolism, 38 percent had cancer; 45 percent had central venous catheter-related DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/124\">",
"     124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Multiple acquired risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with an episode of VTE have more than one acquired risk factor for thrombosis. This was shown in a population-based study of the incidence of VTE in residents of Worcester, MA during 1999. The six most prevalent pre-existing medical characteristics of patients in this study were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More than 48 hours of immobility in the preceding month &mdash; 45 percent",
"     </li>",
"     <li>",
"      Hospital admission in the past three months &mdash; 39 percent",
"     </li>",
"     <li>",
"      Surgery in the past three months &mdash; 34 percent",
"     </li>",
"     <li>",
"      Malignancy in the past three months &mdash; 34 percent",
"     </li>",
"     <li>",
"      Infection in the past three months &mdash; 34 percent",
"     </li>",
"     <li>",
"      Current hospitalization &mdash; 26 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only 11 percent of the 587 episodes of VTE had none of these six characteristics present, while 36 and 53 percent had 1 to 2 and &ge;3 risk factors, respectively.",
"   </p>",
"   <p>",
"    Triggers of hospitalization for VTE were evaluated in a case-crossover study of 16,781 participants in the Health and Retirement Study, a nationally representative sample of older Americans. Exposures to triggering events during the 90-day period prior to 399 hospitalizations for VTE were compared with exposures occurring during four 90-day comparison periods that did not result in hospitalization for VTE. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/125\">",
"     125",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infections, especially for those associated with a previous hospital or skilled nursing facility stay, were the most common trigger of hospitalization for VTE, occurring in 52.4 percent of the risk periods before hospitalization, as compared with 28 percent for the four comparison periods.",
"     </li>",
"     <li>",
"      Other significant triggers included use of erythropoiesis-stimulating agents, blood transfusion, major surgery, fractures, immobility, and chemotherapy.",
"     </li>",
"     <li>",
"      These triggers, when combined, accounted for 70 percent of exposures before VTE hospitalization, as opposed to 35 percent in the comparison periods.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23407368\">",
"    <span class=\"h3\">",
"     Acquired plus inherited thrombophilic defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, patients with VTE may have multiple inherited or multiple acquired thrombophilic defects. In addition, they may also have combinations of both inherited and acquired thrombophilic defects. This was best shown in the MEGA case-control study in 4311 consecutive subjects with a first episode of VTE and 5768 controls, in which the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/123\">",
"     123",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjects with self-reported major medical illnesses (ie, liver or kidney disease, rheumatoid arthritis, multiple sclerosis, heart failure, hemorrhagic stroke, arterial thrombosis) had increased venous thrombotic risk, with odds ratios in the range of 1.5 to 4.9.",
"     </li>",
"     <li>",
"      The combination of a major medical illness, as defined above, plus immobilization increased the odds ratio for development of venous thrombosis to 10.9 (95% CI 4.2-28).",
"     </li>",
"     <li>",
"      The combination of a major medical illness along with immobilization plus an thrombophilic defect increased the risk of venous thrombosis even further, with odds ratios of 80, 35, 88, 84, and 53 for increased factor VIII levels, increased factor IX levels, increased von Willebrand factor levels, presence of factor V Leiden, or the presence of non-O blood groups, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of whether the patient has a genetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an environmental risk factor for VTE, the presence of a positive family history of VTE has been found to be a strong additional risk factor for VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer often have a hypercoagulable state due to the production of substances with procoagulant activity (eg, tissue factor and cancer procoagulant). Clinical venous thromboembolism occurs in approximately 5 percent of such patients and is a common cause of serious clinical outcomes, including major hemorrhage and death, especially in older patients as well as in those malignancies associated with advanced disease at the time of diagnosis (eg, pancreatic cancer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/127-131\">",
"     127-131",
"    </a>",
"    ]. The risk of VTE in such patients appears to be highest during the initial hospitalization and onset of chemotherapy, as well as at the time of disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/132\">",
"     132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link&amp;anchor=H12#H12\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Hospitalized medical patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of thrombosis may be further increased in patients with malignancy and a central venous catheter, in which situation the prevalence of a venous thrombotic event may be as high as 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/117,118,133,134\">",
"     117,118,133,134",
"    </a>",
"    ]. The use of certain drugs may also increase the risk of VTE in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 20 percent of patients with symptomatic deep venous thrombosis have a known active malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/120,135\">",
"     120,135",
"    </a>",
"    ]. In a retrospective study of over 63,000 patients admitted to Danish non-psychiatric hospitals from 1977 through 1992 for a diagnosis of VTE, 18 percent had received a diagnosis of cancer (other than non-melanoma skin cancer) prior to the thromboembolic event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/136\">",
"     136",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link&amp;anchor=H4#H4\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of cancers associated with thromboembolic events are clinically evident and have been previously diagnosed at the time of the event. In the Danish study, 78 percent of the cancers were diagnosed before the event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/136\">",
"     136",
"    </a>",
"    ]. The five most common sites for cancer diagnosed AT THE TIME OF VTE included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lung &mdash; 17 percent",
"     </li>",
"     <li>",
"      Pancreas &mdash; 10 percent",
"     </li>",
"     <li>",
"      Colon and rectum &mdash; 8 percent",
"     </li>",
"     <li>",
"      Kidney &mdash; 8 percent",
"     </li>",
"     <li>",
"      Prostate &mdash; 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, thromboembolism can precede the diagnosis of malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/137-139\">",
"     137-139",
"    </a>",
"    ]. In one report, for example, 250 consecutive patients with symptomatic DVT were evaluated, 105 of whom had an identified cause or risk factor for the thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/137\">",
"     137",
"    </a>",
"    ]. Malignancy was identified at the time of the thrombotic event in five (3.3 percent) of 153 patients with no other identifiable risk factor. During a two-year follow-up, there was an increased incidence of cancer in the patients with idiopathic thrombosis compared with the 105 patients with secondary thrombosis (8 versus 2 percent). The incidence of cancer was considerably higher (17 percent) among the 35 patients with recurrent idiopathic venous thrombosis.",
"   </p>",
"   <p>",
"    Other studies have noted a less prominent association of venous thromboembolism with previously undiagnosed cancer. A Danish study evaluated almost 27,000 patients with VTE; the standardized incidence ratio for cancer was only 1.3 compared with those without DVT or pulmonary embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When compared with a group of patients with cancer who did not have VTE, matched in terms of type of cancer, age, sex, and year of diagnosis, the group with VTE tended to have a higher prevalence of distant metastasis (44 versus 35 percent) and a lower one-year survival (12 versus 36 percent). Similar results were obtained in those patients in whom cancer was diagnosed within one year after an episode of VTE.",
"   </p>",
"   <p>",
"    The role of screening for malignancy in patients with venous thromboembolism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link&amp;anchor=H7#H7\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Occult malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic risk is greatly increased during surgery, particularly orthopedic, major vascular, neurosurgery, and cancer surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/140-142\">",
"     140-142",
"    </a>",
"    ]. Risk factors in this group include older age, previous venous thromboembolism, the coexistence of malignancy or medical illness (eg, cardiac disease), thrombophilia, and longer surgical, anesthesia, and immobilization times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/140,142-147\">",
"     140,142-147",
"    </a>",
"    ]. Without prophylaxis, there is a markedly increased risk of both venous thrombosis and pulmonary embolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H3#H3\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Risk factors for VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    According to the older 2004 ACCP Anticoagulation Guidelines, patients undergoing surgical procedures were divided into the following risk categories (",
"    <a class=\"graphic graphic_table graphicRef58607 \" href=\"mobipreview.htm?38/34/39468\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/148\">",
"     148",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk patients are under the age of 40, have none of the risk factors listed above, will require general anesthesia for less than 30 minutes, and are undergoing minor elective, abdominal, or thoracic surgery. Without prophylaxis their risk of proximal vein thrombosis is less than 1.0 percent, and risk of fatal pulmonary embolism is less than 0.01 percent.",
"     </li>",
"     <li>",
"      Moderate risk patients are over the age of 40, will require general anesthesia for more than 30 minutes, and have one or more of the above risk factors. Without prophylaxis, their risk of proximal vein thrombosis is 2 to 10 percent, and their risk of fatal pulmonary embolism is 0.1 to 0.7 percent.",
"     </li>",
"     <li>",
"      High risk patients include those over the age of 40 who are having surgery for malignancy or an orthopedic procedure of the lower extremity lasting more than 30 minutes, and those who have an inhibitor deficiency state or other risk factors. The risk of proximal vein thrombosis and fatal pulmonary embolism in this group is 10 to 20 percent and 1.0 to 5.0 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These risk groups have been re-defined in the 2012 ACCP Guidelines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Surgical risk groups'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thromboprophylaxis significantly reduces the incidence of symptomatic DVT or pulmonary embolism in the immediate postoperative period. However, there is a continued risk of DVT following hospital discharge in those who have had total knee or hip arthroplasty and the usual 7 to 10 days of thromboprophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/149-152\">",
"     149-152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients so treated, who did not develop a symptomatic venous thromboembolism during hospitalization, the incidence of symptomatic non-fatal venous thromboembolism (VTE) or fatal pulmonary embolism in the subsequent three months has been estimated at 2.2 percent (95% CI: 1.4-3.0) and 0.05 percent (95% CI: 0.0-0.12), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/153\">",
"     153",
"    </a>",
"    ]. The estimated 30-day risk of symptomatic non-fatal VTE was higher for those undergoing total hip replacement than total knee replacement (2.5 versus 1.4 percent), in agreement with other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/143,154\">",
"     143,154",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Major trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of thrombosis is increased in all forms of major injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/155-158\">",
"     155-158",
"    </a>",
"    ]. In one study of 716 patients admitted to a regional trauma unit, DVT in the lower extremities was found in 58 percent of patients with adequate venographic studies; 18 percent had proximal vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/155\">",
"     155",
"    </a>",
"    ]. Thrombi were detected in 54 percent of patients with major head injuries, 61 percent of patients with pelvic fracture, 77 percent of patients with tibial fracture, and 80 percent of those with femoral fracture.",
"   </p>",
"   <p>",
"    The mechanisms of activation of the coagulation system following surgery or trauma are incompletely understood, but may include decreased venous blood flow in the lower extremities, diminished fibrinolysis, immobilization (see",
"    <a class=\"local\" href=\"#H37\">",
"     'Immobilization'",
"    </a>",
"    below), the release or exposure of tissue factor, and depletion of endogenous anticoagulants such as antithrombin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/159\">",
"     159",
"    </a>",
"    ]. In addition, the femoral vein in the operated leg may kink after hip replacement surgery, thereby increasing the risk of proximal venous thrombosis in the absence of calf vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other VTE risk factors in trauma patients may include spinal cord injury, lower extremity or pelvic fracture, need for a surgical procedure, insertion of a femoral venous line or repair of a major vein, increasing age, delayed initiation of thromboprophylaxis, or prolonged immobility either in the hospital or entrapment at the scene of the trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/155,161-164\">",
"     155,161-164",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31066?source=see_link&amp;anchor=H172458244#H172458244\">",
"     \"Overview of inpatient management in the adult trauma patient\", section on 'Thromboprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Minor injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large population-based study investigated the VTE risk following a minor injury (ie, one not requiring surgery, a plaster cast, hospitalization, or extended bed rest at home for at least four days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/165\">",
"     165",
"    </a>",
"    ]. A minor injury occurring in the preceding three to four weeks was associated with a three- to fivefold increase in DVT risk. In carriers of factor V Leiden, this risk was increased 50-fold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Intravenous drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct trauma, irritation, and infection may be responsible for the high prevalence of DVT noted in young drug users who inject these agents directly into their femoral veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/166-168\">",
"     166-168",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is associated with an increased risk of thrombosis that may be due in part to obstruction of venous return by the enlarged uterus, as well as the hypercoagulable state associated with pregnancy. Estimates of the age-adjusted incidence of VTE range from 5 to 50 times higher in pregnant versus non-pregnant women. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Inherited thrombophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of thrombosis is further accentuated in those women who have inherited thrombophilia, as illustrated by the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/169-172\">",
"     169-172",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 60 women with an inherited deficiency of a naturally occurring anticoagulant (antithrombin, protein C, or protein S), the risk of venous thrombosis during pregnancy or the postpartum period was increased eightfold (4.1 versus 0.5 percent in nondeficient women) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/170\">",
"       170",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The thrombotic risk for a woman with factor V Leiden during pregnancy or the puerperium has been estimated at approximately 1 in 400 to 500 compared with 1 in 1400 in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/169\">",
"       169",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link&amp;anchor=H18#H18\">",
"       \"Activated protein C resistance and factor V Leiden\", section on 'Obstetric complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A case-control study looked for factor V Leiden and the prothrombin gene mutation in 190 women with a first history of venous thromboembolism during pregnancy or the postpartum period and 190 controls without a history of thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/172\">",
"       172",
"      </a>",
"      ]. Compared with the controls, the women with a positive history had a higher prevalence of factor V Leiden (30 versus 6 percent), the prothrombin gene mutation (9 versus 2 percent), or both (7 versus zero percent). Women with both mutations had a higher probability of thrombosis during pregnancy than those with only the factor V Leiden or only the prothrombin mutation (5.2 versus 0.3 and 0.4 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of selected thrombophilias in women with no history of thrombosis and the probability of thromboembolism during pregnancy in these carriers are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef76397 \" href=\"mobipreview.htm?22/49/23325\">",
"     table 6",
"    </a>",
"    ). The risk of thromboembolism during pregnancy is also higher among women with inherited thrombophilia who have a past history or family history of thromboembolic events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    .) These data have been derived from essentially white Caucasian populations; there is a paucity of data on the prevalence and clinical significance of these states in non-white populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/173\">",
"     173",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs have been associated with an increased risk of venous thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Oral and transdermal contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their widespread use, oral contraceptives (OCs) are the most important cause of thrombosis in young women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/174\">",
"     174",
"    </a>",
"    ]. The risk of thrombosis increases within four months of the initiation of therapy and is unaffected by duration of use; the risk decreases to previous levels within three months of cessation. An increased risk for VTE has also been found in women using contraceptive transdermal patches (Ortho Evra). The use of OCs in older women to alleviate menopausal symptoms is also associated with a substantially increased risk of VTE, especially in those with inherited thrombophilia or a family history of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/175\">",
"     175",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41127?source=see_link&amp;anchor=H16#H16\">",
"     \"Transdermal contraceptive patch\", section on 'Major adverse events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Hormone replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies, the HERS trials, and a meta-analysis published before the Women's Health Initiative (WHI), evaluated the association between hormone replacement therapy (HRT) and venous thromboembolism (VTE), and suggested that HRT caused an approximately twofold increase in VTE risk, which appeared to be greatest in the first year of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/176-179\">",
"     176-179",
"    </a>",
"    ]. The most definitive data come from the WHI and are consistent with previous estimates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/180\">",
"     180",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk for VTE following the use of HRT appears to be further increased in older women, as well as in those who are obese, have an underlying thrombophilia (eg, factor V Leiden, prothrombin gene mutation), or a past history of venous thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/175,180-184\">",
"     175,180-184",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H18#H18\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies, including the large Breast Cancer Prevention Trials, have demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    use is associated with an increased rate of venous thromboembolic events and that there is a significant additional procoagulant effect when tamoxifen is added to chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/185,186\">",
"     185,186",
"    </a>",
"    ]. As an example, the role of tamoxifen in thromboembolic events was assessed in seven Eastern Cooperative Oncology Group (ECOG) trials, three of which randomly allocated patients to receive or not receive tamoxifen as part of their design [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/187\">",
"     187",
"    </a>",
"    ]. Each trial with a tamoxifen versus no tamoxifen randomization showed a trend toward more venous events in the tamoxifen-containing arm. Using data from all seven studies, premenopausal, but not postmenopausal, women who received chemotherapy and tamoxifen developed more venous thrombosis than those who received chemotherapy alone (3 versus 1 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\", section on 'Tamoxifen and raloxifene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of the monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    has been associated with an increased risk for both arterial and venous thromboembolic events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link&amp;anchor=H18#H18\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous stasis associated with bed rest or prolonged immobilization (eg, heart failure, stroke, myocardial infarction, leg injury) is an important risk factor for venous thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/188,189\">",
"     188,189",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link&amp;anchor=H3#H3\">",
"     \"Medical complications of stroke\", section on 'Venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a trial in patients who required immobilization in a cast after leg injury, DVT on venography occurred in 19 percent of patients treated with placebo compared with 9 percent of those treated with low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/189\">",
"     189",
"    </a>",
"    ]. Most of the thromboses were distal; two patients with proximal DVT had a pulmonary embolism, both in the placebo group. A subsequent meta-analysis of the incidence of asymptomatic DVT in patients with immobilization of the lower extremities found similar results when comparing the prophylactic use of low molecular weight heparin versus placebo or no treatment (17.1 versus 9.6 percent, relative risk 0.58; 95% CI 0.39-0.86) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/190,191\">",
"     190,191",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1959550\">",
"    <span class=\"h3\">",
"     Prolonged sitting",
"    </span>",
"    &nbsp;&mdash;&nbsp;VTE has also been associated with prolonged sitting, such as might occur during attendance at a theater, prolonged immobility at work, or sitting at a computer for long periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/192-195\">",
"     192-195",
"    </a>",
"    ]. The latter condition has been called &ldquo;seated immobility thromboembolism&rdquo; or &ldquo;e-thrombosis&rdquo;.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Extended travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged travel (car, train, airplane) appears to confer a two- to fourfold increase in risk of venous thromboembolism (VTE), a phenomenon that has been termed the \"economy class syndrome\" when applied to air travel (",
"    <a class=\"graphic graphic_figure graphicRef57367 \" href=\"mobipreview.htm?7/7/7294\">",
"     figure 1",
"    </a>",
"    ). This subject, including possible preventive measures, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13737?source=see_link&amp;anchor=H8#H8\">",
"     \"Patient assessment for air travel\", section on 'Deep vein thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure appears to be a hypercoagulable state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/196\">",
"     196",
"    </a>",
"    ] that can result in intracardiac thrombi and DVT. The major risk factors for intracardiac thrombi are reduced left ventricular function and atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of DVT may be greatest in patients with right heart failure (eg, those with peripheral edema). Thromboprophylaxis during immobilization or hospital admission in such patients may be advisable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/196,197\">",
"     196,197",
"    </a>",
"    ], especially since heart failure and immobility have been shown to be potent risk factors for in-hospital death as well as death within 30 days in patients with VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/198\">",
"     198",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiphospholipid syndrome (APS) is characterized by the presence of antibodies directed against plasma proteins bound to anionic phospholipids. Patients may present with venous or arterial thrombosis, recurrent fetal loss,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia. The disorder may be primary or associated with systemic lupus erythematosus and other rheumatic diseases. In one large series, aPL were present in 4.1 percent of 2132 consecutive patients presenting with deep vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Myeloproliferative neoplasms and PNH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic myeloproliferative neoplasms, particularly polycythemia vera and essential thrombocythemia, are characterized by thrombotic complications. These complications include both arterial and venous thrombosis and microcirculatory disorders such as erythromelalgia and visual and neurologic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/199\">",
"     199",
"    </a>",
"    ]. Hyperviscosity may play a contributing role. (See",
"    <a class=\"local\" href=\"#H47\">",
"     'Hyperviscosity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28554?source=see_link\">",
"     \"Prognosis and treatment of polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A high percent of patients with idiopathic hepatic (eg, Budd-Chiari syndrome) or portal vein thrombosis, but not those with idiopathic lower extremity DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/200-203\">",
"     200-203",
"    </a>",
"    ], have had in vitro evidence (eg, spontaneous erythroid colony growth in the absence of erythropoietin, presence of the JAK2 mutation, clonal karyotypic abnormalities on bone marrow examination) suggestive of an occult myeloproliferative neoplasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/204-207\">",
"     204-207",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31575?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology of the Budd-Chiari syndrome\", section on 'Myeloproliferative disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal disorder of bone marrow stem cells. Affected patients generally have chronic intravascular hemolysis with episodes of gross hemoglobinuria accompanied by leukopenia and thrombocytopenia. PNH is also associated with an approximately 40 percent prevalence (in the United States and Europe) of venous thrombosis in the intraabdominal venous network (mesenteric, hepatic, portal, splenic, and renal veins) and cerebral vessels, as opposed to deep vein thrombosis or pulmonary embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/208\">",
"     208",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism for the increased tendency to thrombosis in PNH is not completely understood, but may be related to abnormal platelet activation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14121?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Renal diseases",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Chronic renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy series have suggested that VTE events are relatively common in patients with end stage renal disease, and epidemiologic studies have reported an increased risk for VTE in those receiving dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/209-212\">",
"     209-212",
"    </a>",
"    ]. As an example, using the Healthcare Cost and Utilization Project&rsquo;s Nationwide Inpatient sample, the annual frequency of pulmonary embolism in adults with end-stage renal disease, chronic kidney disease, and normal renal function was 527, 204, and 66 per 100,000 persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/213\">",
"     213",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LITE study of 19,071 middle-aged and elderly non-dialysis, non-renal transplant patients demonstrated a relative VTE risk of 1.7 (95% CI 1.2-2.5) for patients with stage",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    chronic renal disease (ie, estimated glomerular filtration rate (eGFR) 15 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ), compared with patients with normal renal function (ie, eGFR &gt;90",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/212\">",
"     212",
"    </a>",
"    ]. Data from the PREVEND study have shown that the major risk factor for VTE in subjects with stages 1 to 3 chronic renal disease is the presence of albuminuria (urinary albumin &ge;30",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/214\">",
"     214",
"    </a>",
"    ]. As an example, the adjusted hazard ratio for those with an eGFR of 30 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and albuminuria was 4.1 (95% CI 1.5-11) when compared with those having an eGFR &gt;90",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and no albuminuria.",
"   </p>",
"   <p>",
"    Of importance, pooled individual data from the HUNT2, PREVEND, and Troms&oslash; studies have shown that both the estimated glomerular filtration rate and the urinary albumin-creatinine ratio are independently associated with an increased risk for VTE in the general population, even across the normal ranges for these two tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/215\">",
"     215",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the nephrotic syndrome have an increased prevalence (10 to 40 percent) of both arterial and venous thromboemboli, particularly deep vein and renal vein thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link&amp;anchor=H6#H6\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25033?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\", section on 'Renal vein thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms responsible for the hypercoagulability in the nephrotic syndrome are not understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/216,217\">",
"     216,217",
"    </a>",
"    ]. Alterations in many blood coagulation parameters have been described, but most are inconsistently reported, of relatively minor magnitude, and correlate poorly with thrombotic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/218\">",
"     218",
"    </a>",
"    ]. Among the natural anticoagulant proteins, plasma antithrombin levels are often reduced due, at least in part, to increased urinary excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/219,220\">",
"     219,220",
"    </a>",
"    ]. The antigenic levels of protein C and protein S are generally increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/221,222\">",
"     221,222",
"    </a>",
"    ] but functionally active protein S may be reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/221\">",
"     221",
"    </a>",
"    ]. Platelet hyperreactivity or increased whole blood viscosity may contribute to the thrombotic diathesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/223,224\">",
"     223,224",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of VTE following renal transplantation (RT) is increased, in the range of 5 to 8 percent, with pulmonary embolism being a common cause of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/225-228\">",
"     225-228",
"    </a>",
"    ]. In one study of 484 RT patients, 34 (7 percent) developed a first VTE at a median time of 6.5 months post-RT (range 1 to 81 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/225\">",
"     225",
"    </a>",
"    ]. Of importance, the incidence of recurrent VTE following cessation of oral anticoagulants (OAC) after a median treatment time of six months (range 3 to 43 months) was 50 percent (14 of 28). This recurrence risk was 10 times that of an age- and sex-matched group of patients with normal renal function who were treated with OAC for a similar period of time for a first episode of idiopathic VTE. RT patients may need treatment with OAC for longer period of time, especially if a hypercoagulable state has been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/228\">",
"     228",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Chronic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has often been stated that patients with chronic liver disease (CLD) and an elevated INR are \"auto-anticoagulated\" and are therefore not at risk for VTE. This notion is unfounded, as shown in a retrospective cohort study of 190 hospitalized patients with CLD, 12 of whom (6.3 percent) developed VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/229\">",
"     229",
"    </a>",
"    ]. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33914?source=see_link&amp;anchor=H5858386#H5858386\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Hypercoagulability in cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Hyperviscosity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis can be a manifestation of diseases associated with hyperviscosity secondary to increased plasma viscosity, an increased number of red or white blood cells, or decreased deformability of cells.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased plasma viscosity can result from hyperfibrinogenemia or hypergammaglobulinemia. Hypergammaglobulinemia associated with the hyperviscosity syndrome is most commonly encountered in patients with Waldenstrom macroglobulinemia or multiple myeloma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12484?source=see_link\">",
"       \"Plasma exchange in the hyperviscosity syndrome due to immunoglobulins\"",
"      </a>",
"      .) Thrombosis in hypergammaglobulinemic states is attributable to abnormal rheology (ie, increased serum viscosity). Presenting symptoms of the hyperviscosity syndrome include bleeding due to platelet dysfunction, visual disturbances, and neurologic defects. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link&amp;anchor=H7#H7\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Hyperviscosity syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased whole blood viscosity plays an important role in the pathogenesis of thrombosis in polycythemia vera, a major complication of this disorder. Acquired qualitative platelet defects have also been implicated in the hypercoagulable state. Common thrombotic complications include cerebrovascular accidents, myocardial infarction, peripheral arterial occlusion, deep venous thrombosis, pulmonary embolism, and portal and hepatic vein thrombosis (Budd-Chiari syndrome). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31575?source=see_link\">",
"       \"Etiology of the Budd-Chiari syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased whole blood viscosity also occurs in occasional patients with myeloid and monocytic leukemias who have markedly elevated white blood counts (generally",
"      <span class=\"nowrap\">",
"       &gt;100,000/microL).",
"      </span>",
"      Small vessels in the lungs, brain, and less commonly other organs may be obstructed by high levels of immature leukocytes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19576?source=see_link\">",
"       \"Hyperleukocytosis and leukostasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased whole blood viscosity in sickle cell disease is due primarily to decreased deformability of sickled erythrocytes, and may contribute to the occlusion of small blood vessels. Other factors that may play a role in this complication include enhanced adhesion of sickle erythrocytes to vascular endothelium and increased coagulation and platelet activation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/230-232\">",
"       230-232",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Hyperhomocysteinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperhomocysteinemia may be both a genetic and acquired abnormality. The most common genetic defect is homozygosity for a thermolabile mutant of the enzyme methylenetetrahydrofolate reductase (MTHFR). Plasma homocysteine concentrations can also be increased by deficiencies in vitamin B6, B12, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    . Hyperhomocysteinemia is an independent risk factor for atherosclerotic vascular disease, with the risk increasing in a graded fashion with increasing plasma homocysteine concentrations.",
"   </p>",
"   <p>",
"    Hyperhomocysteinemia has also been associated with an increased risk for VTE. Reducing levels of homocysteine with B vitamin supplements, however, has not resulted in a reduction in the incidence of recurrent VTE or arterial thrombotic complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Screening for hyperhomocysteinemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of homocysteine\", section on 'Role in venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Seasonal variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospital admission rates for both pulmonary embolism and deep venous thrombosis are highest during the winter months and lowest during the summer months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/233,234\">",
"     233,234",
"    </a>",
"    ]. This was demonstrated in a retrospective study of records linking discharge data and diagnostic test results complied over a four-year period (",
"    <a class=\"graphic graphic_figure graphicRef72351 \" href=\"mobipreview.htm?16/31/16880\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/233\">",
"     233",
"    </a>",
"    ]. Possible explanations for this observation include vasoconstriction due to reduced activity or cold weather, superimposed infection, or seasonal variation in thrombogenic factors, including fibrinogen and factor VII activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/235\">",
"     235",
"    </a>",
"    ] and active sun exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/234\">",
"     234",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Cardiovascular risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Longitudinal Investigation of Thromboembolism Etiology, which combined information from two prospective cohort studies, the Atherosclerosis Risk in Communities (ARIC) and the Cardiovascular Health Study (CHS) investigated the relationship between risk factors for arterial disease and occurrence of a first episode of VTE in 19,293 subjects, with over 148,000 person-years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/236\">",
"     236",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factors associated with an increased risk of a first episode of VTE were obesity (hazard ratio 2.7 for a body mass index &gt;40), increased age, male sex, black ethnicity, and diabetes. (See",
"      <a class=\"local\" href=\"#H52\">",
"       'Obesity'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H54\">",
"       'Age'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hypertension, dyslipidemia, physical inactivity, smoking, and alcohol consumption were not associated with an increased risk of VTE. Specifically, there was no trend of VTE hazard across quartiles of high-density lipoprotein cholesterol or apolipoprotein A-I [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/237\">",
"       237",
"      </a>",
"      ]. The lack of an association between both apolipoproteins and the classical lipoproteins and VTE risk was also noted in the population-based PREVEND cohort study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/238\">",
"       238",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H53\">",
"       'Smoking'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Increased baseline levels of D-dimer were strongly and positively related to the future occurrence of venous thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/239\">",
"       239",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=see_link&amp;anchor=H21#H21\">",
"       \"Diagnosis of suspected deep vein thrombosis of the lower extremity\", section on 'D-dimer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of cardiovascular risk factors in patients with VTE included 21 case-control and cohort studies, and came to slightly different conclusions. When compared with control subjects, VTE risks were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/240\">",
"     240",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity 2.3 (95% CI 1.7-3.2)",
"     </li>",
"     <li>",
"      Hypertension 1.5 (95% CI 1.2-1.8)",
"     </li>",
"     <li>",
"      Diabetes mellitus 1.4 (95% CI 1.1-1.8)",
"     </li>",
"     <li>",
"      Smoking 1.2 (95% CI 0.95-1.5)",
"     </li>",
"     <li>",
"      Hypercholesterolemia 1.2 (95% CI 0.67-2.0)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective, population-based study of 27,158 inhabitants of Tromso in Norway, independent risk factors for VTE included increased age, male sex, obesity, and a positive family history of myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/241\">",
"     241",
"    </a>",
"    ]. In a cohort study of 40,000 women taken from the South Sweden population registry and followed over a 10-year period, women non-smokers who were physically active and who consumed alcohol in moderation were at lower risk of developing VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/242\">",
"     242",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h3\">",
"     VTE and atherosclerotic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a population-based case control study of 5824 patients with VTE and 58,240 controls, an arterial cardiovascular event within 3 months conferred a short-term increased risk of VTE of 4.22 (95% CI 2.33-7.64) following myocardial infarction and 4.41 (95% CI 2.92-6.65) after stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/243\">",
"     243",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association between atherosclerotic disease and spontaneous venous thrombosis was also detected in a study of unselected patients with DVT who did not have symptomatic atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/244\">",
"     244",
"    </a>",
"    ]. The odds ratio for detecting at least one carotid artery plaque by ultrasonography in 153 subjects with spontaneous DVT was 1.8 (95% CI 1.1-2.9) when compared with 150 controls. The strength of this association did not change in a multivariate analysis including risk factors for atherosclerosis. The prevalence of carotid lesions in 146 patients with secondary DVT (eg, active cancer, recent trauma or surgery, prolonged immobilization) did not differ significantly from that in controls.",
"   </p>",
"   <p>",
"    A number of studies and a metaanalysis have suggested that subjects with VTE are at increased risk for acute cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/245-248\">",
"     245-248",
"    </a>",
"    ]. The following two cohort studies are instructive in this regard.",
"   </p>",
"   <p>",
"    In a 20-year population-based Danish cohort study, the risk of subsequent myocardial infarction (MI) and stroke was assessed in subjects with VTE and no history of cardiovascular disease (eg, no hypertension, stroke, heart failure, angina, or MI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/245\">",
"     245",
"    </a>",
"    ]. The following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the 25,199 patients with DVT, relative risks were 1.6 (95% CI 1.4-1.9) for MI and 2.2 (95% CI 1.8-2.6) for stroke in the first year after the thrombotic event.",
"     </li>",
"     <li>",
"      Relative risks were higher for the 16,925 patients with PE, being 2.6 (95% CI 2.1-3.1) and 2.9 (95% CI 2.3-3.7), respectively.",
"     </li>",
"     <li>",
"      Relative risks for arterial cardiovascular events were raised 20 to 40 percent over those of the 163,566 matched controls during the subsequent 20 years of follow-up, and were similar for both provoked and unprovoked VTE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a population-based cohort study of all inhabitants of Groningen, the Netherlands aged 28 to 75 years, and with a median follow-up of 10.7 years, the annual incidence of arterial thromboembolism after an episode of VTE was 2.03 percent, compared with 0.87 percent in those without VTE (adjusted HR 1.40; 95% CI 1.04-1.88) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/248\">",
"     248",
"    </a>",
"    ]. The risk of arterial thromboembolism was highest in the first year after VTE (3.0 percent) and after an unprovoked event (2.53 percent).",
"   </p>",
"   <p>",
"    Why this relationship exists is not clear, although VTE and arterial cardiovascular events share similar risk factors, such as obesity, hypertension, smoking, and",
"    <span class=\"nowrap\">",
"     diabetes/hyperglycemia",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/2,240,249-253\">",
"     2,240,249-253",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have found a significantly increased risk for deep vein thrombosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary embolism in obese subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/240,252,254-261\">",
"     240,252,254-261",
"    </a>",
"    ], and a reduced risk for underweight subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/259\">",
"     259",
"    </a>",
"    ], as well as an increased risk of recurrent VTE once anticoagulation treatment has been withdrawn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/262\">",
"     262",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Atherosclerosis Risk in Communities (ARIC) and the Cardiovascular Health Study (CHS) found an increased risk of a first episode of VTE with obesity (hazard ratio 2.7 for a body mass index &gt;40) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/236\">",
"       236",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Analysis of data from the National Hospital Discharge Survey indicated an increased relative risk for DVT (RR 2.50, 95% CI 2.49-2.51) and PE (RR 2.21, 95% CI 2.20-2.23) in obese subjects, with the greatest impact being seen in obese men and women below the age of 40 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/263\">",
"       263",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Obesity also appears to be a contributing factor for further increasing the risk of VTE in a number of high-risk settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/258\">",
"     258",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Along with smoking and age in patients with factor V Leiden or the prothrombin gene mutation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/264\">",
"       264",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In obese passengers undertaking long-duration air travel. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13737?source=see_link&amp;anchor=H8#H8\">",
"       \"Patient assessment for air travel\", section on 'Deep vein thrombosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In obese women taking oral contraceptives. In one study, obese women who used oral contraceptives had a 24-fold higher thrombotic risk than women with a normal body mass index who did not use these agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/258\">",
"       258",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The increased risk of VTE in individuals with a high BMI is partly mediated by factor VIII-related APC resistance. This risk is more pronounced when other causes of APC resistance are also present (eg, factor V Leiden, blood group non-O carriers) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/265\">",
"       265",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link&amp;anchor=H14#H14\">",
"       \"Activated protein C resistance and factor V Leiden\", section on 'Risk of DVT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h3\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although an initial report from the Leiden group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/266\">",
"     266",
"    </a>",
"    ], the ARIC and CHS studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/236\">",
"     236",
"    </a>",
"    ], a Norwegian study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/241\">",
"     241",
"    </a>",
"    ], and a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/240\">",
"     240",
"    </a>",
"    ] found no significant relationship between smoking and VTE, at least six other studies, including an update from the ARIC study, have detected a relationship between the two, with relative risks ranging from 1.3 to 3.3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/252,261,264,267-272\">",
"     252,261,264,267-272",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, a high number of pack-years resulted in the highest risk of venous thrombosis among young current smokers (OR for &ge;20 pack-years of 4.3; 95% CI 2.6-7.1), when compared with young nonsmokers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/269\">",
"       269",
"      </a>",
"      ]. In addition, women who were current smokers and used oral contraceptives had an 8.8-fold higher risk (95% CI 5.7-13) than nonsmoking women who did not use oral contraceptives.",
"     </li>",
"     <li>",
"      In a Danish case-cohort study, the adjusted hazard ratio for VTE emerging from the combined exposure to the non-O blood type and heavy smoking was 2.98 (95% CI 1.89-4.69), which exceeded the sum of the individual effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many risk factors for venous thrombosis, such as immobilization and malignancy, also correlate with age, although few studies adequately address the confounding variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/273-275\">",
"     273-275",
"    </a>",
"    ]. Two studies worthy of mentioning include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Worcester DVT study, based on previously hospitalized patients, found that annual incidence rates for DVT increased from 17 per 100,000",
"      <span class=\"nowrap\">",
"       persons/year",
"      </span>",
"      for those between the ages of 40 and 49 to 232 per 100,000",
"      <span class=\"nowrap\">",
"       persons/year",
"      </span>",
"      for those between the ages of 70 and 79 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/276\">",
"       276",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ARIC and CHS studies found an increasing incidence of first VTE with age, with a hazard ratio of 1.7 (95 percent confidence interval: 1.5 to 2.0) for every decade of life after age 55 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/236\">",
"       236",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h3\">",
"     Air pollution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies have demonstrated an association between fine particulate air pollution and distance from a major urban road or freeway, and cardiovascular and cardiopulmonary mortality as well as an increased risk for the development of acute coronary syndromes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link&amp;anchor=H1267133#H1267133\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Air pollution'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there is conflicting evidence concerning whether air pollution is [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/277-279\">",
"     277-279",
"    </a>",
"    ], or is not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/280,281\">",
"     280,281",
"    </a>",
"    ], causally related to VTE development. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study from the Lombardy region of Italy examined the association between exposure to particulate matter &lt;10 microns in aerodynamic diameter (PM10) and DVT risk in 870 patients and 1210 controls. Findings included [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/277\">",
"       277",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Each increase of 10",
"      <span class=\"nowrap\">",
"       microg/cubic",
"      </span>",
"      meter in PM10 was associated with a 70 percent increase in DVT risk (OR 1.70; 95% CI 1.30-2.23). The exposure-response relationship was approximately linear over the observed PM10 range (12 to 62",
"      <span class=\"nowrap\">",
"       microg/cubic",
"      </span>",
"      meter).",
"     </li>",
"     <li>",
"      In an extension of this Italian study in 663 patients with DVT of the lower limbs and 859 age-matched controls, individuals living at an index distance of three meters from a major traffic road had a 47 percent increase in DVT risk compared with those living at an index distance of 245 meters (OR 1.47; 95% CI 1.11-1.96) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/278\">",
"       278",
"      </a>",
"      ]. The increase in DVT risk was approximately linear over the distance range from zero to 718 meters, and was not modified after adjusting for background levels of particulate matter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population-based prospective cohort study from the Atherosclerosis Risk in Communities Study of 13,143 middle-aged men and women without a history of VTE evaluated the association between traffic exposure and incident VTE. Findings included [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/281\">",
"       281",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Traffic density was not significantly associated with development of VTE. Relative to those in the lowest quartile of traffic density, the adjusted hazard ratio for those in the highest quartile was 1.14 (95% CI 0.86-1.51).",
"     </li>",
"     <li>",
"      For those residents living within 150 meters of major roads, as compared with subjects living further away, the adjusted hazard ratio for development of VTE was 1.16 (95% CI 0.95-1.42).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h3\">",
"     Microalbuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ongoing community-based prospective cohort study (the PREVEND cohort) evaluated the association between microalbuminuria, a known cardiovascular risk factor, and the risk of developing VTE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/282\">",
"     282",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The annual incidences of VTE were 0.12, 0.20, 0.40, and 0.56 percent for those with urinary albumin excretion (UAE) of &lt;15, 15 to 29, 30 to 300, and &gt;300",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours, respectively.",
"     </li>",
"     <li>",
"      When adjusted for age, cancer, use of oral contraceptives, and atherosclerosis risk factors, hazard ratios associated with UAE of 15 to 29, 30 to 300, and &gt;300",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours were 1.40 (95% CI 0.86-2.35), 2.20 (95% CI 1.44-3.36) and 2.82 (95% CI 1.21-6.61) respectively, when compared with those having UAE &lt;15",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Heparin-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical problem associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) is thrombosis, both venous and arterial (ie, heparin-induced thrombocytopenia with thrombosis, HITT). Thus, if a patient receiving heparin develops an arterial or venous thromboembolic event, the presence of thrombocytopenia suggests that this is due to HIT rather than failure of anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H12#H12\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency with which initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy for thromboprophylaxis or treatment was associated with new or recurrent VTE and HIT was explored in a comprehensive literature search. The following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/283\">",
"     283",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 3792 patients treated with intravenous or subcutaneous unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (UFH), there were 242 episodes of VTE (6.4 percent). Thirteen percent of the episodes of VTE (0.8 percent of the patients treated with UFH) were associated with serologically-confirmed HIT.",
"     </li>",
"     <li>",
"      In 2427 patients treated with low molecular weight",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (LMW heparin), there were 144 episodes of VTE (5.9 percent). Only one of the 144 episodes (0.04 percent of patients treated with LMW heparin) was HIT-associated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this study, approximately one in every eight episodes of VTE occurring in UFH-treated patients was due to HIT. Accordingly, clinicians should suspect the possibility of HIT if VTE, along with thrombocytopenia, develops soon after the use of UFH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/284\">",
"     284",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H23#H23\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Pretest probability of HIT (the 4 T's)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thromboembolism is a known complication of inflammatory bowel disease (IBD, Crohn's disease, ulcerative colitis). In one study, for example, the absolute risks for development of VTE were, as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/285\">",
"     285",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospitalized patients with IBD flare &mdash;",
"      <span class=\"nowrap\">",
"       37.5/1000",
"      </span>",
"      person-years compared to",
"      <span class=\"nowrap\">",
"       13.9/1000",
"      </span>",
"      person-years for controls (HR 3.2; 95% CI 1.7-6.3)",
"     </li>",
"     <li>",
"      Ambulatory patients with IBD flare &mdash;",
"      <span class=\"nowrap\">",
"       9.0/1000",
"      </span>",
"      person-years compared to",
"      <span class=\"nowrap\">",
"       0.6/100",
"      </span>",
"      person-years for controls (HR 8.4; 95% CI 5.5-12.8).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This subject is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11386?source=see_link&amp;anchor=H1844647817#H1844647817\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\", section on 'Extraintestinal manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h1\">",
"     PREVIOUS THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous thrombotic episodes are a major risk factor for recurrent VTE. In an outpatient prospective cohort study, the risk of recurrence after an acute episode of venous thrombosis was 18, 25, and 30 percent at two, five, and eight years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/286\">",
"     286",
"    </a>",
"    ]. In a community epidemiologic study, a previous history of VTE conferred a relative risk (RR) of 7.9 for VTE recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/257\">",
"     257",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of this risk is highly dependent upon patient-specific factors. Those with an episode of thrombosis in the absence of known risk factors (ie, idiopathic VTE), or in association with permanent risk factors (eg, cancer) have a higher rate of recurrence than those with time-limited, reversible risk factors (eg, recent major surgery, immobilization) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/286-288\">",
"     286-288",
"    </a>",
"    ]. In one study, for example, the influence of these risk factors on the two-year cumulative incidence of VTE recurrence was as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/289\">",
"     289",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with surgery in the six weeks prior to a first VTE &mdash; zero percent recurrence; a much lower risk for recurrence in patients with surgery associated VTE (hazard ratio 0.36) was also noted in another study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/286\">",
"       286",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnancy-associated VTE &mdash; zero percent recurrence",
"     </li>",
"     <li>",
"      Patients with nonsurgical risk factors (eg, oral contraceptive use, fracture or application of plaster cast, immobilization) &mdash; 8.8 percent",
"     </li>",
"     <li>",
"      Patients with an unprecipitated VTE in whom there was no identifiable clinical risk factor &mdash; 19.4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence or absence of these risk factors (eg, pregnancy, surgery) becomes important in the therapeutic approach to patients with a first or recurrent episode of VTE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the site of the first VTE appears to be a predictor of the site and perhaps frequency of future episodes of VTE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a PE during the first episode of VTE are much more likely to have a PE during recurrence. One study followed 436 patients recovering from a first episode of idiopathic VTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/290\">",
"       290",
"      </a>",
"      ]. When compared with subjects with DVT and no symptoms of PE, those with symptomatic PE had a significantly higher risk of VTE recurrence (RR 2.2) and a higher risk of developing symptomatic PE at recurrence (RR 4.0). In another report of 165 patients presenting with PE, approximately 60 percent of the recurrences were a second episode of PE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/287\">",
"       287",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with a DVT during the first episode of VTE are highly likely to have a DVT during recurrence. This was illustrated in a study of 267 patients with a first episode of idiopathic DVT; 34 of the 42 recurrences were DVTs, with the most common site of recurrence being in the contralateral leg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/48/43786/abstract/288\">",
"       288",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2517?source=see_link\">",
"       \"Patient information: Pulmonary embolism (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16642?source=see_link\">",
"       \"Patient information: The antiphospholipid syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A risk factor can now be identified in many patients with venous thromboembolism (VTE); they are divided into two groups: hereditary and acquired (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"mobipreview.htm?1/6/1132\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is often more than one factor at play in a given patient, which may include both hereditary and acquired factors.",
"     </li>",
"     <li>",
"      The most frequent hereditary causes of VTE are the factor V Leiden and prothrombin gene mutations, which account for 50 to 60 percent of cases.",
"     </li>",
"     <li>",
"      The major acquired risk factors for VTE include recent major surgery (",
"      <a class=\"graphic graphic_table graphicRef58607 \" href=\"mobipreview.htm?38/34/39468\">",
"       table 5",
"      </a>",
"      ), trauma, immobilization, lupus anticoagulant and elevated levels of antiphospholipid antibodies, malignancy, pregnancy, oral contraceptives, and myeloproliferative disorders.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/1\">",
"      Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 2010; 149:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/2\">",
"      Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/3\">",
"      Dickson BC. Venous thrombosis: on the history of Virchow's triad. Univ Toronto Med J 2004; 81:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/4\">",
"      Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol 2008; 143:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/5\">",
"      Bertina RM. Genetic approach to thrombophilia. Thromb Haemost 2001; 86:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/6\">",
"      Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/7\">",
"      Lowe GD. Virchow's triad revisited: abnormal flow. Pathophysiol Haemost Thromb 2003; 33:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/8\">",
"      Chung I, Lip GY. Virchow's triad revisited: blood constituents. Pathophysiol Haemost Thromb 2003; 33:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/9\">",
"      Blann AD. How a damaged blood vessel wall contibutes to thrombosis and hypertenasion. Pathophysiol Haemost Thromb 2003; 33:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/10\">",
"      Chengelis DL, Bendick PJ, Glover JL, et al. Progression of superficial venous thrombosis to deep vein thrombosis. J Vasc Surg 1996; 24:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/11\">",
"      de Moerloose P, Wutschert R, Heinzmann M, et al. Superficial vein thrombosis of lower limbs: influence of factor V Leiden, factor II G20210A and overweight. Thromb Haemost 1998; 80:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/12\">",
"      Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/13\">",
"      Decousus H, Qu&eacute;r&eacute; I, Presles E, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 2010; 152:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/14\">",
"      Martinelli I, Cattaneo M, Taioli E, et al. Genetic risk factors for superficial vein thrombosis. Thromb Haemost 1999; 82:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/15\">",
"      Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/16\">",
"      Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G--&gt;A20210 gene variant. Ann Intern Med 1998; 129:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/17\">",
"      Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003; 138:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/18\">",
"      Dahlb&auml;ck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/19\">",
"      Heijboer H, Brandjes DP, B&uuml;ller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/20\">",
"      Ben-Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/21\">",
"      Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/22\">",
"      Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/23\">",
"      Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/24\">",
"      Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997; 34:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/25\">",
"      Mustafa S, Mannhalter C, Rintelen C, et al. Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coagul Fibrinolysis 1998; 9:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/26\">",
"      Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997; 78:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/27\">",
"      Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/28\">",
"      van Vlijmen EF, Brouwer JL, Veeger NJ, et al. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med 2007; 167:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/29\">",
"      Bovill EG, Hasstedt SJ, Callas PW, et al. The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred. Thromb Haemost 2000; 83:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/30\">",
"      Bertina RM, van der Linden IK, Engesser L, et al. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost 1987; 57:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/31\">",
"      Bernardi F, Legnani C, Micheletti F, et al. A heparin cofactor II mutation (HCII Rimini) combined with factor V Leiden or type I protein C deficiency in two unrelated thrombophilic subjects. Thromb Haemost 1996; 76:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/32\">",
"      Schott D, Dempfle CE, Beck P, et al. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N Engl J Med 1998; 339:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/33\">",
"      Tait RC, Walker ID, Conkie JA, et al. Isolated familial plasminogen deficiency may not be a risk factor for thrombosis. Thromb Haemost 1996; 76:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/34\">",
"      Patrassi GM, Sartori MT, Viero ML, et al. Venous thrombosis and tissue plasminogen activator release deficiency: a family study. Blood Coagul Fibrinolysis 1991; 2:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/35\">",
"      Segu&iacute; R, Estell&eacute;s A, Mira Y, et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 2000; 111:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/36\">",
"      Bolan CD, Krishnamurti C, Tang DB, et al. Association of protein S deficiency with thrombosis in a kindred with increased levels of plasminogen activator inhibitor-1. Ann Intern Med 1993; 119:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/37\">",
"      Martinez J. Congenital dysfibrinogenemia. Curr Opin Hematol 1997; 4:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/38\">",
"      Schorer AE, Singh J, Basara ML. Dysfibrinogenemia: a case with thrombosis (fibrinogen Richfield) and an overview of the clinical and laboratory spectrum. Am J Hematol 1995; 50:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/39\">",
"      Saito H. Contact factors in health and disease. Semin Thromb Hemost 1987; 13:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/40\">",
"      Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 1983; 62:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/41\">",
"      Ratnoff OD, Busse RJ, Sheon RP. The demise of John Hageman. N Engl J Med 1968; 279:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/42\">",
"      Lodi S, Isa L, Pollini E, et al. Defective intrinsic fibrinolytic activity in a patient with severe factor XII-deficiency and myocardial infarction. Scand J Haematol 1984; 33:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/43\">",
"      L&auml;mmle B, Wuillemin WA, Huber I, et al. Thromboembolism and bleeding tendency in congenital factor XII deficiency--a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/44\">",
"      Rodeghiero F, Castaman G, Ruggeri M, Tosetto A. Thrombosis in subjects with homozygous and heterozygous factor XII deficiency. Thromb Haemost 1992; 67:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/45\">",
"      Mannhalter C, Fischer M, Hopmeier P, et al. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/46\">",
"      Kibbe MR, Ujiki M, Goodwin AL, et al. Iliac vein compression in an asymptomatic patient population. J Vasc Surg 2004; 39:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/47\">",
"      Fazel R, Froehlich JB, Williams DM, et al. Clinical problem-solving. A sinister development--a 35-year-old woman presented to the emergency department with a 2-day history of progressive swelling and pain in her left leg, without antecedent trauma. N Engl J Med 2007; 357:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/48\">",
"      O'Sullivan GJ, Semba CP, Bittner CA, et al. Endovascular management of iliac vein compression (May-Thurner) syndrome. J Vasc Interv Radiol 2000; 11:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/49\">",
"      Patel NH, Stookey KR, Ketcham DB, Cragg AH. Endovascular management of acute extensive iliofemoral deep venous thrombosis caused by May-Thurner syndrome. J Vasc Interv Radiol 2000; 11:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/50\">",
"      Carr S, Chan K, Rosenberg J, et al. Correlation of the diameter of the left common iliac vein with the risk of lower-extremity deep venous thrombosis. J Vasc Interv Radiol 2012; 23:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/51\">",
"      Narayan A, Eng J, Carmi L, et al. Iliac vein compression as risk factor for left- versus right-sided deep venous thrombosis: case-control study. Radiology 2012; 265:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/52\">",
"      Sharaf M. Recurrent left-leg venous thrombosis in a woman despite a therapeutic international normalized ratio. CMAJ 2005; 173:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/53\">",
"      Lamont JP, Pearl GJ, Patetsios P, et al. Prospective evaluation of endoluminal venous stents in the treatment of the May-Thurner syndrome. Ann Vasc Surg 2002; 16:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/54\">",
"      Thijs W, Rabe KF, Rosendaal FR, Middeldorp S. Predominance of left-sided deep vein thrombosis and body weight. J Thromb Haemost 2010; 8:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/55\">",
"      Chee YL, Culligan DJ, Watson HG. Inferior vena cava malformation as a risk factor for deep venous thrombosis in the young. Br J Haematol 2001; 114:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/56\">",
"      Ruggeri M, Tosetto A, Castaman G, Rodeghiero F. Congenital absence of the inferior vena cava: a rare risk factor for idiopathic deep-vein thrombosis. Lancet 2001; 357:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/57\">",
"      Hamoud S, Nitecky S, Engel A, et al. Hypoplasia of the inferior vena cava with azygous continuation presenting as recurrent leg deep vein thrombosis. Am J Med Sci 2000; 319:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/58\">",
"      Motwani J, Rose PE, Shatwell W. An unusual case of venous thromboembolism. Br J Haematol 2005; 128:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/59\">",
"      Obernosterer A, Aschauer M, Schnedl W, Lipp RW. Anomalies of the inferior vena cava in patients with iliac venous thrombosis. Ann Intern Med 2002; 136:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/60\">",
"      Lambert M, Marboeuf P, Midulla M, et al. Inferior vena cava agenesis and deep vein thrombosis: 10 patients and review of the literature. Vasc Med 2010; 15:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/61\">",
"      Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 361:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/62\">",
"      Koster T, Blann AD, Bri&euml;t E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/63\">",
"      O'Donnell J, Tuddenham EG, Manning R, et al. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/64\">",
"      Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/65\">",
"      Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/66\">",
"      Bombeli T, de Conno E, Jutzi M, Fehr J. In patients symptomatic for deep-vein thrombosis factor VIII elevation is found twice as frequent as in patients symptomatic for pulmonary embolism. Thromb Haemost 2003; 89:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/67\">",
"      Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 2012; 157:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/68\">",
"      Bloemenkamp KW, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost 1999; 82:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/69\">",
"      Bank I, van de Poel MH, Coppens M, et al. Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort study. Thromb Haemost 2007; 98:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/70\">",
"      Patel RK, Ford E, Thumpston J, Arya R. Risk factors for venous thrombosis in the black population. Thromb Haemost 2003; 90:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/71\">",
"      O'Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/72\">",
"      Kamphuisen PW, Eikenboom JC, Vos HL, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/73\">",
"      de Lange M, Snieder H, Ari&euml;ns RA, et al. The genetics of haemostasis: a twin study. Lancet 2001; 357:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/74\">",
"      Morange PE, Tregouet DA, Frere C, et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br J Haematol 2005; 128:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/75\">",
"      Smith NL, Chen MH, Dehghan A, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/76\">",
"      Mansvelt EP, Laffan M, McVey JH, Tuddenham EG. Analysis of the F8 gene in individuals with high plasma factor VIII: C levels and associated venous thrombosis. Thromb Haemost 1998; 80:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/77\">",
"      Kamphuisen PW, Eikenboom JC, Rosendaal FR, et al. High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 2001; 115:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/78\">",
"      Berger M, Mattheisen M, Kulle B, et al. High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11. Blood 2005; 105:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/79\">",
"      Viel KR, Machiah DK, Warren DM, et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 2007; 109:3713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/80\">",
"      van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95:3678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/81\">",
"      Lowe GD. Factor IX and thrombosis. Br J Haematol 2001; 115:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/82\">",
"      Ameri A, Kurachi S, Sueishi K, et al. Myocardial fibrosis in mice with overexpression of human blood coagulation factor IX. Blood 2003; 101:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/83\">",
"      Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/84\">",
"      Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 2009; 114:2878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/85\">",
"      van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/86\">",
"      Eichinger S, Sch&ouml;nauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103:3773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/87\">",
"      Martini CH, Brandts A, de Bruijne EL, et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006; 134:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/88\">",
"      Folkeringa N, Coppens M, Veeger NJ, et al. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Thromb Haemost 2008; 100:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/89\">",
"      Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/90\">",
"      van Aken BE, den Heijer M, Bos GM, et al. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 2000; 83:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/91\">",
"      van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002; 116:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/92\">",
"      Pecheniuk NM, Elias DJ, Deguchi H, et al. Elevated plasma fibronectin levels associated with venous thromboembolism. Thromb Haemost 2008; 100:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/93\">",
"      Nossent AY, VAN Marion V, VAN Tilburg NH, et al. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006; 4:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/94\">",
"      Wiggins KL, Smith NL, Glazer NL, et al. ABO genotype and risk of thrombotic events and hemorrhagic stroke. J Thromb Haemost 2009; 7:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/95\">",
"      Smith NL, Rice KM, Bovill EG, et al. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood 2011; 117:6007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/96\">",
"      Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/97\">",
"      Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood 2011; 117:4953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/98\">",
"      Undas A, Zawilska K, Ciesla-Dul M, et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114:4272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/99\">",
"      Dahm A, Van Hylckama Vlieg A, Bendz B, et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101:4387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/100\">",
"      Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/101\">",
"      Tang L, Wang HF, Lu X, et al. Common genetic risk factors for venous thrombosis in the chinese population. Am J Hum Genet 2013; 92:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/102\">",
"      Bucciarelli P, Passamonti SM, Biguzzi E, et al. Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. J Thromb Haemost 2012; 10:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/103\">",
"      Tripodi A, Chantarangkul V, Martinelli I, et al. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004; 104:3631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/104\">",
"      van Hylckama Vlieg A, Christiansen SC, Luddington R, et al. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007; 138:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/105\">",
"      Lutsey PL, Folsom AR, Heckbert SR, Cushman M. Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study. J Thromb Haemost 2009; 7:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/106\">",
"      Bezemer ID, Bare LA, Doggen CJ, et al. Gene variants associated with deep vein thrombosis. JAMA 2008; 299:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/107\">",
"      Reiner AP, Lange LA, Smith NL, et al. Common hemostasis and inflammation gene variants and venous thrombosis in older adults from the Cardiovascular Health Study. J Thromb Haemost 2009; 7:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/108\">",
"      Morange PE, Tregouet DA. Deciphering the molecular basis of venous thromboembolism: where are we and where should we go? Br J Haematol 2010; 148:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/109\">",
"      Heit JA, Cunningham JM, Petterson TM, et al. Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism. J Thromb Haemost 2011; 9:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/110\">",
"      Dennis J, Johnson CY, Adediran AS, et al. The endothelial protein C receptor (PROCR) Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies. Blood 2012; 119:2392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/111\">",
"      El-Galaly TC, Severinsen MT, Overvad K, et al. Single nucleotide polymorphisms and the risk of venous thrombosis: results from a Danish case-cohort study. Br J Haematol 2013; 160:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/112\">",
"      Li Y, Bezemer ID, Rowland CM, et al. Genetic variants associated with deep vein thrombosis: the F11 locus. J Thromb Haemost 2009; 7:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/113\">",
"      Austin H, De Staercke C, Lally C, et al. New gene variants associated with venous thrombosis: a replication study in White and Black Americans. J Thromb Haemost 2011; 9:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/114\">",
"      de Haan HG, Bezemer ID, Doggen CJ, et al. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood 2012; 120:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/115\">",
"      Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/116\">",
"      El-Galaly TC, Kristensen SR, Overvad K, et al. Interaction between blood type, smoking and factor V Leiden mutation and risk of venous thromboembolism: a Danish case-cohort study. J Thromb Haemost 2012; 10:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/117\">",
"      van Rooden CJ, Schippers EF, Barge RM, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005; 23:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/118\">",
"      Cortelezzi A, Moia M, Falanga A, et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 2005; 129:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/119\">",
"      Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/120\">",
"      Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/121\">",
"      Goldhaber SZ, Tapson VF, DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/122\">",
"      Huerta C, Johansson S, Wallander MA, Garc&iacute;a Rodr&iacute;guez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/123\">",
"      Ocak G, Vossen CY, Verduijn M, et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost 2013; 11:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/124\">",
"      Mu&ntilde;oz FJ, Mismetti P, Poggio R, et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008; 133:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/125\">",
"      Rogers MA, Levine DA, Blumberg N, et al. Triggers of hospitalization for venous thromboembolism. Circulation 2012; 125:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/126\">",
"      Bezemer ID, van der Meer FJ, Eikenboom JC, et al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/127\">",
"      Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/128\">",
"      Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/129\">",
"      Stein PD, Beemath A, Meyers FA, et al. Pulmonary embolism as a cause of death in patients who died with cancer. Am J Med 2006; 119:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/130\">",
"      Gross CP, Galusha DH, Krumholz HM. The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. J Gen Intern Med 2007; 22:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/131\">",
"      Ku GH, White RH, Chew HK, et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 2009; 113:3911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/132\">",
"      Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011; 117:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/133\">",
"      Mohren M, Markmann I, Jentsch-Ullrich K, et al. Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer 2006; 94:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/134\">",
"      Gerber DE, Segal JB, Levy MY, et al. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/135\">",
"      Bauer KA. Venous thromboembolism in malignancy. J Clin Oncol 2000; 18:3065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/136\">",
"      S&oslash;rensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/137\">",
"      Prandoni P, Lensing AW, B&uuml;ller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/138\">",
"      S&oslash;rensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/139\">",
"      Douketis JD, Gu C, Piccioli A, et al. The long-term risk of cancer in patients with a first episode of venous thromboembolism. J Thromb Haemost 2009; 7:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/140\">",
"      White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/141\">",
"      Lee AY, Gent M, Julian JA, et al. Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review. J Thromb Haemost 2004; 2:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/142\">",
"      Maxwell GL, Synan I, Dodge R, et al. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol 2001; 98:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/143\">",
"      White RH, Gettner S, Newman JM, et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000; 343:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/144\">",
"      Jaffer AK, Barsoum WK, Krebs V, et al. Duration of anesthesia and venous thromboembolism after hip and knee arthroplasty. Mayo Clin Proc 2005; 80:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/145\">",
"      Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006; 243:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/146\">",
"      Rogers SO Jr, Kilaru RK, Hosokawa P, et al. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg 2007; 204:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/147\">",
"      Beyer J, Wessela S, Hakenberg OW, et al. Incidence, risk profile and morphological pattern of venous thromboembolism after prostate cancer surgery. J Thromb Haemost 2009; 7:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/148\">",
"      Merli GJ. Update. Deep vein thrombosis and pulmonary embolism prophylaxis in orthopedic surgery. Med Clin North Am 1993; 77:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/149\">",
"      Leclerc JR, Gent M, Hirsh J, et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 1998; 158:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/150\">",
"      White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/151\">",
"      Bergqvist D, Benoni G, Bj&ouml;rgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/152\">",
"      Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/153\">",
"      Douketis JD, Eikelboom JW, Quinlan DJ, et al. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002; 162:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/154\">",
"      Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/155\">",
"      Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994; 331:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/156\">",
"      Montgomery KD, Geerts WH, Potter HG, Helfet DL. Thromboembolic complications in patients with pelvic trauma. Clin Orthop Relat Res 1996; :68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/157\">",
"      Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/158\">",
"      McLaughlin DF, Wade CE, Champion HR, et al. Thromboembolic complications following trauma. Transfusion 2009; 49 Suppl 5:256S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/159\">",
"      Owings JT, Gosselin R. Acquired antithrombin deficiency following severe traumatic injury: rationale for study of antithrombin supplementation. Semin Thromb Hemost 1997; 23 Suppl 1:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/160\">",
"      Plan&egrave;s A, Vochelle N, Fagola M. Total hip replacement and deep vein thrombosis. A venographic and necropsy study. J Bone Joint Surg Br 1990; 72:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/161\">",
"      Rogers FB, Cipolle MD, Velmahos G, et al. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. J Trauma 2002; 53:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/162\">",
"      Rogers FB, Hammaker SJ, Miller JA, et al. Does prehospital prolonged extrication (entrapment) place trauma patients at higher risk for venous thromboembolism? Am J Surg 2011; 202:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/163\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/164\">",
"      Thorson CM, Ryan ML, Van Haren RM, et al. Venous thromboembolism after trauma: a never event?*. Crit Care Med 2012; 40:2967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/165\">",
"      van Stralen KJ, Rosendaal FR, Doggen CJ. Minor injuries as a risk factor for venous thrombosis. Arch Intern Med 2008; 168:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/166\">",
"      Roszler MH, McCarroll KA, Donovan KR, et al. The groin hit: complications of intravenous drug abuse. Radiographics 1989; 9:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/167\">",
"      Mackenzie AR, Laing RB, Douglas JG, et al. High prevalence of iliofemoral venous thrombosis with severe groin infection among injecting drug users in North East Scotland: successful use of low molecular weight heparin with antibiotics. Postgrad Med J 2000; 76:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/168\">",
"      McColl MD, Tait RC, Greer IA, Walker ID. Injecting drug use is a risk factor for deep vein thrombosis in women in Glasgow. Br J Haematol 2001; 112:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/169\">",
"      McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/170\">",
"      Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/171\">",
"      Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/172\">",
"      Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003; 90:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/173\">",
"      Stein PD, Kayali F, Olson RE, Milford CE. Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 2004; 116:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/174\">",
"      Kujovich JL. Hormones and pregnancy: thromboembolic risks for women. Br J Haematol 2004; 126:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/175\">",
"      Roach RE, Lijfering WM, Helmerhorst FM, et al. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost 2013; 11:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/176\">",
"      Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/177\">",
"      Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/178\">",
"      P&eacute;rez Gutthann S, Garc&iacute;a Rodr&iacute;guez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/179\">",
"      Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/180\">",
"      Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/181\">",
"      Glueck CJ, Wang P, Fontaine RN, et al. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C). Am J Cardiol 1999; 84:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/182\">",
"      Rosendaal FR, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/183\">",
"      Herrington DM, Vittinghoff E, Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002; 22:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/184\">",
"      H&oslash;ibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/185\">",
"      Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/186\">",
"      Fogarty PF, Rick ME, Swain SM. Tamoxifen and thrombosis: Current clinical observations and guidelines. Principles and Practice of Oncology Updates 2002; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/187\">",
"      Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/188\">",
"      Kierkegaard A, Norgren L, Olsson CG, et al. Incidence of deep vein thrombosis in bedridden non-surgical patients. Acta Med Scand 1987; 222:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/189\">",
"      Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med 2002; 347:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/190\">",
"      Ettema HB, Kollen BJ, Verheyen CC, B&uuml;ller HR. Prevention of venous thromboembolism in patients with immobilization of the lower extremities: a meta-analysis of randomized controlled trials. J Thromb Haemost 2008; 6:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/191\">",
"      Nokes TJ, Keenan J. Thromboprophylaxis in patients with lower limb immobilisation - review of current status. Br J Haematol 2009; 146:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/192\">",
"      Beasley R, Raymond N, Hill S, et al. eThrombosis: the 21st century variant of venous thromboembolism associated with immobility. Eur Respir J 2003; 21:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/193\">",
"      Beasley R, Heuser P, Raymond N. SIT (seated immobility thromboembolism) syndrome: a 21st century lifestyle hazard. N Z Med J 2005; 118:U1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/194\">",
"      Aldington S, Pritchard A, Perrin K, et al. Prolonged seated immobility at work is a common risk factor for venous thromboembolism leading to hospital admission. Intern Med J 2008; 38:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/195\">",
"      Patel T, Cohen D. Work ergonomics and e-thrombosis: a grievous yet preventable combination. Am J Med 2011; 124:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/196\">",
"      Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999; 33:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/197\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/198\">",
"      Piazza G, Goldhaber SZ, Lessard DM, et al. Venous thromboembolism in heart failure: preventable deaths during and after hospitalization. Am J Med 2011; 124:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/199\">",
"      Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997; 78:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/200\">",
"      Pardanani A, Lasho TL, Hussein K, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008; 83:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/201\">",
"      Colaizzo D, Amitrano L, Iannaccone L, et al. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet 2007; 44:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/202\">",
"      Ugo V, Le Gal G, Lecucq L, et al. Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. J Thromb Haemost 2008; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/203\">",
"      Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009; 113:5617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/204\">",
"      De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/205\">",
"      Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/206\">",
"      Pagliuca A, Mufti GJ, Janossa-Tahernia M, et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis--possible evidence of an occult myeloproliferative state. Q J Med 1990; 76:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/207\">",
"      Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120:4921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/208\">",
"      Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/209\">",
"      Wiesholzer M, Kitzw&ouml;gerer M, Harm F, et al. Prevalence of preterminal pulmonary thromboembolism among patients on maintenance hemodialysis treatment before and after introduction of recombinant erythropoietin. Am J Kidney Dis 1999; 33:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/210\">",
"      Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/211\">",
"      Tveit DP, Hypolite IO, Hshieh P, et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 2002; 39:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/212\">",
"      Wattanakit K, Cushman M, Stehman-Breen C, et al. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008; 19:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/213\">",
"      Kumar G, Sakhuja A, Taneja A, et al. Pulmonary embolism in patients with CKD and ESRD. Clin J Am Soc Nephrol 2012; 7:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/214\">",
"      Ocak G, Verduijn M, Vossen CY, et al. Chronic kidney disease stages 1-3 increase the risk of venous thrombosis. J Thromb Haemost 2010; 8:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/215\">",
"      Mahmoodi BK, Ganservoort RT, Naess IA, et al. Association of mild to moderate chronic kidney disease with venous thromboembolism: Pooled analysis of five prospective general population cohorts. Circulation 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/216\">",
"      Chen TY, Huang CC, Tsao CJ. Hemostatic molecular markers in nephrotic syndrome. Am J Hematol 1993; 44:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/217\">",
"      Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 1997; 23:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/218\">",
"      Robert A, Olmer M, Sampol J, et al. Clinical correlation between hypercoagulability and thrombo-embolic phenomena. Kidney Int 1987; 31:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/219\">",
"      Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/220\">",
"      Vaziri ND, Paule P, Toohey J, et al. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med 1984; 144:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/221\">",
"      Vigano-D'Angelo S, D'Angelo A, Kaufman CE Jr, et al. Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 1987; 107:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/222\">",
"      Cosio FG, Harker C, Batard MA, et al. Plasma concentrations of the natural anticoagulants protein C and protein S in patients with proteinuria. J Lab Clin Med 1985; 106:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/223\">",
"      Adler AJ, Lundin AP, Feinroth MV, et al. Beta-thromboglobulin levels in the nephrotic syndrome. Am J Med 1980; 69:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/224\">",
"      Ozanne P, Francis RB, Meiselman HJ. Red blood cell aggregation in nephrotic syndrome. Kidney Int 1983; 23:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/225\">",
"      Poli D, Zanazzi M, Antonucci E, et al. High rate of recurrence in renal transplant recipients after a first episode of venous thromboembolism. Transplantation 2005; 80:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/226\">",
"      Allen RD, Michie CA, Murie JA, Morris PJ. Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet 1987; 164:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/227\">",
"      Abbott KC, Cruess DF, Agodoa LY, et al. Early renal insufficiency and late venous thromboembolism after renal transplantation in the United States. Am J Kidney Dis 2004; 43:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/228\">",
"      Andrassy J, Zeier M, Andrassy K. Do we need screening for thrombophilia prior to kidney transplantation? Nephrol Dial Transplant 2004; 19 Suppl 4:iv64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/229\">",
"      Dabbagh O, Oza A, Prakash S, et al. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010; 137:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/230\">",
"      Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med 1980; 302:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/231\">",
"      Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood 2001; 98:3228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/232\">",
"      Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003; 115:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/233\">",
"      Boulay F, Berthier F, Schoukroun G, et al. Seasonal variations in hospital admission for deep vein thrombosis and pulmonary embolism: analysis of discharge data. BMJ 2001; 323:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/234\">",
"      Lindqvist PG, Epstein E, Olsson H. Does an active sun exposure habit lower the risk of venous thrombotic events? A D-lightful hypothesis. J Thromb Haemost 2009; 7:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/235\">",
"      Woodhouse PR, Khaw KT, Plummer M, et al. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994; 343:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/236\">",
"      Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/237\">",
"      Chamberlain AM, Folsom AR, Heckbert SR, et al. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 2008; 112:2675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/238\">",
"      van Schouwenburg IM, Mahmoodi BK, Gansevoort RT, et al. Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study. Thromb Haemost 2012; 108:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/239\">",
"      Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 2003; 101:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/240\">",
"      Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/241\">",
"      Braekkan SK, Mathiesen EB, Nj&oslash;lstad I, et al. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Troms&oslash; study. J Thromb Haemost 2008; 6:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/242\">",
"      Lindqvist PG, Epstein E, Olsson H. The relationship between lifestyle factors and venous thromboembolism among women: a report from the MISS study. Br J Haematol 2009; 144:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/243\">",
"      S&oslash;rensen HT, Horvath-Puho E, S&oslash;gaard KK, et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009; 7:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/244\">",
"      Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/245\">",
"      S&oslash;rensen HT, Horvath-Puho E, Pedersen L, et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/246\">",
"      Klok FA, Mos IC, Broek L, et al. Risk of arterial cardiovascular events in patients after pulmonary embolism. Blood 2009; 114:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/247\">",
"      Becattini C, Vedovati MC, Ageno W, et al. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost 2010; 8:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/248\">",
"      van Schouwenburg IM, Gansevoort RT, Mahmoodi BK, et al. Increased risk of arterial thromboembolism after a prior episode of venous thromboembolism: results from the Prevention of REnal and Vascular ENd stage Disease (PREVEND) Study. Br J Haematol 2012; 159:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/249\">",
"      Lowe GD. Is venous thrombosis a risk factor for arterial thrombosis? Lancet 2007; 370:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/250\">",
"      Lowe GD. Common risk factors for both arterial and venous thrombosis. Br J Haematol 2008; 140:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/251\">",
"      Hermanides J, Cohn DM, Devries JH, et al. Venous thrombosis is associated with hyperglycemia at diagnosis: a case-control study. J Thromb Haemost 2009; 7:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/252\">",
"      Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 2010; 121:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/253\">",
"      Piazza G, Goldhaber SZ. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation 2010; 121:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/254\">",
"      Goldhaber SZ, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism. The Framingham Study. Am J Med 1983; 74:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/255\">",
"      Hansson PO, Eriksson H, Welin L, et al. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: \"the study of men born in 1913\". Arch Intern Med 1999; 159:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/256\">",
"      Kucher N, Tapson VF, Goldhaber SZ, DVT FREE Steering Committee. Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients. Thromb Haemost 2005; 93:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/257\">",
"      Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160:3415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/258\">",
"      Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/259\">",
"      Delluc A, Mottier D, Le Gal G, et al. Underweight is associated with a reduced risk of venous thromboembolism. Results from the EDITH case-control study. J Thromb Haemost 2009; 7:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/260\">",
"      Severinsen MT, Kristensen SR, Johnsen SP, et al. Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study. Circulation 2009; 120:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/261\">",
"      Wattanakit K, Lutsey PL, Bell EJ, et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost 2012; 108:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/262\">",
"      Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/263\">",
"      Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/264\">",
"      Severinsen MT, Overvad K, Johnsen SP, et al. Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br J Haematol 2010; 149:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/265\">",
"      Christiansen SC, Lijfering WM, Naess IA, et al. The relationship between body mass index, activated protein&nbsp;C resistance and risk of venous thrombosis. J Thromb Haemost 2012; 10:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/266\">",
"      Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost 1997; 78:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/267\">",
"      Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/268\">",
"      Farmer RD, Lawrenson RA, Todd JC, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000; 49:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/269\">",
"      Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008; 83:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/270\">",
"      Severinsen MT, Kristensen SR, Johnsen SP, et al. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost 2009; 7:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/271\">",
"      Enga KF, Braekkan SK, Hansen-Krone IJ, et al. Cigarette smoking and the risk of venous thromboembolism: the Troms&oslash; Study. J Thromb Haemost 2012; 10:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/272\">",
"      Sweetland S, Parkin L, Balkwill A, et al. Smoking, surgery, and venous thromboembolism risk in women: United kingdom cohort study. Circulation 2013; 127:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/273\">",
"      Oger E, Bressollette L, Nonent M, et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost 2002; 88:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/274\">",
"      Silverstein RL, Bauer KA, Cushman M, et al. Venous thrombosis in the elderly: more questions than answers. Blood 2007; 110:3097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/275\">",
"      Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010; 8:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/276\">",
"      Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/277\">",
"      Baccarelli A, Martinelli I, Zanobetti A, et al. Exposure to particulate air pollution and risk of deep vein thrombosis. Arch Intern Med 2008; 168:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/278\">",
"      Baccarelli A, Martinelli I, Pegoraro V, et al. Living near major traffic roads and risk of deep vein thrombosis. Circulation 2009; 119:3118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/279\">",
"      Dales RE, Cakmak S, Vidal CB. Air pollution and hospitalization for venous thromboembolic disease in Chile. J Thromb Haemost 2010; 8:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/280\">",
"      Shih RA, Griffin BA, Salkowski N, et al. Ambient particulate matter air pollution and venous thromboembolism in the Women's Health Initiative Hormone Therapy trials. Environ Health Perspect 2011; 119:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/281\">",
"      Kan H, Folsom AR, Cushman M, et al. Traffic exposure and incident venous thromboembolism in the Atherosclerosis Risk in Communities (ARIC) Study. J Thromb Haemost 2011; 9:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/282\">",
"      Mahmoodi BK, Gansevoort RT, Veeger NJ, et al. Microalbuminuria and risk of venous thromboembolism. JAMA 2009; 301:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/283\">",
"      Levine RL, McCollum D, Hursting MJ. How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? Chest 2006; 130:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/284\">",
"      Warkentin TE, Davidson BL, B&uuml;ller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011; 140:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/285\">",
"      Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/286\">",
"      Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/287\">",
"      Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/288\">",
"      Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/289\">",
"      Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/48/43786/abstract/290\">",
"      Eichinger S, Weltermann A, Minar E, et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164:92.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1361 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43786=[""].join("\n");
var outline_f42_48_43786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H61\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIRCHOW'S TRIAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUPERFICIAL VEIN THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INHERITED THROMBOPHILIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Common inherited hypercoagulable states",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Thrombotic risk in families",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Multiple inherited thrombotic defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4518697\">",
"      Other alleged inherited thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Heparin cofactor II deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Plasminogen deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dysfibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Factor XII deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4518711\">",
"      ANATOMIC RISK FACTORS FOR DEEP VENOUS THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Paget-Schroetter syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      May-Thurner syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Inferior vena cava abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ELEVATED CLOTTING FACTORS AND CHEMOKINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Factor VIII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other plasma components",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2575893\">",
"      - Elevated levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2575901\">",
"      - Reduced levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Single nucleotide polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26581288\">",
"      - Non-O blood type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ACQUIRED THROMBOPHILIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Multiple acquired risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23407368\">",
"      - Acquired plus inherited thrombophilic defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Major trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Minor injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Intravenous drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Oral and transdermal contraceptives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Hormone replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Immobilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1959550\">",
"      - Prolonged sitting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Extended travel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Myeloproliferative neoplasms and PNH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Renal diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Chronic renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Hyperviscosity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Hyperhomocysteinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Seasonal variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Cardiovascular risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      - VTE and atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      - Smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      - Air pollution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      - Microalbuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      PREVIOUS THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1361\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1361|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/7/7294\" title=\"figure 1\">",
"      Pulm embolism and air travel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/31/16880\" title=\"figure 2\">",
"      Seasonal variation VTE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1361|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/6/1132\" title=\"table 1\">",
"      Causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/4/21579\" title=\"table 2\">",
"      Risk factors VTE genetic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/22/44396\" title=\"table 3\">",
"      Thrombophilia test interference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/60/42955\" title=\"table 4\">",
"      Coagulant factors and DVT risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/34/39468\" title=\"table 5\">",
"      Surgical risk groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/49/23325\" title=\"table 6\">",
"      VTE risk in pregnancy by thrombophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17049?source=related_link\">",
"      Biology and normal function of von Willebrand factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14121?source=related_link\">",
"      Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31575?source=related_link\">",
"      Etiology of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19576?source=related_link\">",
"      Hyperleukocytosis and leukostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=related_link\">",
"      Medical complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31066?source=related_link\">",
"      Overview of inpatient management in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1224?source=related_link\">",
"      Pathogenesis of the hypercoagulable state associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13737?source=related_link\">",
"      Patient assessment for air travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2517?source=related_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16642?source=related_link\">",
"      Patient information: The antiphospholipid syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12484?source=related_link\">",
"      Plasma exchange in the hyperviscosity syndrome due to immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27754?source=related_link\">",
"      Primary (spontaneous) upper extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28554?source=related_link\">",
"      Prognosis and treatment of polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/25/43417?source=related_link\">",
"      Superficial thrombophlebitis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41127?source=related_link\">",
"      Transdermal contraceptive patch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_48_43787="Thyroid evaluation CA survivors";
var content_f42_48_43787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation for hypothyroidism in childhood cancer survivors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"3\">",
"        History",
"       </td>",
"       <td>",
"        Cranial irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total body radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"2\">",
"        Clinical evidence",
"       </td>",
"       <td>",
"        Slow growth rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delayed puberty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"6\">",
"        Review of systems*",
"       </td>",
"       <td>",
"        Fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive sleeping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disinterest in physical activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dry skin or eczema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constipation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"3\">",
"        Screening and diagnostic tests",
"       </td>",
"       <td>",
"        Free T4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         TSH (in some cases, a ratio of 8 AM to 4 PM TSH levels",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;&nbsp;may&nbsp; confirm central or mixed hypothyroidism)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone maturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" rowspan=\"4\">",
"        Associated endocrinopathies",
"       </td>",
"       <td>",
"        GH deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ACTH deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Precocious puberty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonadotropin deficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TSH: thyrotropin (thyroid stimulating hormone); TRH:&nbsp;thyrotropin releasing hormone; GH: growth hormone; ACTH: adrenocorticotropin.",
"     <br>",
"      * Patients have often accommodated to their symptoms and do not complain.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43787=[""].join("\n");
var outline_f42_48_43787=null;
var title_f42_48_43788="Clinical features of common optic neuropathies";
var content_f42_48_43788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of more common optic neuropathies*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Optic neuritis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Non-arteritic ischemic optic neuropathy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arteritic ischemic optic neuropathy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Leber's hereditary optic neuropathy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neuroretinitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"       <td>",
"        20 to 50 years",
"       </td>",
"       <td>",
"        &gt;50 years",
"       </td>",
"       <td>",
"        &gt;70 years",
"       </td>",
"       <td>",
"        25 to 40 years",
"       </td>",
"       <td>",
"        Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gender",
"       </td>",
"       <td>",
"        2:1 female",
"       </td>",
"       <td>",
"        Equal",
"       </td>",
"       <td>",
"        3.5:1 female",
"       </td>",
"       <td>",
"        80 to 90 percent male",
"       </td>",
"       <td>",
"        Equal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"       <td>",
"        Present in &gt;90 percent",
"       </td>",
"       <td>",
"        Present in &lt;10 percent",
"       </td>",
"       <td>",
"        Headache, scalp tenderness, jaw claudication",
"       </td>",
"       <td>",
"        Not present",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onset",
"       </td>",
"       <td>",
"        Hours to days",
"       </td>",
"       <td>",
"        Sudden",
"       </td>",
"       <td>",
"        Sudden",
"       </td>",
"       <td>",
"        Weeks to months",
"       </td>",
"       <td>",
"        Hours to days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unilateral or bilateral",
"       </td>",
"       <td>",
"        Usually unilateral",
"       </td>",
"       <td>",
"        Usually unilateral; low chance may recur in other eye years later",
"       </td>",
"       <td>",
"        May occur in both eyes in rapid sequence",
"       </td>",
"       <td>",
"        Bilateral - but presentation often unilateral",
"       </td>",
"       <td>",
"        Often bilateral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Funduscopic examination",
"       </td>",
"       <td>",
"        Papillitis present in one-third",
"       </td>",
"       <td>",
"        Papillitis present in most",
"       </td>",
"       <td>",
"        Pale swelling of disc; fundus may also be normal (posterior ischemic optic neuropathy - indicates giant cell arteritis)",
"       </td>",
"       <td>",
"        Disc hyperemia but no swelling; peripapillary telangiectasia",
"       </td>",
"       <td>",
"        Papillitis, macular edema, exudates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visual field defect",
"       </td>",
"       <td>",
"        Central scotoma",
"       </td>",
"       <td>",
"        Altitudinal (usually inferior) defect",
"       </td>",
"       <td>",
"        Altitudinal or generalized constriction",
"       </td>",
"       <td>",
"        Central or cecocentral defect",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnetic resonance imaging: optic nerve",
"       </td>",
"       <td>",
"        Inflammation of optic nerve in most (one-third to one-half will have other demyelinating lesions)",
"       </td>",
"       <td>",
"        Often normal",
"       </td>",
"       <td>",
"        May show enhancement",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Variably abnormal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prognosis",
"       </td>",
"       <td>",
"        Begins within two to four weeks, most achieve 20/40 or better",
"       </td>",
"       <td>",
"        Over several months, only 40 percent improve by three or more lines",
"       </td>",
"       <td>",
"        Poor once vision loss has occurred; may cause rapid blindness untreated",
"       </td>",
"       <td>",
"        One-third achieve some improvement",
"       </td>",
"       <td>",
"        Most recover fully",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Other diagnoses are described in the text \"Optic neuropathies.\"",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43788=[""].join("\n");
var outline_f42_48_43788=null;
var title_f42_48_43789="ECG strip atrial bigeminy and blocked APB";
var content_f42_48_43789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Single-lead electrocardiogram (ECG) showing atrial bigeminy and blocked atrial premature beats (APBs)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 89px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The single channel electrocardiographic recording shows a sinus P wave (P) followed by an atrial premature beat (P') in a repeating pattern, termed atrial bigeminy. The P' does not result in ventricular activation since conduction is blocked within the atrioventricular node (blocked atrial premature beat).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43789=[""].join("\n");
var outline_f42_48_43789=null;
var title_f42_48_43790="Choosing an antiarrhythmic drug to prevent atrial fibrillation";
var content_f42_48_43790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Choosing an antiarrhythmic drug to prevent atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 357px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Within each box, the antiarrhythmic drugs are listed alphabetically. The vertical flow represents the order of preference for each condition.",
"    <div class=\"footnotes\">",
"     HTN: hypertension; CAD: coronary artery disease; HF: heart failure; LVH: left ventricular hypertrophy; NYHA: New York Heart Association class; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.",
"    </div>",
"    <div class=\"reference\">",
"     Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12:1360. By permission of Oxford University Press. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43790=[""].join("\n");
var outline_f42_48_43790=null;
var title_f42_48_43791="Diag primary hyperpara";
var content_f42_48_43791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Diagnosis of primary hyperparathyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 662px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PHPT: primary hyperparathyroidism; FHH: familial hypocalciuric hypercalcemia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_48_43791=[""].join("\n");
var outline_f42_48_43791=null;
